BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken J, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'hoore A, Diaz-rubio E, Douillard J, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne C, Labianca R, Laurent-puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen W, Papamichael D, Pentheroudakis G, Pfeiffer P, Price T, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll H, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology 2016;27:1386-422. [DOI: 10.1093/annonc/mdw235] [Cited by in Crossref: 1387] [Cited by in F6Publishing: 1614] [Article Influence: 231.2] [Reference Citation Analysis]
Number Citing Articles
1 Hao M, Wang K, Ding Y, Li H, Liu Y, Ding L. Which patients are prone to suffer liver metastasis? A review of risk factors of metachronous liver metastasis of colorectal cancer. Eur J Med Res 2022;27. [DOI: 10.1186/s40001-022-00759-z] [Reference Citation Analysis]
2 Li Y, Hu J, Wang M, Yuan Y, Zhou F, Zhao H, Qiu T, Liang L. Exosomal circPABPC1 promotes colorectal cancer liver metastases by regulating HMGA2 in the nucleus and BMP4/ADAM19 in the cytoplasm. Cell Death Discov 2022;8. [DOI: 10.1038/s41420-022-01124-z] [Reference Citation Analysis]
3 Xiong L, He H, Fan M, Hu L, Wang F, Song X, Shi S, Qi B. Discovery of novel conjugates of quinoline and thiazolidinone urea as potential anti-colorectal cancer agent. J Enzyme Inhib Med Chem 2022;37:2334-47. [PMID: 36043496 DOI: 10.1080/14756366.2022.2117318] [Reference Citation Analysis]
4 Araujo RLC, Carvalho CGCY, Maeda CT, Milani JM, Bugano DG, de Moraes PHZ, Linhares MM. Oncologic aspects of the decision-making process for surgical approach for colorectal liver metastases progressing during chemotherapy. World J Gastrointest Surg 2022; 14(9): 877-886 [DOI: 10.4240/wjgs.v14.i9.877] [Reference Citation Analysis]
5 Osterlund E, Glimelius B. Temporal development in survival, and gender and regional differences in the Swedish population of patients with synchronous and metachronous metastatic colorectal cancer. Acta Oncol 2022;:1-11. [PMID: 36152023 DOI: 10.1080/0284186X.2022.2126327] [Reference Citation Analysis]
6 Hewitt DB, Brown ZJ, Pawlik TM. The Role of Biomarkers in the Management of Colorectal Liver Metastases. Cancers 2022;14:4602. [DOI: 10.3390/cancers14194602] [Reference Citation Analysis]
7 Lee HS, Kwon HW, Lim S, Kim JC, Yu CS, Hong YS, Kim TW, Oh M, Han S, Oh JH, Park S, Kim T, Kim S, Kim HJ, Kwak JY, Oh H, Kim S, Kwak J, Lee JS, Kim JS. FDG metabolic parameter-based models for predicting recurrence after upfront surgery in synchronous colorectal cancer liver metastasis. Eur Radiol. [DOI: 10.1007/s00330-022-09141-3] [Reference Citation Analysis]
8 D’onofrio R, Caputo F, Prampolini F, Spallanzani A, Gelsomino F, Bettelli S, Manfredini S, Reggiani Bonetti L, Carotenuto P, Bocconi A, Dominici M, Luppi G, Salati M. CtDNA-guided rechallenge with anti-EGFR therapy in RASwt metastatic colorectal cancer: Evidence from clinical practice. Tumori. [DOI: 10.1177/03008916221122554] [Reference Citation Analysis]
9 Valenzuela G, Burotto M, Marcelain K, González-Montero J. Liquid biopsy to detect resistance mutations against anti-epidermal growth factor receptor therapy in metastatic colorectal cancer. World J Gastrointest Oncol 2022; 14(9): 1654-1664 [DOI: 10.4251/wjgo.v14.i9.1654] [Reference Citation Analysis]
10 Bargellini I, Bozzi E, Lorenzoni G, Boni G, Bianchi F, Traino CA, Masi G, Cioni R, Crocetti L. Role of Transhepatic Arterial Radioembolization in Metastatic Colorectal Cancer. Cardiovasc Intervent Radiol. [DOI: 10.1007/s00270-022-03268-y] [Reference Citation Analysis]
11 Alghamdi M, Bazarbashi S, Mahrous M, Alshaer O, Mostafa Gad A, Aseafan M, Abdelgelil M, Alshabi RM, Alghanmi HA, Naser NA, Al Hariri H, Alhamad A, Al-saleh K, Abdel-aziz N, Elsamany S, Kolla J. Outcomes of Patients with Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil beyond the Second Line: A Multicenter Retrospective Study from Saudi Arabia. Journal of Oncology 2022;2022:1-8. [DOI: 10.1155/2022/3796783] [Reference Citation Analysis]
12 Mathieu V, Laguera B, Masi M, Dulanto SA, Bingham TW, Hernandez LW, Sarlah D, Evidente A, Lafontaine DLJ, Kornienko A, Lane MA. Amaryllidaceae Alkaloids Decrease the Proliferation, Invasion, and Secretion of Clinically Relevant Cytokines by Cultured Human Colon Cancer Cells. Biomolecules 2022;12:1267. [DOI: 10.3390/biom12091267] [Reference Citation Analysis]
13 Takamizawa Y, Inoue M, Moritani K, Tsukamoto S, Esaki M, Shimada K, Kanemitsu Y. Prognostic impact of conversion hepatectomy for initially unresectable colorectal liver metastasis. Langenbecks Arch Surg 2022. [PMID: 36068379 DOI: 10.1007/s00423-022-02666-7] [Reference Citation Analysis]
14 Innominato PF, Cailliez V, Allard MA, Lopez-Ben S, Ferrero A, Marques H, Hubert C, Giuliante F, Pereira F, Cugat E, Mirza DF, Costa-Maia J, Serrablo A, Lapointe R, Dopazo C, Tralhao J, Kaiser G, Chen JS, Garcia-Borobia F, Regimbeau JM, Skipenko O, Lin JK, Laurent C, Opocher E, Goto Y, Chibaudel B, de Gramont A, Adam R. Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey Analysis. Cancers (Basel) 2022;14:4340. [PMID: 36077874 DOI: 10.3390/cancers14174340] [Reference Citation Analysis]
15 Chen F, Wang Y, Liu W, Xing B. Neoadjuvant chemotherapy improves overall survival in resectable colorectal liver metastases patients with high clinical risk scores—— A retrospective, propensity score matching analysis. Front Oncol 2022;12:973418. [DOI: 10.3389/fonc.2022.973418] [Reference Citation Analysis]
16 Lindberg S, Onjukka E, Wersäll P, Staff C, Lewensohn R, Masucci G, Lindberg K. Predicting the benefit of stereotactic body radiotherapy of colorectal cancer metastases. Clinical and Translational Radiation Oncology 2022;36:91-8. [DOI: 10.1016/j.ctro.2022.07.006] [Reference Citation Analysis]
17 Stahler A, Modest DP, Fischer von Weikersthal L, Kaiser F, Decker T, Held S, Graeven U, Schwaner I, Denzlinger C, Schenk M, Kurreck A, Heinrich K, Gießen-Jung C, Neumann J, Kirchner T, Jung A, Stintzing S, Heinemann V. First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110). Eur J Cancer 2022;173:194-203. [PMID: 35940054 DOI: 10.1016/j.ejca.2022.06.019] [Reference Citation Analysis]
18 Modest DP, Karthaus M, Kasper S, Moosmann N, Keitel V, Kiani A, Uhlig J, Jacobasch L, Fischer V Weikersthal L, Fuchs M, Kaiser F, Lerchenmüller C, Sent D, Junghanß C, Held S, Lorenzen S, Kaczirek K, Jung A, Stintzing S, Heinemann V. FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases - The PARLIM trial (AIO KRK 0314). Eur J Cancer 2022;173:297-306. [PMID: 35970102 DOI: 10.1016/j.ejca.2022.07.012] [Reference Citation Analysis]
19 Domper-Arnal MJ, Hijos-Mallada G, Lanas Á. The impact of COVID-19 pandemic in the diagnosis and management of colorectal cancer patients. Therap Adv Gastroenterol 2022;15:17562848221117636. [PMID: 36035306 DOI: 10.1177/17562848221117636] [Reference Citation Analysis]
20 Özet A, Dane F, Aykan NF, Yalçın Ş, Evrensel T, Özkan M, Karabulut B, Ormeci MN, Atasev O, Vidot L, Çiçin İ. Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey. Future Oncol 2022. [PMID: 36040321 DOI: 10.2217/fon-2022-0455] [Reference Citation Analysis]
21 Rugo HS, Tolaney SM, Loirat D, Punie K, Bardia A, Hurvitz SA, O'Shaughnessy J, Cortés J, Diéras V, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo M, Itri LM, Kalinsky K. Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ Breast Cancer 2022;8:98. [PMID: 36038616 DOI: 10.1038/s41523-022-00467-1] [Reference Citation Analysis]
22 Martínez-Lago N, Chucla TC, De Castro BA, Ponte RV, Rendo CR, Rodriguez MIG, Diaz SS, Suarez BG, de la Cámara Gomez J, Fernández FB, Salvador MM, Lopez MR. Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting. Sci Rep 2022;12:14612. [PMID: 36028552 DOI: 10.1038/s41598-022-18871-9] [Reference Citation Analysis]
23 Tabernero J, Grothey A, Arnold D, de Gramont A, Ducreux M, O'Dwyer P, Tahiri A, Gilberg F, Irahara N, Schmoll HJ, Van Cutsem E. MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAFwt metastatic colorectal cancer. ESMO Open 2022;7:100559. [PMID: 36029653 DOI: 10.1016/j.esmoop.2022.100559] [Reference Citation Analysis]
24 Mendoza-Moreno F, Diez-Alonso M, Matías-García B, Ovejero-Merino E, Gómez-Sanz R, Blázquez-Martín A, Quiroga-Valcárcel A, Vera-Mansilla C, Molina R, San-Juan A, Barrena-Blázquez S, Ortega MA, Alvarez-Mon M, Gutiérrez-Calvo A. Prognostic Factors of Survival in Patients with Peritoneal Metastasis from Colorectal Cancer. J Clin Med 2022;11:4922. [PMID: 36013160 DOI: 10.3390/jcm11164922] [Reference Citation Analysis]
25 Bohlok A, Inchiostro L, Lucidi V, Vankerckhove S, Hendlisz A, Van Laethem JL, Craciun L, Demetter P, Larsimont D, Dirix L, Vermeulen P, Donckier V. Tumor biology reflected by histological growth pattern is more important than surgical margin for the prognosis of patients undergoing resection of colorectal liver metastases. Eur J Surg Oncol 2022:S0748-7983(22)00595-9. [PMID: 36031469 DOI: 10.1016/j.ejso.2022.08.006] [Reference Citation Analysis]
26 Riesco-Martinez MC, Modrego A, Espinosa-Olarte P, La Salvia A, Garcia-Carbonero R. Perioperative Chemotherapy for Liver Metastasis of Colorectal Cancer: Lessons Learned and Future Perspectives. Curr Treat Options Oncol 2022. [PMID: 35980520 DOI: 10.1007/s11864-022-01008-5] [Reference Citation Analysis]
27 Hofmann FO, Heinemann V, D'Anastasi M, Gesenhues AB, Hesse N, von Weikersthal LF, Decker T, Kiani A, Moehler M, Kaiser F, Heintges T, Kahl C, Kullmann F, Scheithauer W, Link H, Modest DP, Stintzing S, Holch JW. Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306. Eur Radiol 2022. [PMID: 35976398 DOI: 10.1007/s00330-022-09053-2] [Reference Citation Analysis]
28 Dank M, Mühl D, Herold M, Hornyák L, Szasz AM, Herold Z. Does Elevated Pre-Treatment Plasma PD-L1 Level Indicate an Increased Tumor Burden and Worse Prognosis in Metastatic Colorectal Cancer? JCM 2022;11:4815. [DOI: 10.3390/jcm11164815] [Reference Citation Analysis]
29 Milana F, Famularo S, Luberto A, Rimassa L, Scorsetti M, Comito T, Pressiani T, Franzese C, Poretti D, Di Tommaso L, Personeni N, Rodari M, Pedicini V, Donadon M, Torzilli G. Multidisciplinary Tumor Board in the Management of Patients with Colorectal Liver Metastases: A Single-Center Review of 847 Patients. Cancers 2022;14:3952. [DOI: 10.3390/cancers14163952] [Reference Citation Analysis]
30 Makutani Y, Kawakami H, Tsujikawa T, Yoshimura K, Chiba Y, Ito A, Kawamura J, Haratani K, Nakagawa K. Contribution of MMP14-expressing cancer-associated fibroblasts in the tumor immune microenvironment to progression of colorectal cancer. Front Oncol 2022;12:956270. [DOI: 10.3389/fonc.2022.956270] [Reference Citation Analysis]
31 Moretto R, Borelli B, Boraschi P, Roffi N, Donati F, Antoniotti C, Della Pina C, Colombatto P, Balestri R, Signori S, Gigoni R, Guidoccio F, Volterrani D, Masi G, Cremolini C, Urbani L. Impact of baseline gadoxetic acid-enhanced liver magnetic resonance and diffusion-weighted imaging in resectable colorectal liver metastases: A prospective, monocentric study. Surg Oncol 2022;44:101836. [PMID: 35998501 DOI: 10.1016/j.suronc.2022.101836] [Reference Citation Analysis]
32 Heisser T, Simon A, Hapfelmeier J, Hoffmeister M, Brenner H. Treatment Costs of Colorectal Cancer by Sex and Age: Population-Based Study on Health Insurance Data from Germany. Cancers (Basel) 2022;14:3836. [PMID: 35954499 DOI: 10.3390/cancers14153836] [Reference Citation Analysis]
33 Ponziani FR, Santopaolo F, Posa A, Pompili M, Tanzilli A, Maestri M, Pallozzi M, Ibba F, Manfredi R, Gasbarrini A, Iezzi R. SIRT in 2025. Cardiovasc Intervent Radiol 2022. [PMID: 35941244 DOI: 10.1007/s00270-022-03228-6] [Reference Citation Analysis]
34 Loosen SH, Schöler D, Labuhn S, Mertens A, Jördens MS, Luedde M, Kostev K, Luedde T, Roderburg C. The Spectrum of Co-Diagnoses in Patients with Colorectal Cancer: A Retrospective Cohort Study of 17,824 Outpatients in Germany. Cancers (Basel) 2022;14:3825. [PMID: 35954488 DOI: 10.3390/cancers14153825] [Reference Citation Analysis]
35 Baba O, Bidikian A, Mukherji D, Shamseddin A, Temraz S, Fakhruddin N, Khazzouh M, Ghizzawi D, Abdel Khalek R, Zaatari G, Mahfouz R. Tumor profiling of KRAS, BRAF, and NRAS gene mutations in patients with colorectal cancer: A Lebanese major center cohort study. Gene 2022;834:146646. [PMID: 35680020 DOI: 10.1016/j.gene.2022.146646] [Reference Citation Analysis]
36 Liu F, Liang Y, Sun R, Yang W, Liang Z, Gu J, Zhao F, Tang D. Astragalus mongholicus Bunge and Curcuma aromatica Salisb. inhibits liver metastasis of colon cancer by regulating EMT via the CXCL8/CXCR2 axis and PI3K/AKT/mTOR signaling pathway. Chin Med 2022;17:91. [PMID: 35922850 DOI: 10.1186/s13020-022-00641-4] [Reference Citation Analysis]
37 Strickler JH, Cubillo A, Liang JT, Matrana M, Kozloff M, Lowe T, Blaney M, Sahtout M, Naumovski L, Wainberg ZA. Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study. Future Oncol 2022. [PMID: 35920133 DOI: 10.2217/fon-2021-1603] [Reference Citation Analysis]
38 De Cobelli F, Della Corte A. Thermal Ablation for Colorectal Liver Metastases: The Time has Come. Cardiovasc Intervent Radiol 2022;45:1090-1. [PMID: 35761091 DOI: 10.1007/s00270-022-03198-9] [Reference Citation Analysis]
39 Shimozaki K, Hirata K, Sato T, Nakamura M, Kato K, Hirano H, Kumekawa Y, Hino K, Kawakami K, Kito Y, Matsumoto T, Kawakami T, Komoda M, Nagashima K, Sato Y, Yamazaki K, Hironaka S, Takaishi H, Hamamoto Y, Muro K. WJOG13219G: The Efficacy and Safety of FOLFOXIRI or Doublet plus Anti-VEGF Therapy in Previously Untreated BRAFV600E Mutant Metastatic Colorectal Cancer: A Multi-institutional Registry-based Study (BRACELET Study). Clinical Colorectal Cancer 2022. [DOI: 10.1016/j.clcc.2022.08.002] [Reference Citation Analysis]
40 Torres-jiménez J, Esteban-villarrubia J, Ferreiro-monteagudo R. Precision Medicine in Metastatic Colorectal Cancer: Targeting ERBB2 (HER-2) Oncogene. Cancers 2022;14:3718. [DOI: 10.3390/cancers14153718] [Reference Citation Analysis]
41 Yu IS, Aubin F, Goodwin R, Loree JM, Mather C, Sheffield BS, Snow S, Gill S. Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline. Ther Adv Med Oncol 2022;14:17588359221111705. [PMID: 35898967 DOI: 10.1177/17588359221111705] [Reference Citation Analysis]
42 Sommerhäuser G, Kurreck A, Stintzing S, Heinemann V, von Weikersthal LF, Dechow T, Kaiser F, Karthaus M, Schwaner I, Fuchs M, König A, Roderburg C, Hoyer I, Quante M, Kiani A, Fruehauf S, Müller L, Reinacher-Schick A, Ettrich TJ, Stahler A, Modest DP. Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer. BMC Cancer 2022;22:820. [PMID: 35897060 DOI: 10.1186/s12885-022-09892-8] [Reference Citation Analysis]
43 Wang C, Aikemu B, Shao Y, Zhang S, Yang G, Hong H, Huang L, Jia H, Yang X, Zheng M, Sun J, Li J. Genomic signature of MTOR could be an immunogenicity marker in human colorectal cancer. BMC Cancer 2022;22:818. [PMID: 35883111 DOI: 10.1186/s12885-022-09901-w] [Reference Citation Analysis]
44 Ottaiano A, de Vera d’Aragona RP, Trotta AM, Santorsola M, Napolitano M, Scognamiglio G, Tatangelo F, Grieco P, Zappavigna S, Granata V, Perri F, Luce A, Savarese G, Ianniello M, Casillo M, Petrillo N, Belli A, Izzo F, Nasti G, Caraglia M, Scala S. Characterization of KRAS Mutational Regression in Oligometastatic Patients. Front Immunol 2022;13:898561. [DOI: 10.3389/fimmu.2022.898561] [Reference Citation Analysis]
45 Hervieu C, Verdier M, Barthout E, Bégaud G, Christou N, Sage M, Pannequin J, Battu S, Mathonnet M. A Label-Free Cell Sorting Approach to Highlight the Impact of Intratumoral Cellular Heterogeneity and Cancer Stem Cells on Response to Therapies. Cells 2022;11:2264. [DOI: 10.3390/cells11152264] [Reference Citation Analysis]
46 Zou Q, Lei X, Xu A, Li Z, He Q, Huang X, Xu G, Tian F, Ding Y, Zhu W. Chemokines in progression, chemoresistance, diagnosis, and prognosis of colorectal cancer. Front Immunol 2022;13:724139. [DOI: 10.3389/fimmu.2022.724139] [Reference Citation Analysis]
47 Ito T, Takashima A, Yamazaki K, Yukami H, Uetake H, Tsuda M, Suto T, Moriwaki T, Sugimoto N, Ojima H, Takii Y, Yasui H, Esaki T, Tsuji A, Goto M, Saruta M, Otsu S, Shinozaki K, Fujiwara T, Tamura T, Baba E, Shiozawa M, Denda T, Ueno H, Nagashima K, Shimada Y. Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum. Int J Clin Oncol 2022. [PMID: 35861943 DOI: 10.1007/s10147-022-02208-7] [Reference Citation Analysis]
48 Di Martino M, Primavesi F, Syn N, Dorcaratto D, de la Hoz Rodríguez Á, Dupré A, Piardi T, Rhaiem R, Blanco Fernández G, de Armas Conde N, Rodríguez Sanjuán JC, Fernández Santiago R, Fernández-Moreno MC, Ferret G, López Ben S, Suárez Muñoz MÁ, Perez-Alonso AJ, Koh YX, Jones R, Martín-Pérez E. Long-Term Outcomes of Perioperative Versus Neoadjuvant Chemotherapy for Resectable Colorectal Liver Metastases: An International Multicentre Propensity-Score Matched Analysis with Stratification by Contemporary Risk-Scoring. Ann Surg Oncol 2022. [PMID: 35849284 DOI: 10.1245/s10434-022-12027-9] [Reference Citation Analysis]
49 Ji J, Wang C, Fakih M. Targeting KRAS G12C-Mutated Advanced Colorectal Cancer: Research and Clinical Developments. Onco Targets Ther 2022;15:747-56. [PMID: 35837349 DOI: 10.2147/OTT.S340392] [Reference Citation Analysis]
50 Gao XH, Li J, Liu LJ, Zheng NX, Zheng K, Mei Z, Bai CG, Zhang W. Trends, clinicopathological features, surgical treatment patterns and prognoses of early-onset versus late-onset colorectal cancer: A retrospective cohort study on 34067 patients managed from 2000 to 2021 in a Chinese tertiary center. Int J Surg 2022;104:106780. [PMID: 35850466 DOI: 10.1016/j.ijsu.2022.106780] [Reference Citation Analysis]
51 Herold Z, Herold M, Lohinszky J, Szasz AM, Dank M, Somogyi A. Longitudinal changes in personalized platelet count metrics are good indicators of initial 3-year outcome in colorectal cancer. World J Clin Cases 2022; 10(20): 6825-6844 [DOI: 10.12998/wjcc.v10.i20.6825] [Reference Citation Analysis]
52 Vasantharajan SS, Barnett E, Gray ES, McCall JL, Rodger EJ, Eccles MR, Munro F, Pattison S, Chatterjee A. Assessment of a Size-Based Method for Enriching Circulating Tumour Cells in Colorectal Cancer. Cancers (Basel) 2022;14:3446. [PMID: 35884509 DOI: 10.3390/cancers14143446] [Reference Citation Analysis]
53 Krawczyk P, Jassem J, Wojas-krawczyk K, Krzakowski M, Dziadziuszko R, Olszewski W. New Genetic Technologies in Diagnosis and Treatment of Cancer of Unknown Primary. Cancers 2022;14:3429. [DOI: 10.3390/cancers14143429] [Reference Citation Analysis]
54 Ros J, Saoudi N, Baraibar I, Salva F, Tabernero J, Elez E. Encorafenib plus cetuximab for the treatment of BRAF-V600E-mutated metastatic colorectal cancer. Therap Adv Gastroenterol 2022;15:17562848221110644. [PMID: 35812780 DOI: 10.1177/17562848221110644] [Reference Citation Analysis]
55 Mentrasti G, Cantini L, Zichi C, D'Ostilio N, Gelsomino F, Martinelli E, Chiari R, La Verde N, Bisonni R, Cognigni V, Pinterpe G, Pecci F, Migliore A, Aimar G, De Vita F, Traisci D, Spallanzani A, Martini G, Nicolardi L, Cona MS, Baleani MG, Rocchi MLB, Berardi R. Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak: A Real-World Analysis from the Italian COVID-DELAY Study. Oncologist 2022:oyac129. [PMID: 35815922 DOI: 10.1093/oncolo/oyac129] [Reference Citation Analysis]
56 Heinrich K, Miller-Phillips L, Ziemann F, Hasselmann K, Rühlmann K, Flach M, Biro D, von Bergwelt-Baildon M, Holch J, Herold T, von Baumgarten L, Greif PA, Jeremias I, Wuerstlein R, Casuscelli J, Spitzweg C, Seidensticker M, Renz B, Corradini S, Baumeister P, Goni E, Tufman A, Jung A, Kumbrink J, Kirchner T, Klauschen F, Metzeler KH, Heinemann V, Westphalen CB. Lessons learned: the first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board. J Cancer Res Clin Oncol 2022. [PMID: 35796778 DOI: 10.1007/s00432-022-04165-0] [Reference Citation Analysis]
57 Collienne M, Loghmani H, Heineman TC, Arnold D. GOBLET: a phase I/II study of pelareorep and atezolizumab +/- chemo in advanced or metastatic gastrointestinal cancers. Future Oncol 2022;:0. [PMID: 35796248 DOI: 10.2217/fon-2022-0453] [Reference Citation Analysis]
58 Kourie HR, Ibnshamsah F, Zouein J, Naim N, Abbasi S, Allahloubi N, Al-naqqash M, Alolayan A, Alshehri A, Bitar N, Bounedjar A, Farsi AA, Shamsi HE, Ghali R, Jaafar H, Larbaoui B, Mahrous M, Mrabti H, Nweir AR, Oukkal M, Rasul K, Razavi M, Turfa R, Khatib S, Shamseddine A. The first Middle East and North Africa expert consensus recommendations for the management of advanced colorectal cancer. Future Oncology. [DOI: 10.2217/fon-2022-0282] [Reference Citation Analysis]
59 Liu D, Sun LM, Liang JH, Song L, Liu XP. Diagnostic accuracy of ≥ 16-slice spiral computed tomography for local staging of colon cancer: A systematic review and meta-analysis. World J Clin Cases 2022; 10(19): 6483-6495 [DOI: 10.12998/wjcc.v10.i19.6483] [Reference Citation Analysis]
60 Varughese LA, Bhupathiraju M, Hoffecker G, Terek S, Harr M, Hakonarson H, Cambareri C, Marini J, Landgraf J, Chen J, Kanter G, Lau-min KS, Massa RC, Damjanov N, Reddy NJ, Oyer RA, Teitelbaum UR, Tuteja S. Implementing Pharmacogenetic Testing in Gastrointestinal Cancers (IMPACT-GI): Study Protocol for a Pragmatic Implementation Trial for Establishing DPYD and UGT1A1 Screening to Guide Chemotherapy Dosing. Front Oncol 2022;12:859846. [DOI: 10.3389/fonc.2022.859846] [Reference Citation Analysis]
61 Pfohl U, Loskutov J, Bashir S, Kühn R, Herter P, Templin M, Mamlouk S, Belanov S, Linnebacher M, Bürtin F, Vetter M, Reinhard C, Wedeken L, Regenbrecht CRA. A RAS-Independent Biomarker Panel to Reliably Predict Response to MEK Inhibition in Colorectal Cancer. Cancers 2022;14:3252. [DOI: 10.3390/cancers14133252] [Reference Citation Analysis]
62 Ren T, Jia H, Wu Q, Zhang Y, Ma Q, Yao D, Gao X, Xie D, Xu Z, Zhao Q, Zhang Y. Inhibition of Angiogenesis and Extracellular Matrix Remodeling: Synergistic Effect of Renin-Angiotensin System Inhibitors and Bevacizumab. Front Oncol 2022;12:829059. [DOI: 10.3389/fonc.2022.829059] [Reference Citation Analysis]
63 Wong GYM, Diakos C, Molloy MP, Hugh TJ. Prognostic Models Incorporating RAS Mutation to Predict Survival in Patients with Colorectal Liver Metastases: A Narrative Review. Cancers 2022;14:3223. [DOI: 10.3390/cancers14133223] [Reference Citation Analysis]
64 Janssen JBE, Medema JP, Gootjes EC, Tauriello DVF, Verheul HMW. Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer. Cancer Treat Rev 2022;109:102433. [PMID: 35905558 DOI: 10.1016/j.ctrv.2022.102433] [Reference Citation Analysis]
65 Yang H, Rong D, Yang W, Li W. Clinical Characteristics of Metastatic Colorectal Cancer Combined with Gastrointestinal Perforation and Prognostic Value of Circulating Tumor DNA. Emergency Medicine International 2022;2022:1-5. [DOI: 10.1155/2022/6989583] [Reference Citation Analysis]
66 Ceccon C, Angerilli V, Rasola C, Procaccio L, Sabbadin M, Bergamo F, Malapelle U, Lonardi S, Fassan M. Microsatellite Instable Colorectal Adenocarcinoma Diagnostics: The Advent of Liquid Biopsy Approaches. Front Oncol 2022;12:930108. [DOI: 10.3389/fonc.2022.930108] [Reference Citation Analysis]
67 Ooki A, Morita S, Tsuji A, Iwamoto S, Hara H, Tanioka H, Satake H, Kataoka M, Kotaka M, Kagawa Y, Nakamura M, Shingai T, Ishikawa M, Miyake Y, Suto T, Hashiguchi Y, Yabuno T, Ando M, Sakamoto J, Yamaguchi K. Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trial. BMC Cancer 2022;22:711. [PMID: 35765021 DOI: 10.1186/s12885-022-09811-x] [Reference Citation Analysis]
68 Napolitano S, Martini G, Ciardiello D, Di Maio M, Normanno N, Avallone A, Martinelli E, Maiello E, Troiani T, Ciardiello F. CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients. Front Oncol 2022;12:940523. [DOI: 10.3389/fonc.2022.940523] [Reference Citation Analysis]
69 Xiong Q, Zeng Z, Yang Y, Wang Y, Xu Y, Zhou Y, Liu J, Zhang Z, Qiu M, Zhu Q. KRAS Gene Copy Number as a Negative Predictive Biomarker for the Treatment of Metastatic Rectal Cancer With Cetuximab: A Case Report. Front Oncol 2022;12:872630. [PMID: 35734602 DOI: 10.3389/fonc.2022.872630] [Reference Citation Analysis]
70 Lin W, Zhu C, Yao J, Liu Y, Lin H, Liu Y. Multifactorial Analysis of Clinical Prognosis of Liver Metastasis and Vascular Intervention Combined with Ablation in Colorectal Cancer. J Oncol 2022;2022:9690401. [PMID: 35726221 DOI: 10.1155/2022/9690401] [Reference Citation Analysis]
71 Henderson RH, French D, McFerran E, Adams R, Wasan H, Glynne-Jones R, Fisher D, Richman S, Dunne PD, Wilde L, Maughan TS, Sullivan R, Lawler M. Spend less to achieve more: Economic analysis of intermittent versus continuous cetuximab in KRAS wild-type patients with metastatic colorectal cancer. J Cancer Policy 2022;:100342. [PMID: 35718327 DOI: 10.1016/j.jcpo.2022.100342] [Reference Citation Analysis]
72 Fiehn AK, Reiss B, Gögenur M, Bzorek M, Gögenur I. Development of a Fully Automated Method to Obtain Reproducible Lymphocyte Counts in Patients With Colorectal Cancer. Appl Immunohistochem Mol Morphol 2022. [PMID: 35703148 DOI: 10.1097/PAI.0000000000001041] [Reference Citation Analysis]
73 Deng S, Jiang Z, Cao Y, Gu J, Mao F, Xue Y, Qin L, Liu K, Wang J, Wu K, Cai K. Development and validation of a prognostic scoring system for patients with colorectal cancer hepato-pulmonary metastasis: a retrospective study. BMC Cancer 2022;22:643. [PMID: 35690752 DOI: 10.1186/s12885-022-09738-3] [Reference Citation Analysis]
74 Chung EM, Gong J, Zaghiyan K, Kamrava M, Atkins KM. Local Therapies for Colorectal Cancer Oligometastases to the Lung. Curr Colorectal Cancer Rep 2022;18:45-53. [DOI: 10.1007/s11888-022-00477-y] [Reference Citation Analysis]
75 Raimondi A, Randon G, Prisciandaro M, Pagani F, Lonardi S, Antoniotti C, Bozzarelli S, Sartore-Bianchi A, Tampellini M, Fanchini L, Murialdo R, Clavarezza M, Zaniboni A, Berenato R, Ratti M, Petrelli F, Antonuzzo L, Giordano M, Rossi A, Di Bartolomeo M, Di Maio M, Pietrantonio F, Morano F. Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trial. Int J Cancer 2022. [PMID: 35678328 DOI: 10.1002/ijc.34156] [Reference Citation Analysis]
76 Vogl TJ, Zitsch M, Albrecht M, D'Angelo T, Basten L, Gruber-Rouh T, Nour-Eldin NA, Naguib NNN. Long-term outcomes following percutaneous microwave ablation for colorectal cancer liver metastases. Int J Hyperthermia 2022;39:788-95. [PMID: 35658772 DOI: 10.1080/02656736.2022.2077991] [Reference Citation Analysis]
77 Rossini D, Antoniotti C, Lonardi S, Pietrantonio F, Moretto R, Antonuzzo L, Boccaccino A, Morano F, Brugia M, Pozzo C, Marmorino F, Bergamo F, Tamburini E, Passardi A, Randon G, Murgioni S, Borelli B, Buonadonna A, Giordano M, Fontanini G, Conca V, Formica V, Aglietta M, Bordonaro R, Aprile G, Masi G, Boni L, Cremolini C. Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO. J Clin Oncol 2022;:JCO2200839. [PMID: 35666229 DOI: 10.1200/JCO.22.00839] [Reference Citation Analysis]
78 Cheng X, Li Y, Chen D, Xu X, Liu F, Zhao F. Nomogram Predicting the Survival of Young-Onset Patients with Colorectal Cancer Liver Metastases. Diagnostics 2022;12:1395. [DOI: 10.3390/diagnostics12061395] [Reference Citation Analysis]
79 Moretto R, Elliott A, Rossini D, Intini R, Conca V, Pietrantonio F, Sartore-bianchi A, Antoniotti C, Rasola C, Scartozzi M, Salati M, Pella N, Calegari MA, Carullo M, Corti F, Mauri G, Fassan M, Masi G, Brodskiy P, Lenz H, Shields A, Lonardi S, Korn M, Cremolini C. Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter? Br J Cancer. [DOI: 10.1038/s41416-022-01852-0] [Reference Citation Analysis]
80 Fischer LE, Stintzing S, Heinemann V, Keilholz U, Keune D, Vollbrecht C, Burmeister T, Kind A, Weiss L, Horst D, Kirchner T, Klauschen F, Jung A, Westphalen CB, Jelas I. Liquid Biopsy in Colorectal Cancer: Quo Vadis? Implementation of Liquid Biopsies in Routine Clinical Patient Care in Two German Comprehensive Cancer Centers. Front Oncol 2022;12:870411. [PMID: 35646657 DOI: 10.3389/fonc.2022.870411] [Reference Citation Analysis]
81 Villard C, Abdelrafee A, Habib M, Ndegwa N, Jorns C, Sparrelid E, Allard M, Adam R. Prediction of survival in patients with colorectal liver metastases- development and validation of a prognostic score model. European Journal of Surgical Oncology 2022. [DOI: 10.1016/j.ejso.2022.06.021] [Reference Citation Analysis]
82 Raphael MJ, Karanicolas PJ. Regional Therapy for Colorectal Cancer Liver Metastases: Which Modality and When? J Clin Oncol 2022;:JCO2102505. [PMID: 35649228 DOI: 10.1200/JCO.21.02505] [Reference Citation Analysis]
83 Ahmadzadehfar H, Ilhan H, Lam MGEH, Sraieb M, Stegger L. Radioembolization, Principles and indications. Nuklearmedizin 2022;61:262-72. [PMID: 35354218 DOI: 10.1055/a-1759-4238] [Reference Citation Analysis]
84 Satake H, Kagawa Y, Shinozaki E, Tanizawa Y, Jin L, Cai Z, Makiyama A. Real-World Data Analysis of Second-Line Antiangiogenic Targeted Treatments Following Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies and First-Line FOLFOX for Patients with Metastatic Colorectal Cancer. Adv Ther 2022;39:2596-613. [PMID: 35384550 DOI: 10.1007/s12325-022-02122-4] [Reference Citation Analysis]
85 Birgin E, Doyon F, Burkert J, Téoule P, Rasbach E, Rahbari M, Reissfelder C, Betzler A, Rahbari NN. Prognostic value of disease-free interval in colorectal cancer: Is it time? European Journal of Surgical Oncology 2022. [DOI: 10.1016/j.ejso.2022.06.001] [Reference Citation Analysis]
86 Van den Bosch V, Pedersoli F, Keil S, Neumann UP, Kuhl CK, Bruners P, Zimmermann M. Safety and efficacy of right portal vein embolization in patients with prior left lateral liver resection. Acta Radiol 2022;63:727-33. [PMID: 33951926 DOI: 10.1177/02841851211014192] [Reference Citation Analysis]
87 Hafliger E, Boccaccino A, Lapeyre-prost A, Perret A, Gallois C, Antista M, Pilla L, Lecomte T, Scartozzi M, Soularue E, Salvatore L, Bourgeois V, Salati M, Tougeron D, Evesque L, Vaillant J, El-khoury R, Lonardi S, Cremolini C, Taieb J. Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series. European Journal of Cancer 2022;168:34-40. [DOI: 10.1016/j.ejca.2022.03.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Fernández Montes A, Élez E, Vivancos A, Martínez N, González P, Covela M, de la Cámara J, Cousillas A, Méndez JC, Graña B, Aranda E. Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer. Clin Transl Oncol 2022;24:1209-14. [PMID: 34997474 DOI: 10.1007/s12094-021-02767-7] [Reference Citation Analysis]
89 Yoshino T, Van Cutsem E, Li J, Shen L, Kim T, Sriuranpong V, Xuereb L, Aubel P, Fougeray R, Cattan V, Amellal N, Ohtsu A, Mayer R. Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis. ESMO Open 2022;7:100511. [DOI: 10.1016/j.esmoop.2022.100511] [Reference Citation Analysis]
90 Paul M, Gope TK, Das P, Ain R. Nitric-Oxide Synthase trafficking inducer (NOSTRIN) is an emerging negative regulator of colon cancer progression. BMC Cancer 2022;22:594. [PMID: 35642021 DOI: 10.1186/s12885-022-09670-6] [Reference Citation Analysis]
91 Lorton O, Guillemin PC, M’rad Y, Peloso A, Boudabbous S, Charbonnier C, Holman R, Crowe LA, Gui L, Poletti P, Ricoeur A, Terraz S, Salomir R. A Novel Concept of a Phased-Array HIFU Transducer Optimized for MR-Guided Hepatic Ablation: Embodiment and First In-Vivo Studies. Front Oncol 2022;12:899440. [DOI: 10.3389/fonc.2022.899440] [Reference Citation Analysis]
92 Fischer LE, Stintzing S, von Weikersthal LF, Modest DP, Decker T, Kiani A, Kaiser F, Al-batran S, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Giessen-jung C, Uhlig J, Peuser B, Denzlinger C, Stahler A, Weiss L, Heinrich K, Held S, Jung A, Kirchner T, Heinemann V. Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3. Br J Cancer. [DOI: 10.1038/s41416-022-01854-y] [Reference Citation Analysis]
93 Wong GYM, Diakos C, Hugh TJ, Molloy MP. Proteomic Profiling and Biomarker Discovery in Colorectal Liver Metastases. IJMS 2022;23:6091. [DOI: 10.3390/ijms23116091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Jacques C, Marchesi I, Fiorentino FP, Chatelais M, Lilli NL, Appel K, Lejeune B, Floris I. A Micro-Immunotherapy Sequential Medicine MIM-seq Displays Immunomodulatory Effects on Human Macrophages and Anti-Tumor Properties towards In Vitro 2D and 3D Models of Colon Carcinoma and in an In Vivo Subcutaneous Xenograft Colon Carcinoma Model. Int J Mol Sci 2022;23:6059. [PMID: 35682738 DOI: 10.3390/ijms23116059] [Reference Citation Analysis]
95 Maruyama K, Tominaga T, Nonaka T, Moriyama M, Oyama S, Ishii M, Sawai T, Nagayasu T. Efficacy of risk-stratified indicators for adjuvant chemotherapy with fluorouracil and oxaliplatin after hepatectomy for colorectal cancer liver metastasis. Int J Colorectal Dis 2022. [PMID: 35624174 DOI: 10.1007/s00384-022-04189-5] [Reference Citation Analysis]
96 Shimagaki T, Sugimachi K, Mano Y, Onishi E, Iguchi T, Uehara H, Sugiyama M, Yamamoto M, Morita M, Toh Y. Simple systemic index associated with oxaliplatin‐induced liver damage can be a novel biomarker to predict prognosis after resection of colorectal liver metastasis. Annals of Gastroent Surgery. [DOI: 10.1002/ags3.12580] [Reference Citation Analysis]
97 Chen Q, Zhang Y, Deng Y, Huang Z, Zhao H, Cai J. Outcomes of simultaneous resection for elderly patients with colorectal liver metastasis: A propensity score matching analysis. Cancer Med 2022. [PMID: 35608250 DOI: 10.1002/cam4.4826] [Reference Citation Analysis]
98 Jing Z, Ziwang F, Yinhang W, Yani Z, Jian C, Jingwen W, Shuwen H. Novel acetylation-related gene signatures for predicting the prognosis of patients with colorectal cancer. Hum Cell 2022. [PMID: 35604486 DOI: 10.1007/s13577-022-00720-6] [Reference Citation Analysis]
99 Damm R, Pech M, Cavalli P, Haag F, Gylstorff S, Omari J, Thormann M, Seidensticker R, Ricke J, Seidensticker M, Relja B. Correlation of chemokines and growth factors with radiation-induced liver injury after interstitial high dose rate (HDR) brachytherapy of liver metastases. J Cancer Res Clin Oncol 2022. [PMID: 35596772 DOI: 10.1007/s00432-022-04041-x] [Reference Citation Analysis]
100 Wu B, Yang J, Qin Z, Yang H, Shao J, Shang Y. Prognosis prediction of stage IV colorectal cancer patients by mRNA transcriptional profile. Cancer Med 2022. [PMID: 35587572 DOI: 10.1002/cam4.4824] [Reference Citation Analysis]
101 Liu W, Jiang H, Li Y. Silencing circular RNA-friend leukemia virus integration 1 restrained malignancy of CC cells and oxaliplatin resistance by disturbing dyskeratosis congenita 1. Open Life Sciences 2022;17:563-76. [DOI: 10.1515/biol-2022-0036] [Reference Citation Analysis]
102 Rossini D, Germani MM, Lonardi S, Pietrantonio F, Dell'Aquila E, Borelli B, Allegrini G, Maddalena G, Randon G, Marmorino F, Zaniboni A, Buonadonna A, Boccaccino A, Conca V, Antoniotti C, Passardi A, Masi G, Cremolini C. Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies. Eur J Cancer 2022;170:64-72. [PMID: 35594613 DOI: 10.1016/j.ejca.2022.04.019] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Lamtha T, Krobthong S, Yingchutrakul Y, Samutrtai P, Gerner C, Tabtimmai L, Choowongkomon K. A novel nanobody as therapeutics target for EGFR-positive colorectal cancer therapy: exploring the effects of the nanobody on SW480 cells using proteomics approach. Proteome Sci 2022;20. [DOI: 10.1186/s12953-022-00190-6] [Reference Citation Analysis]
104 Bolhuis K, Wensink GE, Elferink MAG, Bond MJG, Dijksterhuis WPM, Fijneman RJA, Kranenburg OW, Rinkes IHMB, Koopman M, Swijnenburg RJ, Vink GR, Hagendoorn J, Punt CJA, Elias SG, Roodhart JML. External Validation of Two Established Clinical Risk Scores Predicting Outcome after Local Treatment of Colorectal Liver Metastases in a Nationwide Cohort. Cancers (Basel) 2022;14:2356. [PMID: 35625968 DOI: 10.3390/cancers14102356] [Reference Citation Analysis]
105 Jo Y, Lee J, Cho E, Lee HS, Shin S, Park EJ, Baik SH, Lee KY, Kang J. Clinical Significance of Early Carcinoembryonic Antigen Change in Patients With Nonmetastatic Colorectal Cancer. Front Oncol 2022;12:739614. [DOI: 10.3389/fonc.2022.739614] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
106 Mizukami T, Takahashi M, Sunakawa Y, Yuki S, Kagawa Y, Takashima A, Kato K, Hara H, Denda T, Yamamoto Y, Shiozawa M, Oki E, Okamoto W, Yoshino T, Eguchi Nakajima T. Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy. Target Oncol 2022. [PMID: 35524872 DOI: 10.1007/s11523-022-00880-3] [Reference Citation Analysis]
107 Liu Y, Xiao Q, He J, Hu H, Du J, Zhu Y, Chen J, Liu Z, Wang J, Sun L, Xu D, Li J, Liao X, Wang J, Cai Y, Cai C, Jin Z, Wang L, Yuan Y, Ding K. Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy. BMC Med 2022;20:155. [PMID: 35513832 DOI: 10.1186/s12916-022-02357-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
108 Tabernero J, Ros J, Élez E. The Evolving Treatment Landscape in BRAF-V600E-Mutated Metastatic Colorectal Cancer. Am Soc Clin Oncol Educ Book 2022;42:1-10. [PMID: 35503983 DOI: 10.1200/EDBK_349561] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Abe S, Kawai K, Nozawa H, Sasaki K, Murono K, Emoto S, Ozawa T, Yokoyama Y, Nagai Y, Anzai H, Sonoda H, Yamauchi S, Sugihara K, Ishihara S. Clinical impact of primary tumor sidedness and sex on unresectable post-recurrence survival in resected pathological stage II-III colorectal cancers: a nationwide multicenter retrospective study. BMC Cancer 2022;22:486. [PMID: 35501727 DOI: 10.1186/s12885-022-09615-z] [Reference Citation Analysis]
110 Derksen JW, Smit KC, May AM, Punt CJ. Systematic review and non-inferiority meta-analysis of randomised phase II/III trials on S-1-based therapy versus 5-fluorouracil- or capecitabine-based therapy in the treatment of patients with metastatic colorectal cancer. European Journal of Cancer 2022;166:73-86. [DOI: 10.1016/j.ejca.2022.02.004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Viñal D, Minaya-Bravo A, Prieto I, Feliu J, Rodriguez-Salas N. Ytrrium-90 transarterial radioembolization in patients with gastrointestinal malignancies. Clin Transl Oncol 2022;24:796-808. [PMID: 35013882 DOI: 10.1007/s12094-021-02745-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
112 Liu JM, Wang YY, Liu W, Xu D, Wang K, Xing BC. Long disease-free interval diminishes the prognostic value of primary tumor stage for patients with colorectal cancer liver metastases. HPB (Oxford) 2022;24:737-48. [PMID: 35123859 DOI: 10.1016/j.hpb.2021.10.001] [Reference Citation Analysis]
113 Stintzing S, Seufferlein T, Rosé C, Reichenbach F, Lüftner D. Encorafenib in combination with cetuximab after systemic therapy in patients with BRAFV600E mutant metastatic colorectal cancer: German health technology assessment-driven analyses from the BEACON CRC study. Clinical Colorectal Cancer 2022. [DOI: 10.1016/j.clcc.2022.04.002] [Reference Citation Analysis]
114 de Jong EJM, Mommers I, Fariña Sarasqueta A, van der Geest LG, Heij L, de Hingh IHJT, Homs MYV, Tjan-Heijnen VCG, Valkenburg-van Iersel LBJ, Wilmink JW, Geurts SME, de Vos-Geelen J; Dutch Pancreatic Cancer Group. Adjuvant and first-line palliative chemotherapy regimens in patients diagnosed with periampullary cancer: a short report from a nationwide registry. Acta Oncol 2022;61:591-6. [PMID: 35382678 DOI: 10.1080/0284186X.2022.2053199] [Reference Citation Analysis]
115 Rosati G, Aprile G, Colombo A, Cordio S, Giampaglia M, Cappetta A, Porretto CM, De Stefano A, Bilancia D, Avallone A. Colorectal Cancer Heterogeneity and the Impact on Precision Medicine and Therapy Efficacy. Biomedicines 2022;10:1035. [DOI: 10.3390/biomedicines10051035] [Reference Citation Analysis]
116 De Baere T, Tselikas L, Delpla A, Roux C, Varin E, Kobe A, Yevich S, Deschamps F. Thermal ablation in the management of oligometastatic colorectal cancer. Int J Hyperthermia 2022;39:627-32. [PMID: 35477367 DOI: 10.1080/02656736.2021.1941311] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 De Vera MA, Gill S, Ashamalla S, Schiller D, Brenner DR, Wong C, Wildgoose P, Esplen MJ, Lieu C, Fitzpatrick R, O’sullivan DE, Servidio-italiano F. Early-Age-Onset Colorectal Cancer in Canada: Evidence, Issues and Calls to Action. Current Oncology 2022;29:3149-59. [DOI: 10.3390/curroncol29050256] [Reference Citation Analysis]
118 Tominaga T, Nonaka T, Oyama S, Shiraishi T, Takeshita H, Hisanaga M, Fukuoka H, Fukuda A, Sumida Y, Hashimoto S, To K, Tanaka K, Sawai T, Nagayasu T. Effect of oxaliplatin in elderly colon cancer patients with pathological T4 and/or N2 disease: a multicenter, propensity score-matched analysis. Int J Colorectal Dis 2022;37:1181-8. [PMID: 35478036 DOI: 10.1007/s00384-022-04159-x] [Reference Citation Analysis]
119 Rousseau B, Boukerma AK, Henriques J, Cohen R, Lucidarme O, Borg C, Tournigand C, Kim S, Bachet JB, Mazard T, Louvet C, Chibaudel B, Vernerey D, Andre T, Hulin A. Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study. Eur J Cancer 2022;168:99-107. [PMID: 35489233 DOI: 10.1016/j.ejca.2022.03.009] [Reference Citation Analysis]
120 Miyakawa T, Kawamura H, Honda M, Takano Y, Kinuta S, Kamiga T, Yamazaki S, Muto A, Shiraso S, Yamashita N, Iwao T, Kono K, Konno S. Impact of histological subtype on prognosis in stage IV colorectal cancer: A population-based cohort study. PLoS One 2022;17:e0264652. [PMID: 35239725 DOI: 10.1371/journal.pone.0264652] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
121 Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA Cancer J Clin 2022. [PMID: 35472088 DOI: 10.3322/caac.21728] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
122 Lin J, Sun H, Zhang W, Hong Z, Lu Z, Pan Z, Hou Z, Peng J. Conversion therapy with the intent to perform radical local treatment may not be suitable for patients with 10 or more liver metastases from colorectal cancer. Cancer Med 2022. [PMID: 35466587 DOI: 10.1002/cam4.4775] [Reference Citation Analysis]
123 Moriwaki T, Nishina T, Sakai Y, Yamamoto Y, Shimada M, Ishida H, Amagai K, Sato M, Endo S, Negoro Y, Kuramochi H, Denda T, Hatachi Y, Ikezawa K, Nakajima G, Bando Y, Tsuji A, Yamamoto Y, Morimoto M, Kobayashi K, Hyodo I. Impact of chronological age on efficacy and safety of fluoropyrimidine plus bevacizumab in older non-frail patients with metastatic colorectal cancer: a combined analysis of individual data from two phase II studies of patients aged >75 years. Jpn J Clin Oncol 2022:hyac073. [PMID: 35470391 DOI: 10.1093/jjco/hyac073] [Reference Citation Analysis]
124 Entezari P, Gabr A, Salem R, Lewandowski RJ. Yttrium-90 for colorectal liver metastasis - the promising role of radiation segmentectomy as an alternative local cure. International Journal of Hyperthermia 2022;39:620-6. [DOI: 10.1080/02656736.2021.1933215] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
125 Thompson SM, Welch BT, Kurup AN. Ablation for oligometastatic colorectal carcinoma in extrahepatic, extrapulmonary sites. International Journal of Hyperthermia 2022;39:633-8. [DOI: 10.1080/02656736.2021.1952318] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 Lin Y, Bale R, Brock KK, Odisio BC. Contemporary evidence on colorectal liver metastases ablation: toward a paradigm shift in locoregional treatment. International Journal of Hyperthermia 2022;39:649-63. [DOI: 10.1080/02656736.2021.1970245] [Reference Citation Analysis]
127 Liu C, Wang T, Yang J, Zhang J, Wei S, Guo Y, Yu R, Tan Z, Wang S, Dong W. Distant Metastasis Pattern and Prognostic Prediction Model of Colorectal Cancer Patients Based on Big Data Mining. Front Oncol 2022;12:878805. [DOI: 10.3389/fonc.2022.878805] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
128 Van Cutsem E, Danielewicz I, Saunders MP, Pfeiffer P, Argilés G, Borg C, Glynne-Jones R, Punt CJA, Van de Wouw AJ, Fedyanin M, Stroyakovskiy D, Kroening H, Garcia-Alfonso P, Wasan H, Falcone A, Fougeray R, Egorov A, Amellal N, Moiseyenko V. First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study. Br J Cancer 2022. [PMID: 35440667 DOI: 10.1038/s41416-022-01737-2] [Reference Citation Analysis]
129 Callesen LB, Hamfjord J, Boysen AK, Pallisgaard N, Guren TK, Kure EH, Spindler KG. Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis. Br J Cancer 2022. [PMID: 35440666 DOI: 10.1038/s41416-022-01816-4] [Reference Citation Analysis]
130 Costa B, Estrada MF, Barroso MT, Fior R. Zebrafish Patient‐Derived Avatars from Digestive Cancers for Anti‐cancer Therapy Screening. Current Protocols 2022;2. [DOI: 10.1002/cpz1.415] [Reference Citation Analysis]
131 Xu YJ, Zhang P, Hu JL, Liang H, Zhu YY, Cui Y, Niu P, Xu M, Liu MY. Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the platelet-to-lymphocyte ratio’s prediction on effectiveness. World J Gastrointest Oncol 2022; 14(4): 920-934 [DOI: 10.4251/wjgo.v14.i4.920] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
132 Chiappetta M, Salvatore L, Congedo MT, Bensi M, De Luca V, Petracca Ciavarella L, Camarda F, Evangelista J, Valentini V, Tortora G, Margaritora S, Lococo F. Management of single pulmonary metastases from colorectal cancer: State of the art. World J Gastrointest Oncol 2022; 14(4): 820-832 [DOI: 10.4251/wjgo.v14.i4.820] [Reference Citation Analysis]
133 Wrana F, Dötzer K, Prüfer M, Werner J, Mayer B. High Dual Expression of the Biomarkers CD44v6/α2β1 and CD44v6/PD-L1 Indicate Early Recurrence after Colorectal Hepatic Metastasectomy. Cancers (Basel) 2022;14:1939. [PMID: 35454846 DOI: 10.3390/cancers14081939] [Reference Citation Analysis]
134 Kasurinen J, Hagström J, Kaprio T, Beilmann-Lehtonen I, Haglund C, Böckelman C. Tumor-associated CD3- and CD8-positive immune cells in colorectal cancer: The additional prognostic value of CD8+-to-CD3+ ratio remains debatable. Tumour Biol 2022;44:37-52. [PMID: 35404299 DOI: 10.3233/TUB-211571] [Reference Citation Analysis]
135 Kang J, li N, Wang F, Wei Y, Zeng Y, Luo Q, Sun X, Xu H, Peng J, Zhou F. Exploration of Reduced Mitochondrial Content–Associated Gene Signature and Immunocyte Infiltration in Colon Adenocarcinoma by an Integrated Bioinformatic Analysis. Front Genet 2022;13:832331. [DOI: 10.3389/fgene.2022.832331] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
136 Su W, Tsai Y, Tsai H, Chang T, Yin T, Huang C, Chen Y, Li C, Chen P, Liu Y, Hsieh T, Wang J. Comparison of Next-Generation Sequencing and Polymerase Chain Reaction for Personalized Treatment-Related Genomic Status in Patients with Metastatic Colorectal Cancer. CIMB 2022;44:1552-63. [DOI: 10.3390/cimb44040106] [Reference Citation Analysis]
137 Raschzok N, Stintzing S, Heinemann V, Rauch G, Ricke J, Guckenberger M, Kurreck A, Alig AHS, Stahler A, Bullinger L, Schmelzle M, Schöning W, Lurje G, Krenzien F, Haase O, Rau B, Gebauer B, Sauer IM, Pratschke J, Modest DP. FIRE-9 – PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09422-6] [Reference Citation Analysis]
138 Ginghina O, Hudita A, Zamfir M, Spanu A, Mardare M, Bondoc I, Buburuzan L, Georgescu SE, Costache M, Negrei C, Nitipir C, Galateanu B. Liquid Biopsy and Artificial Intelligence as Tools to Detect Signatures of Colorectal Malignancies: A Modern Approach in Patient's Stratification. Front Oncol 2022;12:856575. [PMID: 35356214 DOI: 10.3389/fonc.2022.856575] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
139 Antoniotti C, Marmorino F, Boccaccino A, Martini S, Antista M, Rossini D, Zuco V, Prisciandaro M, Conca V, Zucchelli G, Borelli B, Cosentino P, Germani MM, Bosco MF, Carullo M, Vetere G, Moretto R, Giordano M, Masi G, Pietrantonio F, Zaffaroni N, Cremolini C. Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer. European Journal of Cancer 2022;165:116-24. [DOI: 10.1016/j.ejca.2022.01.025] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
140 Nivolli A, Barabino E, Lacelli F, Arnò M, Ivaldi D, Pittaluga G, Percivale A, Gazzo P. Percutaneous microwave ablation of disappearing colorectal liver metastases using US-MR fusion imaging guidance with integration of pre-chemotherapy imaging: a case report. Current Problems in Cancer: Case Reports 2022. [DOI: 10.1016/j.cpccr.2022.100159] [Reference Citation Analysis]
141 Lehtomäki K, Stedt HP, Osterlund E, Muhonen T, Soveri LM, Halonen P, Salminen TK, Kononen J, Kallio R, Ålgars A, Heervä E, Lamminmäki A, Uutela A, Nordin A, Lehto J, Saarto T, Sintonen H, Kellokumpu-Lehtinen PL, Ristamäki R, Glimelius B, Isoniemi H, Osterlund P. Health-Related Quality of Life in Metastatic Colorectal Cancer Patients Treated with Curative Resection and/or Local Ablative Therapy or Systemic Therapy in the Finnish RAXO-Study. Cancers (Basel) 2022;14:1713. [PMID: 35406485 DOI: 10.3390/cancers14071713] [Reference Citation Analysis]
142 Beom SH, Kim JG, Baik SH, Shin SH, Park I, Park YS, Lee MA, Lee S, Jeon SY, Han SW, Kang MH, Oh J, Kim JS, Kim JY, Ahn MS, Zang DY, Bae BN, Jo HJ, Kim HK, Kim JH, Yoon JA, Kim DH. Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen. J Cancer Res Clin Oncol 2022. [PMID: 35344080 DOI: 10.1007/s00432-022-03946-x] [Reference Citation Analysis]
143 Jin H, Amonkar M, Aguiar-Ibáñez R, Thosar M, Chase M, Keeping S. Systematic literature review and network meta-analysis of pembrolizumab versus other interventions for previously untreated, unresectable or metastatic, microsatellite instability-high or mismatch repair-deficient colorectal cancer. Future Oncol 2022. [PMID: 35332802 DOI: 10.2217/fon-2021-1633] [Reference Citation Analysis]
144 Qian S, Villarejo-campos P, Guijo I, Hernández-villafranca S, García-olmo D, González-soares S, Guadalajara H, Jiménez-galanes S, Qian C. Update for Advance CAR-T Therapy in Solid Tumors, Clinical Application in Peritoneal Carcinomatosis From Colorectal Cancer and Future Prospects. Front Immunol 2022;13:841425. [DOI: 10.3389/fimmu.2022.841425] [Reference Citation Analysis]
145 García-Alfonso P, Lièvre A, Loupakis F, Tadmouri A, Khan S, Barcena L, Stintzing S. Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAFV600E-mutant metastatic and/or unresectable colorectal cancer. Crit Rev Oncol Hematol 2022;173:103646. [PMID: 35344913 DOI: 10.1016/j.critrevonc.2022.103646] [Reference Citation Analysis]
146 Tharmaseelan H, Hertel A, Tollens F, Rink J, Woźnicki P, Haselmann V, Ayx I, Nörenberg D, Schoenberg SO, Froelich MF. Identification of CT Imaging Phenotypes of Colorectal Liver Metastases from Radiomics Signatures-Towards Assessment of Interlesional Tumor Heterogeneity. Cancers (Basel) 2022;14:1646. [PMID: 35406418 DOI: 10.3390/cancers14071646] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
147 Lee JW, Park YS, Choi JY, Chang WJ, Lee S, Sung JS, Kim B, Lee SB, Lee SY, Choi J, Kim YH. Genetic Characteristics Associated With Drug Resistance in Lung Cancer and Colorectal Cancer Using Whole Exome Sequencing of Cell-Free DNA. Front Oncol 2022;12:843561. [DOI: 10.3389/fonc.2022.843561] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
148 Schulz MS, Wolf S, Struck V, Thomas N, Husman G, Zeuzem S, Koch C, Trojan J, Schnitzbauer AA, Bechstein WO, Waidmann O. Anti-EGFR Reintroduction and Rechallenge in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis. Cancers (Basel) 2022;14:1641. [PMID: 35406413 DOI: 10.3390/cancers14071641] [Reference Citation Analysis]
149 Rodriquenz MG, Ciardiello D, Latiano TP, Maiorano BA, Martinelli E, Silvestris N, Ciardiello F, Maiello E. Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer. Crit Rev Oncol Hematol 2022;173:103657. [PMID: 35337969 DOI: 10.1016/j.critrevonc.2022.103657] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
150 Germani MM, Borelli B, Boraschi P, Antoniotti C, Ugolini C, Urbani L, Morelli L, Fontanini G, Masi G, Cremolini C, Moretto R. The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features. Cancer Treat Rev 2022;106:102382. [PMID: 35334281 DOI: 10.1016/j.ctrv.2022.102382] [Reference Citation Analysis]
151 Huang S, Lin C, Teng H, Lin H, Chang S, Lan Y, Wang H, Yang S, Chen W, Jiang J. A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer. Front Oncol 2022;12:808808. [DOI: 10.3389/fonc.2022.808808] [Reference Citation Analysis]
152 Zhang X, Wu T, Cai X, Dong J, Xia C, Zhou Y, Ding R, Yang R, Tan J, Zhang L, Zhang Y, Wang Y, Dong C, Li Y. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities. Front Immunol 2022;13:795972. [DOI: 10.3389/fimmu.2022.795972] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
153 Nieuwenhuizen S, Dijkstra M, Puijk RS, Geboers B, Ruarus AH, Schouten EA, Nielsen K, de Vries JJJ, Bruynzeel AME, Scheffer HJ, van den Tol MP, Haasbeek CJA, Meijerink MR. Microwave Ablation, Radiofrequency Ablation, Irreversible Electroporation, and Stereotactic Ablative Body Radiotherapy for Intermediate Size (3-5 cm) Unresectable Colorectal Liver Metastases: a Systematic Review and Meta-analysis. Curr Oncol Rep 2022. [PMID: 35298796 DOI: 10.1007/s11912-022-01248-6] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
154 Wang L, Qiao Y, Zong H, Han L, Ke Y, Pan Z, Chen J, Lu J, Li J, Ying T, Zhang B, Zhu J. IgG-like Bispecific Antibody CD3×EpCAM Generated by Split Intein Against Colorectal Cancer. Front Pharmacol 2022;13:803059. [PMID: 35281893 DOI: 10.3389/fphar.2022.803059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
155 Bijlstra OD, Boreel MME, van Mossel S, Burgmans MC, Kapiteijn EHW, Oprea-lager DE, Rietbergen DDD, van Velden FHP, Vahrmeijer AL, Swijnenburg R, Mieog JSD, de Geus-oei L. The Value of 18F-FDG-PET-CT Imaging in Treatment Evaluation of Colorectal Liver Metastases: A Systematic Review. Diagnostics 2022;12:715. [DOI: 10.3390/diagnostics12030715] [Reference Citation Analysis]
156 Vogl TJ, Lahrsow M. The Role of Conventional TACE (cTACE) and DEBIRI-TACE in Colorectal Cancer Liver Metastases. Cancers (Basel) 2022;14:1503. [PMID: 35326651 DOI: 10.3390/cancers14061503] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
157 Topi G, Ghatak S, Satapathy SR, Ehrnström R, Lydrup M, Sjölander A. Combined Estrogen Alpha and Beta Receptor Expression Has a Prognostic Significance for Colorectal Cancer Patients. Front Med 2022;9:739620. [DOI: 10.3389/fmed.2022.739620] [Reference Citation Analysis]
158 Palmieri L, Buchler T, Meyer A, Veskrnova V, Fiala O, Brabec P, Baranova J, Coriat R. Impact of Delaying the Addition of Anti-EGFR in First Line of RAS Wild-Type Metastatic Colorectal Cancer: A Propensity-Weighted Pooled Data Analysis. Cancers 2022;14:1410. [DOI: 10.3390/cancers14061410] [Reference Citation Analysis]
159 Vietti Violi N, Hajri R, Haefliger L, Nicod-Lalonde M, Villard N, Dromain C. Imaging of Oligometastatic Disease. Cancers (Basel) 2022;14:1427. [PMID: 35326586 DOI: 10.3390/cancers14061427] [Reference Citation Analysis]
160 Kovács A, Bischoff P, Haddad H, Zhou W, Temming S, Schäfer A, Spallek H, Kaupe L, Kovács G, Pinkawa M. Long-Term Comparative Study on the Local Tumour Control of Different Ablation Technologies in Primary and Secondary Liver Malignancies. JPM 2022;12:430. [DOI: 10.3390/jpm12030430] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
161 Catalano F, Borea R, Puglisi S, Boutros A, Gandini A, Cremante M, Martelli V, Sciallero S, Puccini A. Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer. Cancers (Basel) 2022;14:1388. [PMID: 35326540 DOI: 10.3390/cancers14061388] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
162 Osterlund E, Ristimäki A, Kytölä S, Kuopio T, Heervä E, Muhonen T, Halonen P, Kallio R, Soveri LM, Sundström J, Keinänen M, Ålgars A, Ristamäki R, Sorbye H, Pfeiffer P, Nunes L, Salminen T, Lamminmäki A, Mäkinen MJ, Sjöblom T, Isoniemi H, Glimelius B, Osterlund P. KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer. Front Oncol 2022;12:826073. [PMID: 35251991 DOI: 10.3389/fonc.2022.826073] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
163 Archwamety A, Teeyapun N, Siripoon T, Poungvarin N, Tanasanvimon S, Sirachainan E, Akewanlop C, Korphaisarn K. Effect of Primary Tumor Location on Second- or Later-Line Treatment With Anti-Epidermal Growth Factor Receptor Antibodies in Patients With Metastatic Colorectal Cancer: A Retrospective Multi-Center Study. Front Oncol 2022;12:813009. [PMID: 35242708 DOI: 10.3389/fonc.2022.813009] [Reference Citation Analysis]
164 Angerilli V, Sabella G, Centonze G, Lonardi S, Bergamo F, Mangogna A, Pietrantonio F, Fassan M, Milione M. BRAF-mutated colorectal adenocarcinomas: pathological heterogeneity and clinical implications. Crit Rev Oncol Hematol 2022;:103647. [PMID: 35248712 DOI: 10.1016/j.critrevonc.2022.103647] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
165 Strickler JH, Yoshino T, Graham RP, Siena S, Bekaii-Saab T. Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer: A Review. JAMA Oncol 2022. [PMID: 35238866 DOI: 10.1001/jamaoncol.2021.8196] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
166 Morató O, Villamonte M, Sánchez-velázquez P, Pueyo-périz E, Grande L, Ielpo B, Rosso E, Anselmo A, Burdío F. KRAS Assessment Following ESMO Recommendations for Colorectal Liver Metastases. Is It Always Worth It? Healthcare 2022;10:472. [DOI: 10.3390/healthcare10030472] [Reference Citation Analysis]
167 Liang Y, Liang J, Lin B, Huang J, Hung J, Lai S, Chen T, Tsai J, Cheng Y, Tsao T, Hsu W, Chen K, Yeh K. Ramucirumab plus triplet chemotherapy as an alternative salvage treatment for patients with metastatic colorectal cancer. Journal of the Formosan Medical Association 2022. [DOI: 10.1016/j.jfma.2022.02.019] [Reference Citation Analysis]
168 Øgaard N, Reinert T, Henriksen TV, Frydendahl A, Aagaard E, Ørntoft MW, Larsen MØ, Knudsen AR, Mortensen FV, Andersen CL. Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study. European Journal of Cancer 2022;163:163-76. [DOI: 10.1016/j.ejca.2021.12.026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
169 Hamers PA, Vink GR, Elferink MA, Stellato RK, Dijksterhuis WP, Punt CJ, Koopman M, May AM, Beerepoot LV, Creemers G, van Cruijsen H, de Groot JWB, van Halteren HK, Helgason HH, Hendriks MP, Hoekstra R, van Huis-tanja LH, Kapiteijn E, Los M, van Meerten E, Peters NA, Pruijt JF, van Ufford-mannesse PQ, Sie MP, Sommeijer DW, Spierings LE, Terheggen F, Tjin-a-ton ML, Valkenburg-van Iersel LB, van Voorthuizen T, de Vos-geelen J, Vulink AJ, J van de Wouw A. Quality of life and survival of metastatic colorectal cancer patients treated with trifluridine-tipiracil (QUALITAS). Clinical Colorectal Cancer 2022. [DOI: 10.1016/j.clcc.2022.03.002] [Reference Citation Analysis]
170 Roset M, Amonkar M, Patel R, Lara N, Kothari S. Real-World Treatment Patterns and Clinical Outcomes for Standard of Care Regimens in Patients with Deficient MMR or MSI-High Metastatic Colorectal and Non-Colorectal Cancer: A Retrospective Chart Review Study in France. Adv Ther 2022;39:1215-29. [PMID: 35025060 DOI: 10.1007/s12325-021-01956-8] [Reference Citation Analysis]
171 Strömberg C, Martinez de la Maza L, Fernández Moro C, Gerling M, Jorns C, Sparrelid E, Löhr J, Villard C. Prognostic impact of inter-metastatic heterogeneity of viable tumour cells in colorectal liver metastases. European Journal of Surgical Oncology 2022. [DOI: 10.1016/j.ejso.2022.03.004] [Reference Citation Analysis]
172 Engstrand J, Sterner J, Hasselgren K, Stromberg C, Sturesson C. Treatment intention and outcome in patients with simultaneously diagnosed liver and lung metastases from colorectal cancer. European Journal of Surgical Oncology 2022. [DOI: 10.1016/j.ejso.2022.03.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
173 Osterlund P, Kinos S, Pfeiffer P, Salminen T, Kwakman J, Frödin J, Shah C, Sorbye H, Ristamäki R, Halonen P, Soveri L, Heervä E, Ålgars A, Bärlund M, Hagman H, Mcdermott R, O’reilly M, Röckert R, Liposits G, Kallio R, Flygare P, Teske A, van Werkhoven E, Punt C, Glimelius B. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study. ESMO Open 2022. [DOI: 10.1016/j.esmoop.2022.100427] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
174 Wind KL, Serup-Hansen E, Havelund BM, Riber L, Kronborg CJS, Jakobsen A, Spindler KG. Definitive therapy for squamous cell carcinoma of the anus with synchronous metastases - a report from the Danish Anal Cancer Group. Acta Oncol 2022;61:321-7. [PMID: 34818978 DOI: 10.1080/0284186X.2021.1999497] [Reference Citation Analysis]
175 Minier C, Hermida M, Allimant C, Escal L, Pierredon-Foulongne MA, Belgour A, Piron L, Taourel P, Cassinotto C, Guiu B. Software-based assessment of tumor margins after percutaneous thermal ablation of liver tumors: A systematic review. Diagn Interv Imaging 2022:S2211-5684(22)00033-X. [PMID: 35246412 DOI: 10.1016/j.diii.2022.02.004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
176 Aliseda D, Martí-Cruchaga P, Zozaya G, Benito A, Lopez-Olaondo L, Rodríguez-Fraile M, Bilbao JI, Hidalgo F, Iñarrairaegui M, Ciria R, Pardo F, Sangro B, Rotellar F. Pure laparoscopic major liver resection after yttrium90 radioembolization: a case-matched series analysis of feasibility and outcomes. Langenbecks Arch Surg 2022. [PMID: 35229168 DOI: 10.1007/s00423-022-02474-z] [Reference Citation Analysis]
177 Mccleary NJ, Harmsen WS, Haakenstad E, Cleary JM, Meyerhardt JA, Zalcberg J, Adams R, Grothey A, Sobrero AF, Van Cutsem E, Goldberg RM, Peeters M, Tabernero J, Seymour M, Saltz LB, Giantonio BJ, Arnold D, Rothenberg ML, Koopman M, Schmoll H, Pitot HC, Hoff PM, Tebbutt N, Masi G, Souglakos J, Bokemeyer C, Heinemann V, Yoshino T, Chibaudel B, deGramont A, Shi Q, Lichtman SM. Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. JNCI Cancer Spectrum 2022;6:pkac014. [DOI: 10.1093/jncics/pkac014] [Reference Citation Analysis]
178 Amatu A, Mauri G, Tosi F, Bencardino K, Bonazzina E, Gori V, Ruggieri L, Arena S, Bardelli A, Marsoni S, Siena S, Sartore-bianchi A. Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study. Cancers 2022;14:1197. [DOI: 10.3390/cancers14051197] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
179 Matsumura M, Hasegawa K, Oba M, Yamaguchi K, Uetake H, Yoshino T, Morita S, Takahashi K, Unno M, Shimada Y, Muro K, Matsuhashi N, Mori M, Baba H, Shimada M, Mise Y, Kawaguchi Y, Kagimura T, Ishigure K, Saiura A, Sugihara K, Kokudo N. A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study. Langenbecks Arch Surg 2022. [PMID: 35211831 DOI: 10.1007/s00423-022-02434-7] [Reference Citation Analysis]
180 Baldin P, Carrasco J, Beniuga G, Jouret-Mourin A, Demolin G, Roland S, D'Hondt L, Vergauwe P, Van Daele D, Mailleux M, Sinapi I, De Cuyper A, Blétard N, Massart B, Delos M, Castella ML, van Maanen A, Van den Eynde M. Randomized Phase 2 Study Comparing Pathological Responses of Resected Colorectal Cancer Metastases after Bevacizumab with mFOLFOX6 or FOLFIRI (BEV-ONCO Trial). Cancers (Basel) 2022;14:1183. [PMID: 35267491 DOI: 10.3390/cancers14051183] [Reference Citation Analysis]
181 Conradi LC, Ghadimi M. [Oncological surgery in the interdisciplinary context-On the way to personalized medicine]. Chirurg 2022. [PMID: 35201386 DOI: 10.1007/s00104-022-01614-x] [Reference Citation Analysis]
182 Samoon Z, Naher SK, Sjoquist KM, Zalcberg J. Chemotherapy in resectable or potentially resectable colon cancer with liver metastases. Expert Opin Pharmacother 2022;:1-10. [PMID: 35196945 DOI: 10.1080/14656566.2022.2043276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
183 Chen K, Wang H, Collins G, Hollands E, Law IYJ, Toh JWT. Current Perspectives on the Importance of Pathological Features in Prognostication and Guidance of Adjuvant Chemotherapy in Colon Cancer. Current Oncology 2022;29:1370-89. [DOI: 10.3390/curroncol29030116] [Reference Citation Analysis]
184 Xu D, Zhu H, Wang Y, Jin K, Yan X, Li J, Wang K, Xing B. Perioperative second-line chemotherapy is beneficial for resectable liver metastases that occur during or early after adjuvant chemotherapy for colorectal cancer. Int J Colorectal Dis. [DOI: 10.1007/s00384-022-04111-z] [Reference Citation Analysis]
185 Costa G, Torzilli G, Sorrentino M, Donadon M. Horseshoe hepatectomy : Another step pursuing the concept of parenchyma sparing major hepatectomies. Updates Surg 2022. [PMID: 35175537 DOI: 10.1007/s13304-022-01242-4] [Reference Citation Analysis]
186 Vigano L, Terrone A, Costa G, Franchi E, Cimino M, Procopio F, Del Fabbro D, Torzilli G. Effect of chemotherapy on tumour-vessel relationship in colorectal liver metastases. Br J Surg 2022:znac010. [PMID: 35165692 DOI: 10.1093/bjs/znac010] [Reference Citation Analysis]
187 Sorrentino C, D'Antonio L, Fieni C, Ciummo SL, Di Carlo E. Colorectal Cancer-Associated Immune Exhaustion Involves T and B Lymphocytes and Conventional NK Cells and Correlates With a Shorter Overall Survival. Front Immunol 2021;12:778329. [PMID: 34975867 DOI: 10.3389/fimmu.2021.778329] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
188 Siesing C, Petersson A, Ulfarsdottir T, Chattopadhyay S, Nodin B, Eberhard J, Brändstedt J, Syk I, Gisselsson D, Jirström K. Delineating the intra-patient heterogeneity of molecular alterations in treatment-naïve colorectal cancer with peritoneal carcinomatosis. Mod Pathol 2022. [PMID: 35169225 DOI: 10.1038/s41379-022-01012-y] [Reference Citation Analysis]
189 Sougklakos I, Athanasiadis E, Boukovinas I, Karamouzis M, Koutras A, Papakotoulas P, Latsou D, Hatzikou M, Stamuli E, Balasopoulos A, Sideris A. Treatment pathways and associated costs of metastatic colorectal cancer in Greece. Cost Eff Resour Alloc 2022;20. [DOI: 10.1186/s12962-022-00339-2] [Reference Citation Analysis]
190 Viganò L, Jayakody Arachchige VS, Fiz F. Is precision medicine for colorectal liver metastases still a utopia? New perspectives by modern biomarkers, radiomics, and artificial intelligence. World J Gastroenterol 2022; 28(6): 608-623 [DOI: 10.3748/wjg.v28.i6.608] [Reference Citation Analysis]
191 Spallek H, Bischoff P, Zhou W, de Terlizzi F, Jakob F, Kovàcs A. Percutaneous electrochemotherapy in primary and secondary liver malignancies - local tumor control and impact on overall survival. Radiol Oncol 2022;56:102-10. [PMID: 35148468 DOI: 10.2478/raon-2022-0003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
192 Watanabe G, Mise Y, Oba M, Saiura A, Inoue Y, Takahashi Y, Kishi Y, Suyama K, Takayama T, Noie T, Nishioka Y, Akamatsu N, Arita J, Kokudo N, Hasegawa K. A multicenter phase II trial evaluating the efficacy of bevacizumab plus mFOLFOX6 for R0 surgical resection in advanced colorectal liver metastases harboring mutant-type KRAS: NEXTO-mt trial. HPB (Oxford) 2022:S1365-182X(22)00052-1. [PMID: 35216869 DOI: 10.1016/j.hpb.2022.02.001] [Reference Citation Analysis]
193 Weiss L, Karthaus M, Riera-Knorrenschild J, Kretzschmar A, Welslau M, Vehling-Kaiser U, Pelz H, Ettrich TJ, Hess J, Reisländer T, Klein A, Heinemann V; TALLISUR study group. Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial. ESMO Open 2022;7:100391. [PMID: 35149429 DOI: 10.1016/j.esmoop.2022.100391] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
194 Hallermayr A, Steinke-Lange V, Vogelsang H, Rentsch M, de Wit M, Haberl C, Holinski-Feder E, Pickl JMA. Clinical Validity of Circulating Tumor DNA as Prognostic and Predictive Marker for Personalized Colorectal Cancer Patient Management. Cancers (Basel) 2022;14:851. [PMID: 35159118 DOI: 10.3390/cancers14030851] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
195 Ros J, Saoudi N, Salvà F, Baraibar I, Alonso G, Tabernero J, Elez E. Ongoing and evolving clinical trials enhancing future colorectal cancer treatment strategies. Expert Opin Investig Drugs 2022. [PMID: 35133234 DOI: 10.1080/13543784.2022.2040016] [Reference Citation Analysis]
196 Nicolazzo C, Belardinilli F, Vestri A, Magri V, De Renzi G, De Meo M, Caponnetto S, Di Nicolantonio F, Cortesi E, Giannini G, Gazzaniga P. RAS Mutation Conversion in Bevacizumab-Treated Metastatic Colorectal Cancer Patients: A Liquid Biopsy Based Study. Cancers (Basel) 2022;14:802. [PMID: 35159069 DOI: 10.3390/cancers14030802] [Reference Citation Analysis]
197 Rodríguez-Fanjul V, Guerrero-López R, Fernández-Varas B, Perona R, Sastre-Perona A, Sastre L. Comparison of Colorectal Cancer Stem Cells and Oxaliplatin-Resistant Cells Unveils Functional Similarities. Cells 2022;11:511. [PMID: 35159320 DOI: 10.3390/cells11030511] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
198 Shen C, Hu H, Cai Y, Ling J, Zhang J, Wu Z, Xie X, Huang M, Wang H, Kang L, Lan P, Wu X, Liu G, Wan Y, Zhou Z, Huang Y, Li F, Wang H, Ma T, Luo S, Cai Y, Shi L, Deng Y. mFOLFOXIRI with or without bevacizumab for conversion therapy of RAS/BRAF/PIK3CA mutant unresectable colorectal liver metastases: the FORBES non-randomized phase II trial. Ann Transl Med 2022;10:171. [PMID: 35280386 DOI: 10.21037/atm-21-6731] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
199 Imyanitov EN, Iyevleva AG. Molecular tests for prediction of tumor sensitivity to cytotoxic drugs. Cancer Lett 2022;526:41-52. [PMID: 34808283 DOI: 10.1016/j.canlet.2021.11.021] [Reference Citation Analysis]
200 Rashad N, Abdulla M, Farouk M, Elkerm Y, Eid Salem S, Yehia M, Saad AS, Abdel Aziz AH, Refaat G, Awad I, Elnaggar M, Kamal K, Refky B, Abdelkhalek M, Touny A, Kassem L, Shash E, Abdelhay AA, Mahmoud BE, Oualla K, Chraiet N, Awadelkarim H Maki H, Kader YA. Resource Oriented Decision Making for Treatment of Metastatic Colorectal Cancer (mCRC) in a Lower-Middle Income Country: Egyptian Foundation of Medical Sciences (EFMS) Consensus Recommendations 2020. CMAR 2022;Volume 14:821-42. [DOI: 10.2147/cmar.s340030] [Reference Citation Analysis]
201 Lopez-Lopez V, Garcia-Lopez J, Eshmuminov D, Brusadin R, Lopez-Conesa A, Martinez-Insfran L, Fernández-Fernández P, Robles-Campos R. Left renal vein graft and in situ hepatic perfusion in hepatectomy for complete tumor invasion of hepatic veins: hemodynamic optimization and surgical technique. Langenbecks Arch Surg 2022. [PMID: 35102435 DOI: 10.1007/s00423-022-02451-6] [Reference Citation Analysis]
202 Talaat IM, Elemam NM, Saber-ayad M. Complement System: An Immunotherapy Target in Colorectal Cancer. Front Immunol 2022;13:810993. [DOI: 10.3389/fimmu.2022.810993] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
203 De Cobelli F, Calandri M, Della Corte A, Sirovich R, Gazzera C, Della Vigna P, Bonomo G, Varano GM, Maiettini D, Mauri G, Camisassi N, Steidler S, Ratti F, Gusmini S, Ronzoni M, Aldrighetti L, Odisio BC, Racca P, Fonio P, Veltri A, Orsi F. Multi-institutional analysis of outcomes for thermosphere microwave ablation treatment of colorectal liver metastases: the SMAC study. Eur Radiol. [DOI: 10.1007/s00330-021-08497-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
204 Garcia-vicién G, Mezheyeuski A, Micke P, Ruiz N, Ruffinelli JC, Mils K, Bañuls M, Molina N, Losa F, Lladó L, Molleví DG. Spatial Immunology in Liver Metastases from Colorectal Carcinoma according to the Histologic Growth Pattern. Cancers 2022;14:689. [DOI: 10.3390/cancers14030689] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
205 da Silva Dias D, Machado M, Trabulo C, Gosálbez B, Ravasco P. Impact of Body Composition on Prognosis and Dose-Limiting Toxicities on Metastatic Colorectal Cancer. Front Nutr 2022;8:671547. [DOI: 10.3389/fnut.2021.671547] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
206 Shen Y, Yang T, Zeng H, Meng W, Wang Z. Is it worthwhile to perform closure of the pelvic peritoneum in laparoscopic extralevator abdominoperineal resection? Langenbecks Arch Surg 2022. [PMID: 35083567 DOI: 10.1007/s00423-021-02412-5] [Reference Citation Analysis]
207 Duval L, Lam YH, Pons-Tostivint E, Bennouna J, Matysiak-Budnik T, Lepeintre A, Girot P, Touchefeu Y. [Re-visiting the Pronopall score ten years later: A multicenter retrospective study]. Bull Cancer 2022:S0007-4551(22)00016-9. [PMID: 35094840 DOI: 10.1016/j.bulcan.2021.12.016] [Reference Citation Analysis]
208 Lee SW, Park HL, Yoon N, Kim JH, Oh JK, Buyn JH, Choi EK, Hong JH. Prognostic Impact of Total Lesion Glycolysis (TLG) from Preoperative 18F-FDG PET/CT in Stage II/III Colorectal Adenocarcinoma: Extending the Value of PET/CT for Resectable Disease. Cancers (Basel) 2022;14:582. [PMID: 35158851 DOI: 10.3390/cancers14030582] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
209 Shi M, Yuan H, Ji J, Zhang S, Li Q, Chen Y, Gong X, Zhu Z, Zhang J. Mutational landscape of circulating tumor DNA identifies distinct molecular features associated with therapeutic response in patients with metastatic colorectal cancer. Ther Adv Med Oncol 2022;14:175883592110706. [DOI: 10.1177/17588359211070643] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
210 Koopman M, Pinto C, Bodoky G, Garcia-carbonero R, Marti F, Bachet J. Rationale and design of the PROMETCO study: a real-world, prospective, longitudinal cohort on the continuum of care of metastatic colorectal cancer from a clinical and patient perspective. Future Oncology. [DOI: 10.2217/fon-2021-1333] [Reference Citation Analysis]
211 Riedesser JE, Ebert MP, Betge J. Precision medicine for metastatic colorectal cancer in clinical practice. Ther Adv Med Oncol 2022;14:175883592110727. [DOI: 10.1177/17588359211072703] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
212 Gruijs M, Braster R, Overdijk MB, Hellingman T, Verploegen S, Korthouwer R, van der Wilk BJ, Parren PWHI, van der Vliet HJ, Bögels M, van Egmond M. Epidermal Growth Factor Receptor as Target for Perioperative Elimination of Circulating Colorectal Cancer Cells. J Oncol 2022;2022:3577928. [PMID: 35035479 DOI: 10.1155/2022/3577928] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
213 Tufail M, Wu C. Targeting the IGF-1R in prostate and colorectal cancer: reasons behind trial failure and future directions. Ther Deliv 2022. [PMID: 35029130 DOI: 10.4155/tde-2021-0060] [Reference Citation Analysis]
214 Papamichael D, Lopes GS, Olswold CL, Douillard JY, Adams RA, Maughan TS, Van Cutsem E, Venook AP, Lenz HJ, Heinemann V, Kaplan R, Bokemeyer C, Chibaudel B, Grothey A, Yoshino T, Zalcberg J, De Gramont A, Shi Q. Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years. Eur J Cancer 2022;163:1-15. [PMID: 35033994 DOI: 10.1016/j.ejca.2021.12.007] [Reference Citation Analysis]
215 Qin S, Hu H, Cui R, Lin J, Liu Y, Wang Y, Chen Y, Liu G. A prognostic nomogram for intrahepatic progression-free survival in patients with colorectal liver metastases after ultrasound-guided percutaneous microwave ablation. Int J Hyperthermia 2022;39:144-54. [PMID: 35012413 DOI: 10.1080/02656736.2021.2023226] [Reference Citation Analysis]
216 Hamed RA, Marks S, Mcelligott H, Kalachand R, Ibrahim H, Atyani S, Korpanty G, Osman N. Inoperable de novo metastatic colorectal cancer with primary tumour in situ: Evaluating discordant responses to upfront systemic therapy of the primary tumours and metastatic sites and complications arising from primary tumours (experiences from an Irish Cancer Centre). Mol Clin Oncol 2022;16:40. [PMID: 35003738 DOI: 10.3892/mco.2021.2472] [Reference Citation Analysis]
217 Radosevic A, Quesada R, Serlavos C, Sánchez J, Zugazaga A, Sierra A, Coll S, Busto M, Aguilar G, Flores D, Arce J, Maiques JM, Garcia-Retortillo M, Carrion JA, Visa L, Villamonte M, Pueyo E, Berjano E, Trujillo M, Sánchez-Velázquez P, Grande L, Burdio F. Microwave versus radiofrequency ablation for the treatment of liver malignancies: a randomized controlled phase 2 trial. Sci Rep 2022;12:316. [PMID: 35013377 DOI: 10.1038/s41598-021-03802-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
218 Matsui Y, Hamada M, Matsumi Y, Sekimoto M, Ishida M, Satake H, Kurokawa H, Kinoshita H. Curative resection of ureteral metastasis of rectal cancer: a case report and review of literature. Clin J Gastroenterol 2022. [PMID: 35001357 DOI: 10.1007/s12328-021-01568-3] [Reference Citation Analysis]
219 Pernot S, Pellerin O, Mineur L, Monterymard C, Smith D, Lapuyade B, Gallois C, Khemissa Akouz F, De Baere T, Tougeron D, Thirot-Bidault A, Audemar F, Simon M, Lecaille C, Louafi S, Lepage C, Ducreux M, Taieb J. Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49. Dig Liver Dis 2022:S1590-8658(21)00898-7. [PMID: 35027324 DOI: 10.1016/j.dld.2021.12.012] [Reference Citation Analysis]
220 Akhoundova D, Pietge H, Hussung S, Kiessling M, Britschgi C, Zoche M, Rechsteiner M, Weber A, Fritsch RM. Targeting Secondary and Tertiary Resistance to BRAF Inhibition in BRAF V600E-Mutated Metastatic Colorectal Cancer. JCO Precis Oncol 2021;5:1082-7. [PMID: 34994629 DOI: 10.1200/PO.21.00107] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
221 Reinert T, Petersen LMS, Henriksen TV, Larsen MØ, Rasmussen MH, Johansen AFB, Øgaard N, Knudsen M, Nordentoft I, Vang S, Krag SRP, Knudsen AR, Mortensen FV, Andersen CL. Circulating tumor DNA for prognosis assessment and postoperative management after curative-intent resection of colorectal liver metastases. Int J Cancer 2022. [PMID: 34994972 DOI: 10.1002/ijc.33924] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
222 Ychou M, Rivoire M, Thezenas S, Guimbaud R, Ghiringhelli F, Mercier-Blas A, Mineur L, Francois E, Khemissa F, Chauvenet M, Kianmanesh R, Fonck M, Houyau P, Aparicio T, Galais MP, Audemar F, Assenat E, Lopez-Crapez E, Jouffroy C, Adenis A, Adam R, Bouché O. Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial. Br J Cancer 2022. [PMID: 34992255 DOI: 10.1038/s41416-021-01644-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
223 Damato A, Bergamo F, Antonuzzo L, Nasti G, Iachetta F, Romagnani A, Gervasi E, Larocca M, Pinto C. FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial. Front Oncol 2021;11:766500. [PMID: 34970487 DOI: 10.3389/fonc.2021.766500] [Reference Citation Analysis]
224 Reynolds IS, Cromwell PM, Walshe JM, Crown J, Maguire D, Geoghegan J, Swan N, Hoti E. Hepatic resection for breast cancer related liver metastases: A single institution experience. Scand J Surg 2022;111:14574969221088685. [PMID: 35322733 DOI: 10.1177/14574969221088685] [Reference Citation Analysis]
225 Jonsson J, Hemmingsson O, Strengbom R, Axelsson J, Riklund K, Nyström H. Does 18F-FDG PET/CT change the surgical management of potentially resectable colorectal liver metastases? Scand J Surg 2022;111:14574969221083144. [PMID: 35348393 DOI: 10.1177/14574969221083144] [Reference Citation Analysis]
226 Sousa MD, Gomes I, Pereira TC, Magalhães J, Basto R, Paulo J, Jacinto P, Bonito N, Sousa G. The effect of prognostic factors at baseline on the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer: A Portuguese exploratory analysis. Cancer Treatment and Research Communications 2022;31:100531. [DOI: 10.1016/j.ctarc.2022.100531] [Reference Citation Analysis]
227 Cheng K, Zhou YW, Chen Y, Li ZP, Qiu M, Liu JY. Biweekly Raltitrexed Combined With Irinotecan as Second-Line Therapy for Patients With Metastatic Colorectal Cancer: A Phase II Trial. Cancer Control 2022;29:10732748221080332. [PMID: 35343258 DOI: 10.1177/10732748221080332] [Reference Citation Analysis]
228 Bourhis A, Remoué A, Samaison L, Uguen A. Diagnostic mutationnel rapide Idylla™ : applications théranostiques actuelles et futures. Annales de Pathologie 2022. [DOI: 10.1016/j.annpat.2021.12.007] [Reference Citation Analysis]
229 Mangiapane LR, Nicotra A, Turdo A, Gaggianesi M, Bianca P, Di Franco S, Sardina DS, Veschi V, Signore M, Beyes S, Fagnocchi L, Fiori ME, Bongiorno MR, Lo Iacono M, Pillitteri I, Ganduscio G, Gulotta G, Medema JP, Zippo A, Todaro M, De Maria R, Stassi G. PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells. Gut 2022;71:119-28. [PMID: 33436496 DOI: 10.1136/gutjnl-2020-323553] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 12.0] [Reference Citation Analysis]
230 Parisi A, Ghidini M, Giampieri R, Tomasello G, Luciani A, Ferri C, Berardi R, Petrelli F. Post-induction strategies in metastatic colorectal cancer patients treated with first-line anti-EGFR-based treatment: a systematic review and meta-analysis. Clinical Colorectal Cancer 2022. [DOI: 10.1016/j.clcc.2021.12.005] [Reference Citation Analysis]
231 Nagai Y, Kiyomatsu T, Gohda Y, Otani K, Deguchi K, Yamada K. The primary tumor location in colorectal cancer: A focused review on its impact on surgical management. Glob Health Med 2021;3:386-93. [PMID: 35036620 DOI: 10.35772/ghm.2020.01096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
232 Di Martino M, Dorcaratto D, Primavesi F, Syn N, Blanco-Terés L, Dupré A, Piardi T, Rhaiem R, Fernández GB, De Armas Conde N, Rodríguez Sanjuán JC, Santiago RF, Fernández-Moreno MC, Ferret G, Ben SL, Suárez Muñoz MÁ, Perez-Alonso AJ, Koh YX, Jones R, Vennarecci G, Martín-Pérez E. Liver resection in elderly patients with extensive CRLM: Are we offering an adequate treatment? A propensity score matched analysis. Eur J Surg Oncol 2021:S0748-7983(21)01000-3. [PMID: 35000821 DOI: 10.1016/j.ejso.2021.12.028] [Reference Citation Analysis]
233 Borie F, Dubray V, Tretarre B. Impact of recommendations and new therapies on the prognosis of colon cancer with synchronous liver metastasis. Clin Res Hepatol Gastroenterol 2021;:101856. [PMID: 34963650 DOI: 10.1016/j.clinre.2021.101856] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
234 Maclean D, Tsakok M, Gleeson F, Breen DJ, Goldin R, Primrose J, Harris A, Franklin J. Comprehensive Imaging Characterization of Colorectal Liver Metastases. Front Oncol 2021;11:730854. [PMID: 34950575 DOI: 10.3389/fonc.2021.730854] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
235 Hu F, Wang J, Zhang M, Wang S, Zhao L, Yang H, Wu J, Cui B. Comprehensive Analysis of Subtype-Specific Molecular Characteristics of Colon Cancer: Specific Genes, Driver Genes, Signaling Pathways, and Immunotherapy Responses. Front Cell Dev Biol 2021;9:758776. [PMID: 34912802 DOI: 10.3389/fcell.2021.758776] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
236 Acciuffi S, Meyer F, Bauschke A, Croner R, Settmacher U, Altendorf-Hofmann A. Solitary colorectal liver metastasis: overview of treatment strategies and role of prognostic factors. J Cancer Res Clin Oncol 2021. [PMID: 34914005 DOI: 10.1007/s00432-021-03880-4] [Reference Citation Analysis]
237 Kastrisiou M, Zarkavelis G, Kougioumtzi A, Sakaloglou P, Kostoulas C, Georgiou I, Batistatou A, Pentheroudakis G, Magklara A. Development and Validation of a Targeted ‘Liquid’ NGS Panel for Treatment Customization in Patients with Metastatic Colorectal Cancer. Diagnostics 2021;11:2375. [DOI: 10.3390/diagnostics11122375] [Reference Citation Analysis]
238 Eigeliene N, Saarenheimo J, Wichmann V, Österlund P, Jekunen A. Metastatic Rectal Carcinoma with Long-Term Remission due to Modern Multimodality Treatment. Case Rep Oncol 2021;14:1475-82. [PMID: 34899239 DOI: 10.1159/000519044] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
239 Chen K, Collins G, Wang H, Toh JWT. Pathological Features and Prognostication in Colorectal Cancer. Curr Oncol 2021;28:5356-83. [PMID: 34940086 DOI: 10.3390/curroncol28060447] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
240 Walter F, Rottler M, Nierer L, Landry G, Well J, Rogowski P, Mohnike K, Seidensticker M, Ricke J, Belka C, Corradini S. Interstitial High-Dose-Rate Brachytherapy of Liver Metastases in Oligometastatic Patients. Cancers (Basel) 2021;13:6250. [PMID: 34944869 DOI: 10.3390/cancers13246250] [Reference Citation Analysis]
241 Hu LF, Lan HR, Huang D, Li XM, Jin KT. Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand? Front Oncol 2021;11:769305. [PMID: 34888246 DOI: 10.3389/fonc.2021.769305] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
242 Hu M, Gu J, Su W, Zhang Z, Zhu B, Wang Q, Xing C. DNM1: A Prognostic Biomarker Associated with Immune Infiltration in Colon Cancer-A Study Based on TCGA Database. Biomed Res Int 2021;2021:4896106. [PMID: 34888380 DOI: 10.1155/2021/4896106] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
243 Rebersek M. Gut microbiome and its role in colorectal cancer. BMC Cancer 2021;21:1325. [PMID: 34895176 DOI: 10.1186/s12885-021-09054-2] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
244 Nalli M, Puxeddu M, La Regina G, Gianni S, Silvestri R. Emerging Therapeutic Agents for Colorectal Cancer. Molecules 2021;26:7463. [DOI: 10.3390/molecules26247463] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
245 Huang YH, Lin PC, Su WC, Chan RH, Chen PC, Lin BW, Shen MR, Chen SH, Yeh YM. Association between Altered Oncogenic Signaling Pathways and Overall Survival of Patients with Metastatic Colorectal Cancer. Diagnostics (Basel) 2021;11:2308. [PMID: 34943546 DOI: 10.3390/diagnostics11122308] [Reference Citation Analysis]
246 Ruiter SJS, Tinguely P, Paolucci I, Engstrand J, Candinas D, Weber S, de Haas RJ, de Jong KP, Freedman J. 3D Quantitative Ablation Margins for Prediction of Ablation Site Recurrence After Stereotactic Image-Guided Microwave Ablation of Colorectal Liver Metastases: A Multicenter Study. Front Oncol 2021;11:757167. [PMID: 34868968 DOI: 10.3389/fonc.2021.757167] [Reference Citation Analysis]
247 Chen HH, Ke TW, Huang CW, Jiang JK, Chen CC, Hsieh YY, Teng HW, Lin BW, Liang YH, Su YL, Hsu HC, Kuan FC, Chou YH, Lin J, Lin BR, Chang YY, Wang JY. Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC Treatment. Front Oncol 2021;11:764912. [PMID: 34868987 DOI: 10.3389/fonc.2021.764912] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
248 Karas S, Innocenti F. All You Need to Know About UGT1A1 Genetic Testing for Patients Treated With Irinotecan: A Practitioner-Friendly Guide. JCO Oncol Pract 2021;:OP2100624. [PMID: 34860573 DOI: 10.1200/OP.21.00624] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
249 Ebeling Barbier C, Heindryckx F, Lennernäs H. Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma. Int J Mol Sci 2021;22:13051. [PMID: 34884853 DOI: 10.3390/ijms222313051] [Reference Citation Analysis]
250 Deng Y, Yu L, Zhao Y, Peng J, Xu Y, Qin J, Xiao B, Liu S, Li M, Fang Y, Pan Z. RCC1 Expression as a Prognostic Marker in Colorectal Liver Oligometastases. Pathol Oncol Res 2021;27:1610077. [DOI: 10.3389/pore.2021.1610077] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
251 Hu D, Pan Y, Chen G. Colorectal cancer liver metastases: An update of treatment strategy and future perspectives. Surgery in Practice and Science 2021;7:100042. [DOI: 10.1016/j.sipas.2021.100042] [Reference Citation Analysis]
252 Takeda Y, Mise Y, Takahashi Y, Ito H, Inoue Y, Yoshioka R, Ono Y, Saiura A. Limited Prognostic Value of KRAS in Patients Undergoing Hepatectomy for Colorectal Liver Metastases. Ann Surg Oncol 2021. [PMID: 34851437 DOI: 10.1245/s10434-021-11015-9] [Reference Citation Analysis]
253 Brincat A, Vella Bonanno P, Stewart D, Weidmann AE. Patients’ experiences of medicines on initiation of antineoplastic agents for the treatment of colorectal cancer: a qualitative study. BMJ Open 2021;11:e047749. [DOI: 10.1136/bmjopen-2020-047749] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
254 Heinemann V, Singh M, Hardtstock F, Hecker D, Lebioda A, Schaller-kranz T, Bartsch R. Assessment of Metastatic Colorectal Cancer Patients’ Preferences for Biologic Treatments in Germany Using a Discrete Choice Experiment. Clinical Colorectal Cancer 2021. [DOI: 10.1016/j.clcc.2021.12.002] [Reference Citation Analysis]
255 Chen M, Zhong K, Tan J, Meng M, Liu CM, Chen B, Huang C, Wong HLX, Bian Z, Su T, Kwan HY. Baicalein is a novel TLR4-targeting therapeutics agent that inhibits TLR4/HIF-1α/VEGF signaling pathway in colorectal cancer. Clin Transl Med 2021;11:e564. [PMID: 34841696 DOI: 10.1002/ctm2.564] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
256 Keil M, Conrad T, Becker M, Keilholz U, Yaspo ML, Lehrach H, Schütte M, Haybaeck J, Hoffmann J. Modeling of Personalized Treatments in Colon Cancer Based on Preclinical Genomic and Drug Sensitivity Data. Cancers (Basel) 2021;13:6018. [PMID: 34885128 DOI: 10.3390/cancers13236018] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
257 Folprecht G, Martinelli E, Mazard T, Modest DP, Tsuji A, Esser R, Cremolini C, Falcone A. Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives. Cancer Treat Rev 2022;102:102301. [PMID: 34839118 DOI: 10.1016/j.ctrv.2021.102301] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
258 Voutsadakis IA. Biomarkers of Trifluridine-Tipiracil Efficacy. J Clin Med 2021;10:5568. [PMID: 34884270 DOI: 10.3390/jcm10235568] [Reference Citation Analysis]
259 Tanaka Y, Yamaoka Y, Shiomi A, Kagawa H, Hino H, Manabe S, Chen K, Nanishi K, Notsu A. Clinical outcomes following colorectal resection of colorectal cancer with simultaneous hepatic and pulmonary metastases at the time of diagnosis. Langenbecks Arch Surg 2021. [PMID: 34821994 DOI: 10.1007/s00423-021-02385-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
260 Torres-Jiménez J, Esteban-Villarrubia J, Ferreiro-Monteagudo R, Carrato A. Local Treatments in the Unresectable Patient with Colorectal Cancer Metastasis: A Review from the Point of View of the Medical Oncologist. Cancers (Basel) 2021;13:5938. [PMID: 34885047 DOI: 10.3390/cancers13235938] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
261 Valenzuela G, Canepa J, Simonetti C, Solo de Zaldívar L, Marcelain K, González-Montero J. Consensus molecular subtypes of colorectal cancer in clinical practice: A translational approach. World J Clin Oncol 2021; 12(11): 1000-1008 [PMID: 34909395 DOI: 10.5306/wjco.v12.i11.1000] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
262 Čipak Gašparović A, Milković L, Rodrigues C, Mlinarić M, Soveral G. Peroxiporins Are Induced upon Oxidative Stress Insult and Are Associated with Oxidative Stress Resistance in Colon Cancer Cell Lines. Antioxidants (Basel) 2021;10:1856. [PMID: 34829727 DOI: 10.3390/antiox10111856] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
263 Moehler M, Folprecht G, Heinemann V, Holch JW, Maderer A, Kasper S, Hegewisch-Becker S, Schröder J, Overkamp F, Kullmann F, Bechstein WO, Vöhringer M, Öllinger R, Lordick F, Geißler M, Schulz-Abelius A, Linz B, Bernhard H, Paul A, Schmidtmann I, Potthoff K, Schimanski CC. Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3). Int J Cancer 2021. [PMID: 34807464 DOI: 10.1002/ijc.33881] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
264 Moslim MA, Jeyarajah DR. Narrative review of the role of yttrium-90 selective internal radiation therapy in the surgical management of colorectal liver metastases. J Gastrointest Oncol 2021;12:2438-46. [PMID: 34790404 DOI: 10.21037/jgo-21-96] [Reference Citation Analysis]
265 Alzahrani SM, Al Doghaither HA, Al-Ghafari AB. General insight into cancer: An overview of colorectal cancer (Review). Mol Clin Oncol 2021;15:271. [PMID: 34790355 DOI: 10.3892/mco.2021.2433] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
266 Gebauer F, Damanakis AI, Popp F, Quaas A, Kütting F, Lutz K, Held S, Deuß B, Göser T, Waldschmidt D, Bruns C. Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC). BMC Cancer 2021;21:1239. [PMID: 34794396 DOI: 10.1186/s12885-021-08966-3] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
267 Kim TW, Taieb J, Gurary EB, Lerman N, Cui K, Yoshino T. Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003. Future Oncol 2021;17:5013-22. [PMID: 34779646 DOI: 10.2217/fon-2021-0899] [Reference Citation Analysis]
268 Parisi A, Cortellini A, Venditti O, Filippi R, Salvatore L, Tortora G, Ghidini M, Nigro O, Gelsomino F, Zurlo IV, Fulgenzi C, Lombardi P, Roselló Keränen S, Depetris I, Giampieri R, Morelli C, Di Marino P, Di Pietro FR, Zanaletti N, Vitale P, Garajova I, Spinelli GP, Zoratto F, Roberto M, Petrillo A, Aimar G, Patruno L, D'Orazio C, Ficorella C, Ferri C, Porzio G. Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study. Front Oncol 2021;11:712053. [PMID: 34778029 DOI: 10.3389/fonc.2021.712053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
269 Tonello M, Baratti D, Sammartino P, Di Giorgio A, Robella M, Sassaroli C, Framarini M, Valle M, Macrì A, Graziosi L, Coccolini F, Lippolis PV, Roberta G, Deraco M, Biacchi D, Santullo F, Vaira M, Di Lauro K, D'Acapito F, Carboni F, Giuffrè G, Donini A, Fugazzola P, Faviana P, Lorena S, Scapinello A, Del Bianco P, Sommariva A. Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Ann Surg Oncol 2021. [PMID: 34783946 DOI: 10.1245/s10434-021-11045-3] [Reference Citation Analysis]
270 Antonetti P, Fargnoli MC, Porzio G, Salvatore L, Filippi R, Ghidini M, Nigro O, Gelsomino F, Zurlo IV, Dell'Aquila E, Lombardi P, Keränen SR, Depetris I, Giampieri R, Morelli C, De Tursi M, Di Pietro FR, Zanaletti N, Vitale P, Garajova I, Spinelli GP, Zoratto F, Roberto M, Petrillo A, Aimar G, Cortellini A, Pensieri MV, Ficorella C, Ferri C, Parisi A. A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement? Support Care Cancer 2021. [PMID: 34779921 DOI: 10.1007/s00520-021-06652-5] [Reference Citation Analysis]
271 Wang J, Li J, Wei S, Xu J, Jiang X, Yang L. The Ratio of Platelets to Lymphocytes Predicts the Prognosis of Metastatic Colorectal Cancer: A Review and Meta-Analysis. Gastroenterol Res Pract 2021;2021:9699499. [PMID: 34764993 DOI: 10.1155/2021/9699499] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
272 Fiorentini G, Sarti D, Nardella M, Inchingolo R, Nestola M, Rebonato A, Fiorentini C, Aliberti C, Nani R, Guadagni S. Transarterial chemoembolization alone or followed by bevacizumab for treatment of colorectal liver metastases. Hepat Oncol 2022;9:HEP40. [PMID: 34765108 DOI: 10.2217/hep-2020-0031] [Reference Citation Analysis]
273 Bos D, Zensen S, Opitz M, Haubold J, Forsting M, Nassenstein K, Guberina N, Wetter A. IMAGE QUALITY STUDY OF RADIATION-REDUCED COMBINED CHEST AND ABDOMEN/PELVIS CT COMPARED WITH A STANDARD PROTOCOL. Radiat Prot Dosimetry 2021;196:190-8. [PMID: 34635920 DOI: 10.1093/rpd/ncab147] [Reference Citation Analysis]
274 Howe JR. The impact of DNA testing on management of patients with colorectal cancer. Ann Gastroenterol Surg. [DOI: 10.1002/ags3.12526] [Reference Citation Analysis]
275 Ogawa H, Yajima T, Sohda M, Shirabe K, Saeki H. Role of surgical resection and its alternative local therapy for pulmonary metastasis of colorectal cancer. Ann Gastroenterol Surg 2021;5:747-53. [PMID: 34755006 DOI: 10.1002/ags3.12472] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
276 Chen Y, Xu Y, Xu L, Han F, Huang Y, Jiang H, Wu J, Zhang Y. Neoadjuvant Chemotherapy Followed by Radiofrequency Ablation Prolongs Survival for Ablatable Colorectal Liver Metastasis: A Propensity Score Matching Comparative Study. Front Oncol 2021;11:758552. [PMID: 34745996 DOI: 10.3389/fonc.2021.758552] [Reference Citation Analysis]
277 Ettrich TJ, Hüttner FJ, Lisson C, Gani C, Prasad V, Seufferlein T. [Multimodal, interdisciplinary therapeutic concepts for liver metastasized colorectal cancer]. Dtsch Med Wochenschr 2021;146:1468-77. [PMID: 34741292 DOI: 10.1055/a-1391-5273] [Reference Citation Analysis]
278 Peng JH, Tai Y, Zhao YX, Luo BJ, Ou QJ, Pan ZZ, Zhang L, Lu ZH. Programmed death-ligand 1 expression in the tumour stroma of colorectal liver oligometastases and its association with prognosis after liver resection. Gastroenterol Rep (Oxf) 2021;9:443-50. [PMID: 34733530 DOI: 10.1093/gastro/goaa077] [Reference Citation Analysis]
279 Karampinis I, Rathmann N, Kostrzewa M, Diehl SJ, Schoenberg SO, Hohenberger P, Roessner ED. Computer tomography guided thoracoscopic resection of small pulmonary nodules in the hybrid theatre. PLoS One 2021;16:e0258896. [PMID: 34731178 DOI: 10.1371/journal.pone.0258896] [Reference Citation Analysis]
280 Arai H, Elliott A, Millstein J, Xiu J, Ou FS, Innocenti F, Wang J, Battaglin F, Jayachandran P, Kawanishi N, Soni S, Zhang W, Sohal D, Goldberg RM, Hall MJ, Scott AJ, Khushman M, Hwang JJ, Lou E, Weinberg BA, Lockhart AC, Shields AF, Abraham JP, Magee D, Stafford P, Zhang J, Venook AP, Korn WM, Lenz HJ. Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer. Oncogene 2021. [PMID: 34728807 DOI: 10.1038/s41388-021-02074-z] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
281 Tsuji A, Nakamura M, Watanabe T, Manaka D, Matsuoka H, Kataoka M, Takeuchi M, Ichikawa W, Fujii M. Phase II Study of Third-Line Panitumumab Rechallenge in Patients with Metastatic Wild-Type KRAS Colorectal Cancer Who Obtained Clinical Benefit from First-Line Panitumumab-Based Chemotherapy: JACCRO CC-09. Target Oncol 2021;16:753-60. [PMID: 34718946 DOI: 10.1007/s11523-021-00845-y] [Reference Citation Analysis]
282 Czauderna C, Luley K, von Bubnoff N, Marquardt JU. Tailored Systemic Therapy for Colorectal Cancer Liver Metastases. Int J Mol Sci 2021;22:11780. [PMID: 34769209 DOI: 10.3390/ijms222111780] [Reference Citation Analysis]
283 Yamamoto S, Nagashima K, Kawakami T, Mitani S, Komoda M, Tsuji Y, Izawa N, Kawakami K, Yamamoto Y, Makiyama A, Yamazaki K, Masuishi T, Esaki T, Nakajima TE, Okuda H, Moriwaki T, Boku N. Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer. BMC Cancer 2021;21:1159. [PMID: 34715820 DOI: 10.1186/s12885-021-08890-6] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
284 Loosen SH, Roderburg C, Alizai PH, Roeth AA, Schmitz SM, Vucur M, Luedde M, Schöler D, Paffenholz P, Tacke F, Trautwein C, Luedde T, Neumann UP, Ulmer TF. Comparative Analysis of Circulating Biomarkers for Patients Undergoing Resection of Colorectal Liver Metastases. Diagnostics (Basel) 2021;11:1999. [PMID: 34829346 DOI: 10.3390/diagnostics11111999] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
285 Rosati G, Corsi D, Avallone A, Brugnatelli S, Dell'Aquila E, Cinausero M, Aprile G, Cicero G, Carlomagno C, Colombo A, Rapisardi S, Pinto C, Reggiardo G, Bilancia D. Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the REVOLT study. J Geriatr Oncol 2021:S1879-4068(21)00239-3. [PMID: 34716122 DOI: 10.1016/j.jgo.2021.10.007] [Reference Citation Analysis]
286 Lucatelli P, Burrel M, Guiu B, de Rubeis G, van Delden O, Helmberger T. CIRSE Standards of Practice on Hepatic Transarterial Chemoembolisation. Cardiovasc Intervent Radiol 2021;44:1851-67. [PMID: 34694454 DOI: 10.1007/s00270-021-02968-1] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
287 Peng J, Li W, Fan W, Zhang R, Li X, Xiao B, Dong Y, Wan D, Pan Z, Lin J, Wu X. Prognostic value of a novel biomarker combining DNA ploidy and tumor burden score for initially resectable liver metastases from patients with colorectal cancer. Cancer Cell Int 2021;21:554. [PMID: 34688293 DOI: 10.1186/s12935-021-02250-x] [Reference Citation Analysis]
288 Makarem M, García-Pardo M, Leighl NB. Plasma-Based Genotyping in Advanced Solid Tumors: A Comprehensive Review. Cancers (Basel) 2021;13:5299. [PMID: 34771462 DOI: 10.3390/cancers13215299] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
289 Steeghs EMP, Vink GR, Elferink MAG, Voorham QJM, Gelderblom H, Nagtegaal ID, Grünberg K, Ligtenberg MJL; PATH Consortium Members., PATH consortium members. Nationwide evaluation of mutation-tailored anti-EGFR therapy selection in patients with colorectal cancer in daily clinical practice. J Clin Pathol 2021:jclinpath-2021-207865. [PMID: 34675090 DOI: 10.1136/jclinpath-2021-207865] [Reference Citation Analysis]
290 Michal S, Tal GL, Gali P, Miki G, Elana B, Baroch B, Hanoch K, Irit BA, Riad H. Characterization of Biomarkers in Colorectal Cancer Liver Metastases as a Prognostic Tool. J Pers Med 2021;11:1059. [PMID: 34834411 DOI: 10.3390/jpm11111059] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
291 Ottaiano A, Circelli L, Santorsola M, Savarese G, Fontanella D, Gigantino V, Di Mauro A, Capuozzo M, Zappavigna S, Lombardi A, Perri F, Cascella M, Granata V, Capuozzo M, Nasti G, Caraglia M. Metastatic colorectal cancer and type 2 diabetes: prognostic and genetic interactions. Mol Oncol 2021. [PMID: 34668636 DOI: 10.1002/1878-0261.13122] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
292 Görgec B, Hansen I, Kemmerich G, Syversveen T, Abu Hilal M, Belt EJT, Bisschops RHC, Bollen TL, Bosscha K, Burgmans MC, Cappendijk V, De Boer MT, D'Hondt M, Edwin B, Gielkens H, Grünhagen DJ, Gillardin P, Gobardhan PD, Hartgrink HH, Horsthuis K, Kok NFM, Kint PAM, Kruimer JWH, Leclercq WKG, Lips DJ, Lutin B, Maas M, Marsman HA, Morone M, Pennings JP, Peringa J, Te Riele WW, Vermaas M, Wicherts D, Willemssen FEJA, Zonderhuis BM, Bossuyt PMM, Swijnenburg RJ, Fretland ÅA, Verhoef C, Besselink MG, Stoker J; CAMINO Study Group. Clinical added value of MRI to CT in patients scheduled for local therapy of colorectal liver metastases (CAMINO): study protocol for an international multicentre prospective diagnostic accuracy study. BMC Cancer 2021;21:1116. [PMID: 34663243 DOI: 10.1186/s12885-021-08833-1] [Reference Citation Analysis]
293 Rosa F, Galiandro F, Ricci R, Di Miceli D, Quero G, Fiorillo C, Cina C, Alfieri S. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal metastases: analysis of short- and long-term outcomes. Langenbecks Arch Surg 2021. [PMID: 34661754 DOI: 10.1007/s00423-021-02353-z] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
294 Chakwop Ngassa H, Elmenawi KA, Anil V, Gosal H, Kaur H, Mohammed L. Abnormal Dihydropyrimidine Dehydrogenase Activity as an Indicator of Potential 5-Fluorouracil Linked Cardiotoxicity in Colorectal Cancer Patients: Are Toxic Events Inevitable? Cureus 2021;13:e17712. [PMID: 34650886 DOI: 10.7759/cureus.17712] [Reference Citation Analysis]
295 Damm R, Damm R, Heinze C, Surov A, Omari J, Pech M, Powerski M. Radioablation of Upper Abdominal Malignancies by CT-Guided, Interstitial HDR Brachytherapy: A Multivariate Analysis of Catheter Placement Assisted by Ultrasound Imaging. Rofo 2022;194:62-9. [PMID: 34649287 DOI: 10.1055/a-1545-4983] [Reference Citation Analysis]
296 Procaccio L, Bergamo F, Daniel F, Rasola C, Munari G, Biason P, Crucitta S, Barsotti G, Zanella G, Angerilli V, Magro C, Paccagnella S, Di Antonio V, Loupakis F, Danesi R, Zagonel V, Del Re M, Lonardi S, Fassan M. A Real-World Application of Liquid Biopsy in Metastatic Colorectal Cancer: The Poseidon Study. Cancers (Basel) 2021;13:5128. [PMID: 34680277 DOI: 10.3390/cancers13205128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
297 Huang X, Cui J, Li X, Liu C, Sun J, Yue J. The decreased platelet-to-lymphocyte ratio could predict a good prognosis in patients with oligometastatic colorectal cancer: a single-center cohort retrospective study. World J Surg Oncol 2021;19:297. [PMID: 34645481 DOI: 10.1186/s12957-021-02406-z] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
298 Manchec B, Kokabi N, Narayanan G, Niekamp A, Peña C, Powell A, Schiro B, Gandhi R. Radioembolization of Secondary Hepatic Malignancies. Semin Intervent Radiol 2021;38:445-52. [PMID: 34629712 DOI: 10.1055/s-0041-1732318] [Reference Citation Analysis]
299 Tinguely P, Paolucci I, Ruiter SJS, Weber S, de Jong KP, Candinas D, Freedman J, Engstrand J. Stereotactic and Robotic Minimally Invasive Thermal Ablation of Malignant Liver Tumors: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:713685. [PMID: 34631539 DOI: 10.3389/fonc.2021.713685] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
300 D'Agay MG, Galland L, Tharin Z, Truntzer C, Ghiringhelli F. Utility of exome sequencing in routine care for metastatic colorectal cancer. Mol Clin Oncol 2021;15:229. [PMID: 34631054 DOI: 10.3892/mco.2021.2392] [Reference Citation Analysis]
301 Blomberg K, Hansen TF, Brasen CL, Madsen JB, Jensen LH, Thomsen CB. The Soluble Urokinase-Type Plasminogen Activator Receptor as a Biomarker for Survival and Early Treatment Effect in Metastatic Colorectal Cancer. Cancers (Basel) 2021;13:5100. [PMID: 34680247 DOI: 10.3390/cancers13205100] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
302 Shi Z, Zhu X, Ke S, Qiu H, Cai G, Zhangcai Y, Chen Y. Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: A propensity score matching and landmark analyses. Radiother Oncol 2021;164:236-44. [PMID: 34627936 DOI: 10.1016/j.radonc.2021.09.033] [Reference Citation Analysis]
303 Chen H, Stoltzfus KC, Lehrer EJ, Horn SR, Siva S, Trifiletti DM, Meng MB, Verma V, Louie AV, Zaorsky NG. The Epidemiology of Lung Metastases. Front Med (Lausanne) 2021;8:723396. [PMID: 34616754 DOI: 10.3389/fmed.2021.723396] [Reference Citation Analysis]
304 Roberti MP, Rauber C, Kroemer G, Zitvogel L. Impact of the ileal microbiota on colon cancer. Semin Cancer Biol 2021:S1044-579X(21)00250-9. [PMID: 34624451 DOI: 10.1016/j.semcancer.2021.09.016] [Reference Citation Analysis]
305 Bertaut A, Touchefeu Y, Blanc J, Bouché O, François E, Conroy T, Artru P, Adenis A, Gobbo J, Borg C, Ghiringhelli F, Bennouna J. Health-Related Quality of Life Analysis in Metastatic Colorectal Cancer Patients Treated by Second-Line Chemotherapy, Associated With Either Cetuximab or Bevacizumab: The PRODIGE 18 Randomized Phase II Study. Clin Colorectal Cancer 2021:S1533-0028(21)00087-6. [PMID: 34838460 DOI: 10.1016/j.clcc.2021.09.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
306 Filippiadis DK, Velonakis G, Mazioti A, Tsochatzis A, Vrachliotis T, Kelekis A, Kelekis N. Percutaneous Navigation under Local Anesthesia for Computed Tomography-Guided Microwave Ablation of Malignant Liver Lesions Located in the Hepatic Dome. Medicina (Kaunas) 2021;57:1056. [PMID: 34684093 DOI: 10.3390/medicina57101056] [Reference Citation Analysis]
307 Kamiimabeppu D, Osumi H, Shinozaki E, Ooki A, Wakatsuki T, Yoshino K, Sato T, Nakayama I, Ogura M, Takahari D, Chin K, Yamaguchi K. Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine/tipiracil plus bevacizumab. Oncol Lett 2021;22:783. [PMID: 34594424 DOI: 10.3892/ol.2021.13044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
308 Rollet Q, Bouvier V, Moutel G, Launay L, Bignon AL, Bouhier-Leporrier K, Launoy G, Lièvre A. Multidisciplinary team meetings: are all patients presented and does it impact quality of care and survival - a registry-based study. BMC Health Serv Res 2021;21:1032. [PMID: 34592971 DOI: 10.1186/s12913-021-07022-x] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
309 Sun T, Zhang G, Ning T, Chen Q, Chu Y, Luo Y, You H, Su B, Li C, Guo Q, Jiang C. A Versatile Theranostic Platform for Colorectal Cancer Peritoneal Metastases: Real-Time Tumor-Tracking and Photothermal-Enhanced Chemotherapy. Adv Sci (Weinh) 2021;8:e2102256. [PMID: 34398516 DOI: 10.1002/advs.202102256] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
310 Wang H, He F, Wang X, Tao H, Huang Z, Yuan Y, Zhang W. Investigation of the Definition of De Novo Oligometastatic Nasopharyngeal Carcinoma: A Retrospective Study. J Oncol 2021;2021:9977455. [PMID: 34567120 DOI: 10.1155/2021/9977455] [Reference Citation Analysis]
311 Díez-Alonso M, Mendoza-Moreno F, Gómez-Sanz R, Matías-García B, Ovejero-Merino E, Molina R, Soto-Schütte S, San Juan A, Gutierrez-Calvo A. Prognostic Value of KRAS Gene Mutation on Survival of Patients with Peritoneal Metastases of Colorectal Adenocarcinoma. Int J Surg Oncol 2021;2021:3946875. [PMID: 34557315 DOI: 10.1155/2021/3946875] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
312 Ni X, Feng Y, Fu X. Role of salt‑inducible kinase 2 in the malignant behavior and glycolysis of colorectal cancer cells. Mol Med Rep 2021;24:822. [PMID: 34558647 DOI: 10.3892/mmr.2021.12460] [Reference Citation Analysis]
313 Ishikawa M, Takashima A, Nagata Y, Sawada R, Aoki M, Imazeki H, Hirano H, Shoji H, Honma Y, Iwasa S, Okita N, Kato K, Saruta M, Boku N. Tumor growth rate during re-challenge chemotherapy with previously used agents as salvage treatment for metastatic colorectal cancer: A retrospective study. PLoS One 2021;16:e0257551. [PMID: 34559818 DOI: 10.1371/journal.pone.0257551] [Reference Citation Analysis]
314 Ma C, Zhang X, Zhao X, Zhang N, Zhou S, Zhang Y, Li P. Predicting the Survival and Immune Landscape of Colorectal Cancer Patients Using an Immune-Related lncRNA Pair Model. Front Genet 2021;12:690530. [PMID: 34552614 DOI: 10.3389/fgene.2021.690530] [Reference Citation Analysis]
315 Yuan X, Xue J, Tan Y, Yang Q, Qin Z, Bao X, Li S, Pan L, Jiang Z, Wang Y, Lou Y, Jiang L, Du J. Albuca Bracteate Polysaccharides Synergistically Enhance the Anti-Tumor Efficacy of 5-Fluorouracil Against Colorectal Cancer by Modulating β-Catenin Signaling and Intestinal Flora. Front Pharmacol 2021;12:736627. [PMID: 34552494 DOI: 10.3389/fphar.2021.736627] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
316 Bordonaro R, Calvo A, Auriemma A, Hollebecque A, Rubovszky G, Saunders MP, Pápai Z, Prager G, Stein A, André T, Argilés G, Cubillo A, Dahan L, Edeline J, Leger C, Cattan V, Fougeray R, Amellal N, Tabernero J. Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study. ESMO Open 2021;6:100270. [PMID: 34547581 DOI: 10.1016/j.esmoop.2021.100270] [Reference Citation Analysis]
317 Bargellini I, Boni G, Traino AC, Bozzi E, Lorenzoni G, Bianchi F, Cervelli R, Depalo T, Crocetti L, Volterrani D, Cioni R. Management of Liver Tumors during the COVID-19 Pandemic: The Added Value of Selective Internal Radiation Therapy (SIRT). J Clin Med 2021;10:4315. [PMID: 34640332 DOI: 10.3390/jcm10194315] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
318 Li N, Deng W, Zhang G, Du Y, Guo Y, Ma Y, Wei C, Bie L, Zhang C, Song T, Luo S, Fang B. Low-Dose Apatinib Combined With S-1 in Refractory Metastatic Colorectal Cancer: A Phase 2, Multicenter, Single-Arm, Prospective Study. Front Oncol 2021;11:728854. [PMID: 34540697 DOI: 10.3389/fonc.2021.728854] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
319 Gohla G, Archid R, Hoffmann R, Kübler J, Munzel M, Königsrainer A, Nadalin S, Nikolaou K, Winkelmann MT. MRI-guided percutaneous thermoablation as first-line treatment of recurrent hepatic malignancies following hepatic resection: single center long-term experience. Int J Hyperthermia 2021;38:1401-8. [PMID: 34542009 DOI: 10.1080/02656736.2021.1979257] [Reference Citation Analysis]
320 Kobayashi S, Takahashi S, Nomura S, Kojima M, Kudo M, Sugimoto M, Konishi M, Gotohda N, Taniguchi H, Yoshino T. BRAF V600E potentially determines "Oncological Resectability" for "Technically Resectable" colorectal liver metastases. Cancer Med 2021;10:6998-7011. [PMID: 34535965 DOI: 10.1002/cam4.4227] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
321 Xu D, Wang YY, Yan XL, Li J, Wang K, Xing BC. Development of a model to predict pathologic response to chemotherapy in patients with colorectal liver metastases. J Gastrointest Oncol 2021;12:1498-508. [PMID: 34532105 DOI: 10.21037/jgo-21-82] [Reference Citation Analysis]
322 Modest DP, Karthaus M, Fruehauf S, Graeven U, Müller L, König AO, Fischer von Weikersthal L, Caca K, Kretzschmar A, Goekkurt E, Haas S, Kurreck A, Stahler A, Held S, Jarosch A, Horst D, Reinacher-Schick A, Kasper S, Heinemann V, Stintzing S, Trarbach T. Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212). J Clin Oncol 2021;:JCO2101332. [PMID: 34533973 DOI: 10.1200/JCO.21.01332] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
323 Zhou N, Meng X, Zhang Y, Yu B, Yuan J, Yu J, Zhu H, Yang Z. Diagnostic Value of Delayed PET/MR in Liver Metastasis in Comparison With PET/CT. Front Oncol 2021;11:717687. [PMID: 34527587 DOI: 10.3389/fonc.2021.717687] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
324 Kim JH, Lee JH, Lee HS, Shin SJ, Park EJ, Cho ES, Baik SH, Lee KY, Kang J. Elevated Neutrophil-to-Lymphocyte Ratio in Perioperative Periods is Suggestive of Poor Prognosis in Patients with Colorectal Cancer. J Inflamm Res 2021;14:4457-66. [PMID: 34522115 DOI: 10.2147/JIR.S327443] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
325 Arai H, Xiao Y, Loupakis F, Kawanishi N, Wang J, Battaglin F, Soni S, Zhang W, Mancao C, Salhia B, Mumenthaler SM, Weisenberger DJ, Liang G, Cremolini C, Falcone A, Millstein J, Lenz HJ. Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer. J Immunother Cancer 2020;8:e001714. [PMID: 33172883 DOI: 10.1136/jitc-2020-001714] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
326 Guo M, Jin N, Pawlik T, Cloyd JM. Neoadjuvant chemotherapy for colorectal liver metastases: A contemporary review of the literature. World J Gastrointest Oncol 2021; 13(9): 1043-1061 [PMID: 34616511 DOI: 10.4251/wjgo.v13.i9.1043] [Cited by in CrossRef: 2] [Article Influence: 2.0] [Reference Citation Analysis]
327 Doleschel D, Hoff S, Koletnik S, Rix A, Zopf D, Kiessling F, Lederle W. Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth. J Exp Clin Cancer Res 2021;40:288. [PMID: 34517894 DOI: 10.1186/s13046-021-02043-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
328 Adams RA, Fisher DJ, Graham J, Seligmann JF, Seymour M, Kaplan R, Yates E, Parmar M, Richman SD, Quirke P, Butler R, Brown E, Collinson F, Falk S, Wasan H, Shiu KK, Middleton G, Samuel L, Wilson RH, Brown LC, Maughan TS; FOCUS4 Trial Investigators. Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial. J Clin Oncol 2021;:JCO2101436. [PMID: 34516759 DOI: 10.1200/JCO.21.01436] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
329 Stahler A, Heinemann V, Schuster V, Heinrich K, Kurreck A, Gießen-Jung C, Fischer von Weikersthal L, Kaiser F, Decker T, Held S, Graeven U, Schwaner I, Denzlinger C, Schenk M, Neumann J, Kirchner T, Jung A, Kumbrink J, Stintzing S, Modest DP. Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial). Eur J Cancer 2021;157:71-80. [PMID: 34507244 DOI: 10.1016/j.ejca.2021.08.017] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
330 Bonney GK, Chew CA, Lodge P, Hubbard J, Halazun KJ, Trunecka P, Muiesan P, Mirza DF, Isaac J, Laing RW, Iyer SG, Chee CE, Yong WP, Muthiah MD, Panaro F, Sanabria J, Grothey A, Moodley K, Chau I, Chan ACY, Wang CC, Menon K, Sapisochin G, Hagness M, Dueland S, Line PD, Adam R. Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines. Lancet Gastroenterol Hepatol 2021;6:933-46. [PMID: 34506756 DOI: 10.1016/S2468-1253(21)00219-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
331 Viganò L, Gentile D, Galvanin J, Corleone P, Costa G, Cimino M, Procopio F, Torzilli G. Very Early Recurrence After Liver Resection for Colorectal Metastases: Incidence, Risk Factors, and Prognostic Impact. J Gastrointest Surg 2021. [PMID: 34508293 DOI: 10.1007/s11605-021-05123-w] [Reference Citation Analysis]
332 García-Alfonso P, Muñoz A, Jiménez-Castro J, Jiménez-Fonseca P, Pericay C, Longo-Muñoz F, Reyna-Fortes C, Argilés-Martínez G, González-Astorga B, Gómez-Reina MJ, Ruiz-Casado A, Rodríguez-Salas N, López-López R, Carmona-Bayonas A, Conde-Herrero V, Aranda E, On Behalf Of The Ros Study Group. Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study. Cancers (Basel) 2021;13:4514. [PMID: 34572740 DOI: 10.3390/cancers13184514] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
333 Ratti M, Grizzi G, Passalacqua R, Lampis A, Cereatti F, Grassia R, Hahne JC. NTRK fusions in colorectal cancer: clinical meaning and future perspective. Expert Opin Ther Targets 2021;25:677-83. [PMID: 34488530 DOI: 10.1080/14728222.2021.1978070] [Reference Citation Analysis]
334 Kryeziu K, Moosavi SH, Bergsland CH, Guren MG, Eide PW, Totland MZ, Lassen K, Abildgaard A, Nesbakken A, Sveen A, Lothe RA. Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases. J Transl Med 2021;19. [DOI: 10.1186/s12967-021-03062-3] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
335 Frühling P, Urdzik J, Strömberg C, Isaksson B. Composite Score: prognostic tool to predict survival in patients undergoing surgery for colorectal liver metastases. BJS Open 2021;5:zrab104. [PMID: 34697642 DOI: 10.1093/bjsopen/zrab104] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
336 van Nassau SC, Bond MJ, Scheerman I, van Breeschoten J, Kessels R, Valkenburg-van Iersel LB, Verheul HM, Buffart TE, Mekenkamp LJ, Lemmens VE, Koopman M, Bol GM; EXCITE (From Clinical Trial to Bedside: Triplet Chemotherapy in Metastatic Colorectal Cancer) Study Group. Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer. JAMA Netw Open 2021;4:e2124766. [PMID: 34505885 DOI: 10.1001/jamanetworkopen.2021.24766] [Reference Citation Analysis]
337 Moosavi SH, Eide PW, Eilertsen IA, Brunsell TH, Berg KCG, Røsok BI, Brudvik KW, Bjørnbeth BA, Guren MG, Nesbakken A, Lothe RA, Sveen A. De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity. Genome Med 2021;13:143. [PMID: 34470666 DOI: 10.1186/s13073-021-00956-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
338 Bolhuis K, Grosheide L, Wesdorp NJ, Komurcu A, Chapelle T, Dejong CHC, Gerhards MF, Grünhagen DJ, van Gulik TM, Huiskens J, De Jong KP, Kazemier G, Klaase JM, Liem MSL, Molenaar IQ, Patijn GA, Rijken AM, Ruers TM, Verhoef C, de Wilt JHW, Punt CJA, Swijnenburg R. Short-Term Outcomes of Secondary Liver Surgery for Initially Unresectable Colorectal Liver Metastases Following Modern Induction Systemic Therapy in the Dutch CAIRO5 Trial. Annals of Surgery Open 2021;2:e081. [DOI: 10.1097/as9.0000000000000081] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
339 Guerrera LP, Napolitano S, De Falco V, Giunta EF, Vitiello PP, Gravina AG, Suarato G, Perrone A, Napolitano R, Martinelli E, Ciardiello F, Troiani T. Multiple Acquired Mutations Captured by Liquid Biopsy in the EGFR Addicted Metastatic Colorectal Cancer. Clin Colorectal Cancer 2021;20:354-8. [PMID: 34454840 DOI: 10.1016/j.clcc.2021.07.005] [Reference Citation Analysis]
340 Hendlisz A, Sclafani F. Editorial: Radioembolization for metastatic colorectal cancer: towards maturity, at last? Curr Opin Oncol 2021;33:351-2. [PMID: 33966002 DOI: 10.1097/CCO.0000000000000749] [Reference Citation Analysis]
341 Kitano Y, Hayashi H, Matsumoto T, Kinoshita S, Sato H, Shiraishi Y, Nakao Y, Kaida T, Imai K, Yamashita YI, Baba H. Borderline resectable for colorectal liver metastases: Present status and future perspective. World J Gastrointest Surg 2021; 13(8): 756-763 [PMID: 34512899 DOI: 10.4240/wjgs.v13.i8.756] [Reference Citation Analysis]
342 Villard C, Westman J, Frank J, Jynge O, Sparrelid E, Jorns C. The potential use of extended criteria donors and eligible recipients in liver transplantation for unresectable colorectal liver metastases in Central Sweden. Hepatobiliary Surg Nutr 2021;10:476-85. [PMID: 34430526 DOI: 10.21037/hbsn.2020.03.10] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
343 Zhao L, Wang Q, Zhao SD, Zhou J, Jiang KW, Ye YJ, Wang S, Shen ZL. Genetic mutations associated with sensitivity to neoadjuvant chemotherapy in metastatic colon cancer: A case report and review of literature. World J Clin Cases 2021; 9(24): 7099-7109 [PMID: 34540965 DOI: 10.12998/wjcc.v9.i24.7099] [Reference Citation Analysis]
344 García-Fadrique A, Estevan Estevan R, Sabater Ortí L. Quality Standards for Surgery of Colorectal Peritoneal Metastasis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol 2021. [PMID: 34435297 DOI: 10.1245/s10434-021-10642-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
345 Ye LF, Ji XM, Ren C, Wang ZQ, Lin CP, Chen DL, Cai YQ, Jin Y, Qiu MZ, Du ZM, Xi SY, Zhang DS, Wang F, Wang FH, Xu RH, Li YH, Wang DS. The Prognostic Value of Locoregional Interventions for BRAF V600E Metastatic Colorectal Cancer: A Retrospective Cohort Analysis. Biomolecules 2021;11:1268. [PMID: 34572480 DOI: 10.3390/biom11091268] [Reference Citation Analysis]
346 Huang Z, Pan Y, Zhou P, Li S, Li K. Long-term outcomes of ultrasound-guided percutaneous microwave ablation versus resection for colorectal cancer liver metastases: a propensity-score matched study. Int J Hyperthermia 2021;38:1276-84. [PMID: 34423716 DOI: 10.1080/02656736.2021.1968511] [Reference Citation Analysis]
347 Zhu K, Wang W, Luo R, Song D, Wang X, Gao Q, Fan J, Zhou J, Rao S, Wang X. Newly detected liver nodules with a history of colorectal cancer: are they metastatic? Review of 2,632 cases in a single center. Ann Transl Med 2021;9:1079. [PMID: 34422991 DOI: 10.21037/atm-20-8153] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
348 Nishizawa Y, Haraguchi N, Kim H, Ide Y, Nakata K, Okamura S, Kudo T, Satoh T, Uemura M, Matsuda C, Mizushima T, Murata K, Doki Y, Eguchi H. Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study). BMC Cancer 2021;21:947. [PMID: 34425776 DOI: 10.1186/s12885-021-08690-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
349 Raimondi A, Fucà G, Leone AG, Lonardi S, Antoniotti C, Smiroldo V, Amatu A, Tampellini M, Ritorto G, Murialdo R, Clavarezza M, Zaniboni A, Berenato R, Ratti M, Corallo S, Morano F, Di Bartolomeo M, Di Maio M, Pietrantonio F. Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study. ESMO Open 2021;6:100246. [PMID: 34416469 DOI: 10.1016/j.esmoop.2021.100246] [Reference Citation Analysis]
350 Zhang C, Wang X, Han J, Zhang R, Chen Z, Li Y, Ma X, Zhang G, Fan J, Chen J. Histological tumor response to neoadjuvant chemotherapy correlates to Immunoscore in colorectal cancer liver metastases patients. J Surg Oncol 2021;124:1431-41. [PMID: 34406653 DOI: 10.1002/jso.26651] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
351 Hallermayr A, Benet-Pagès A, Steinke-Lange V, Mansmann U, Rentsch M, Holinski-Feder E, Pickl JMA. Liquid Biopsy Hotspot Variant Assays: Analytical Validation for Application in Residual Disease Detection and Treatment Monitoring. Clin Chem 2021:hvab124. [PMID: 34392332 DOI: 10.1093/clinchem/hvab124] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
352 Bordry N, Germann M, Foukas PG, Sempoux C, Yan P, Dormond O, Speiser DE, Demartines N, Sauvain MO. Immune cell infiltration in colonic cancer: correlation between biopsy and surgical specimens. Br J Surg 2021;108:346-50. [PMID: 33792645 DOI: 10.1093/bjs/znaa142] [Reference Citation Analysis]
353 Liu Y, Chang W, Zhou B, Wei Y, Tang W, Liang F, Chen Y, Yan Z, Lv M, Ren L, Xu J. Conventional transarterial chemoembolization combined with systemic therapy versus systemic therapy alone as second-line treatment for unresectable colorectal liver metastases: randomized clinical trial. Br J Surg 2021;108:373-9. [PMID: 33611431 DOI: 10.1093/bjs/znaa155] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
354 Nikravesh H, Khodayar MJ, Behmanesh B, Mahdavinia M, Teimoori A, Alboghobeish S, Zeidooni L. The combined effect of dichloroacetate and 3-bromopyruvate on glucose metabolism in colorectal cancer cell line, HT-29; the mitochondrial pathway apoptosis. BMC Cancer 2021;21:903. [PMID: 34364387 DOI: 10.1186/s12885-021-08564-3] [Reference Citation Analysis]
355 Zhang Y, Ge L, Weng J, Tuo WY, Liu B, Ma SX, Yang KH, Cai H. Neoadjuvant chemotherapy for patients with resectable colorectal cancer liver metastases: A systematic review and meta-analysis. World J Clin Cases 2021; 9(22): 6357-6379 [PMID: 34435001 DOI: 10.12998/wjcc.v9.i22.6357] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
356 Tanabe T, Shida D, Boku N, Yoshida T, Tsukamoto S, Takashima A, Kanemitsu Y. Primary Tumor-Related Complications Among Patients With Unresectable Stage IV Colorectal Cancer in the Era of Targeted Therapy: A Competing Risk Regression Analysis. Dis Colon Rectum 2021;64:1074-82. [PMID: 34397558 DOI: 10.1097/DCR.0000000000002010] [Reference Citation Analysis]
357 Zeng F, Lu T, Xie F, Chen L, Zhang L, Su Y, Yu Z, Xiao Y, Ao F, Li G, Chen Z, Gong X, Li J. Effects of locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A real-world study. Transl Oncol 2021;14:101187. [PMID: 34365221 DOI: 10.1016/j.tranon.2021.101187] [Reference Citation Analysis]
358 Arrichiello G, Poliero L, Borrelli C, Paragliola F, Nacca V, Napolitano S, Corte CMD, Martini G, Martinelli E. Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening? Cancer Treat Res Commun 2021;28:100442. [PMID: 34391139 DOI: 10.1016/j.ctarc.2021.100442] [Reference Citation Analysis]
359 Wang C, Sandhu J, Ouyang C, Ye J, Lee PP, Fakih M. Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases. JAMA Netw Open 2021;4:e2118416. [PMID: 34369992 DOI: 10.1001/jamanetworkopen.2021.18416] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
360 Wei W, Li R, Liu Q, Devanathadesikan Seshadri V, Veeraraghavan VP, Surapaneni KM, Rengarajan T. Amelioration of oxidative stress, inflammation and tumor promotion by Tin oxide-Sodium alginate-Polyethylene glycol-Allyl isothiocyanate nanocomposites on the 1,2-Dimethylhydrazine induced colon carcinogenesis in rats. Arabian Journal of Chemistry 2021;14:103238. [DOI: 10.1016/j.arabjc.2021.103238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
361 Bolhuis K, van 't Erve I, Mijnals C, Delis-Van Diemen PM, Huiskens J, Komurcu A, Lopez-Yurda M, van den Broek D, Swijnenburg RJ, Meijer GA, Punt CJA, Fijneman RJA. Postoperative circulating tumour DNA is associated with pathologic response and recurrence-free survival after resection of colorectal cancer liver metastases. EBioMedicine 2021;70:103498. [PMID: 34333237 DOI: 10.1016/j.ebiom.2021.103498] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
362 Chiorean EG, Nandakumar G, Fadelu T, Temin S, Alarcon-Rozas AE, Bejarano S, Croitoru AE, Grover S, Lohar PV, Odhiambo A, Park SH, Garcia ER, Teh C, Rose A, Zaki B, Chamberlin MD. Treatment of Patients With Late-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline.JCO Glob Oncol. 2020;6:414-438. [PMID: 32150483 DOI: 10.1200/JGO.19.00367] [Cited by in Crossref: 19] [Cited by in F6Publishing: 46] [Article Influence: 19.0] [Reference Citation Analysis]
363 Palacín-Aliana I, García-Romero N, Asensi-Puig A, Carrión-Navarro J, González-Rumayor V, Ayuso-Sacido Á. Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR. Biomedicines 2021;9:906. [PMID: 34440110 DOI: 10.3390/biomedicines9080906] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
364 Catedral LI, Tan HN, Chua A Jr, Benedict Sacdalan D, Sacdalan DL. Patterns of Biomarker Use in Cancer Treatment Among Medical Oncologists in the Philippines. JCO Glob Oncol 2020;6:1593-608. [PMID: 33079606 DOI: 10.1200/GO.20.00265] [Reference Citation Analysis]
365 Hsu HC, Huang KC, Chen WS, Jiang JK, Yang SH, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, Huang SC, Cheng HH, Yang TS, Chen CC, Chao Y, Teng HW. Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread. Sci Rep 2021;11:15370. [PMID: 34321583 DOI: 10.1038/s41598-021-94968-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
366 Uutela A, Ovissi A, Hakkarainen A, Ristimäki A, Lundbom N, Kallio R, Soveri LM, Salminen T, Ålgars A, Halonen P, Ristamäki R, Nordin A, Blanco Sequeiros R, Rinta-Kiikka I, Lantto E, Virtanen J, Pääkkö E, Liukkonen E, Saunavaara J, Ryymin P, Lammentausta E, Osterlund P, Isoniemi H; RAXO Study Group. Treatment response of colorectal cancer liver metastases to neoadjuvant or conversion therapy: a prospective multicentre follow-up study using MRI, diffusion-weighted imaging and 1H-MR spectroscopy compared with histology (subgroup in the RAXO trial). ESMO Open 2021;6:100208. [PMID: 34325107 DOI: 10.1016/j.esmoop.2021.100208] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
367 Stahler A, Heinemann V, Holch JW, von Einem JC, Westphalen CB, Heinrich K, Schlieker L, Jelas I, Alig AHS, Fischer LE, Weiss L, Modest DP, von Weikersthal LF, Decker T, Kiani A, Moehler M, Kaiser F, Kirchner T, Jung A, Stintzing S. Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3). Int J Cancer 2021. [PMID: 34310714 DOI: 10.1002/ijc.33747] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
368 Osei-Bordom DC, Kamarajah S, Christou N. Colorectal Cancer, Liver Metastases and Biotherapies. Biomedicines 2021;9:894. [PMID: 34440099 DOI: 10.3390/biomedicines9080894] [Reference Citation Analysis]
369 Vandeputte C, Bregni G, Gkolfakis P, Guiot T, Pretta A, Kehagias P, Senti C, Reina EA, Van Bogaert C, Deleporte A, Geboes K, Delaunoit T, Demolin G, Peeters M, D'Hondt L, Janssens J, Carrasco J, Holbrechts S, Goeminne JC, Vergauwe P, Van Laethem JL, Flamen P, Hendlisz A, Sclafani F. Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial. Clin Colorectal Cancer 2021:S1533-0028(21)00071-2. [PMID: 34404621 DOI: 10.1016/j.clcc.2021.07.006] [Reference Citation Analysis]
370 Zhao J, Zhu J, Huang C, Yuan R, Zhu Z. Impact of primary tumor resection on the survival of patients with unresectable colon cancer liver metastasis at different colonic subsites: a propensity score matching analysis. Acta Chir Belg 2021;:1-16. [PMID: 34278951 DOI: 10.1080/00015458.2021.1956799] [Reference Citation Analysis]
371 Mauri G, Durinikova E, Amatu A, Tosi F, Cassingena A, Rizzetto F, Buzo K, Arcella P, Aquilano MC, Bonoldi E, Marsoni S, Siena S, Bardelli A, Sartore-Bianchi A, Arena S. Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids. JCO Precis Oncol 2021;5:PO. [PMID: 34327296 DOI: 10.1200/PO.21.00143] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
372 Schlögl M, Pak ES, Bansal AD, Schell JO, Ganai S, Kamal AH, Swetz KM, Maguire JM, Perrakis A, Warraich HJ, Jones CA. Top Ten Tips Palliative Care Clinicians Should Know About Prognostication in Critical Illness and Heart, Kidney, and Liver Diseases. J Palliat Med 2021. [PMID: 34283924 DOI: 10.1089/jpm.2021.0330] [Reference Citation Analysis]
373 Finotti M, Vitale A, Gringeri E, D'Amico FE, Boetto R, Bertacco A, Lonardi S, Bergamo F, Feltracco P, Cillo U. Colon Rectal Liver Metastases: The Role of the Liver Transplantation in the Era of the Transplant Oncology and Precision Medicine. Front Surg 2021;8:693387. [PMID: 34355016 DOI: 10.3389/fsurg.2021.693387] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
374 Giordano G, Parcesepe P, Bruno G, Piscazzi A, Lizzi V, Remo A, Pancione M, D'Andrea MR, De Santis E, Coppola L, Pietrafesa M, Fersini A, Ambrosi A, Landriscina M. Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era. Int J Mol Sci 2021;22:7717. [PMID: 34299337 DOI: 10.3390/ijms22147717] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
375 Furtado FS, Suarez-Weiss KE, Vangel M, Clark JW, Cusack JC, Hong T, Blaszkowsky L, Wo J, Striar R, Umutlu L, Daldrup-Link HE, Groshar D, Rocco R, Bordeianou L, Anderson MA, Mojtahed A, Qadan M, Ferrone C, Catalano OA. Clinical impact of PET/MRI in oligometastatic colorectal cancer. Br J Cancer 2021. [PMID: 34282295 DOI: 10.1038/s41416-021-01494-8] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
376 Bachet JB, Wyrwicz L, Price T, Cremolini C, Phelip JM, Portales F, Ozet A, Cicin I, Atlan D, Becquart M, Vidot L, Mounedji N, Van Cutsem E, Taieb J, Falcone A. Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study. ESMO Open 2020;5:e000698. [PMID: 32487542 DOI: 10.1136/esmoopen-2020-000698] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
377 Tabernero J, Argiles G, Sobrero AF, Borg C, Ohtsu A, Mayer RJ, Vidot L, Moreno Vera SR, Van Cutsem E. Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis. ESMO Open 2020;5:e000752. [PMID: 32817131 DOI: 10.1136/esmoopen-2020-000752] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
378 De Falco V, Napolitano S, Roselló S, Huerta M, Cervantes A, Ciardiello F, Troiani T. How we treat metastatic colorectal cancer. ESMO Open 2020;4:e000813. [PMID: 32817137 DOI: 10.1136/esmoopen-2020-000813] [Cited by in Crossref: 6] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
379 Parisi A, Porzio G, Cannita K, Venditti O, Avallone A, Filippi R, Salvatore L, Tortora G, Ribelli M, Nigro O, Gelsomino F, Spallanzani A, Zurlo V, Leo S, Dell'Aquila E, Claudia F, Lombardi P, Keränen SR, Aimar G, Depetris I, Giampieri R, Morelli C, De Tursi M, Tinari N, Di Pietro FR, De Galitiis F, Zanaletti N, Troiani T, Vitale P, Garajova I, Ghidini M, Spinelli GP, Zoratto F, Roberto M, Ierino D, Petrillo A, D'Orazio C, Ficorella C, Cortellini A. Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study. Clin Colorectal Cancer 2021:S1533-0028(21)00068-2. [PMID: 34380594 DOI: 10.1016/j.clcc.2021.07.003] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
380 Liu C, Meng Q, Zeng Q, Chen H, Shen Y, Li B, Cen R, Huang J, Li G, Liao Y, Wu T. An Exploratory Study on the Stable Radiomics Features of Metastatic Small Pulmonary Nodules in Colorectal Cancer Patients. Front Oncol 2021;11:661763. [PMID: 34336657 DOI: 10.3389/fonc.2021.661763] [Reference Citation Analysis]
381 Chen S, Liu T, Bu D, Zhu J, Wang X, Pan Y, Liu Y, Lu ZJ, Wang P. Methylome profiling identifies TCHH methylation in CfDNA as a noninvasive marker of liver metastasis in colorectal cancer. FASEB J 2021;35:e21720. [PMID: 34110642 DOI: 10.1096/fj.202100266R] [Reference Citation Analysis]
382 Cheng Y, Wu G, Zhang S, Liu Y, Qu J, Qu X. Complete Pathologic Response of Multiple Liver Metastases and Clinical Complete Response of Rectal Cancer in a Patient with Ataxia-Telangiectasia Mutated Gene Mutations After XELOXIRI Plus Bevacizumab: A Case Report. Onco Targets Ther 2021;14:4201-9. [PMID: 34290508 DOI: 10.2147/OTT.S320477] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
383 He K, Liu X, Shahzad R, Reimer R, Thiele F, Niehoff J, Wybranski C, Bunck AC, Zhang H, Perkuhn M. Advanced Deep Learning Approach to Automatically Segment Malignant Tumors and Ablation Zone in the Liver With Contrast-Enhanced CT. Front Oncol 2021;11:669437. [PMID: 34336661 DOI: 10.3389/fonc.2021.669437] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
384 Hummel M, Hegewisch-Becker S, Neumann JHL, Vogel A. BRAF testing in metastatic colorectal carcinoma and novel, chemotherapy-free therapeutic options. Pathologe 2021. [PMID: 34259881 DOI: 10.1007/s00292-021-00946-5] [Reference Citation Analysis]
385 Wei S, Han Y, Zeng H, Ye S, Cheng J, Chai F, Wei J, Zhang J, Hong N, Bao Y, Zhou J, Ye Y, Meng X, Zhou Y, Deng Y, Qiu M, Tian J, Wang Y. Radiomics diagnosed histopathological growth pattern in prediction of response and 1-year progression free survival for colorectal liver metastases patients treated with bevacizumab containing chemotherapy. Eur J Radiol 2021;142:109863. [PMID: 34343846 DOI: 10.1016/j.ejrad.2021.109863] [Reference Citation Analysis]
386 Garattini SK, Basile D, Bonotto M, Ongaro E, Porcu L, Corvaja C, Cattaneo M, Andreotti VJ, Lisanti C, Bertoli E, Pelizzari G, Iacono D, Miolo G, Cardellino GG, Buonadonna A, Aprile G, Fasola G, Puglisi F, Pella N. Drug Holidays and Overall Survival of Patients with Metastatic Colorectal Cancer. Cancers (Basel) 2021;13:3504. [PMID: 34298718 DOI: 10.3390/cancers13143504] [Reference Citation Analysis]
387 Moretto R, Rossini D, Conca V, Lonardi S, Rasola C, Antoniotti C, Santini D, Marmorino F, Tomasello G, Borelli B, Caponnetto S, Zucchelli G, Zaniboni A, Ambrosini M, Buonadonna A, Fanchini L, Cupini S, Masi G, Falcone A, Cremolini C. CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies. Br J Cancer 2021. [PMID: 34253871 DOI: 10.1038/s41416-021-01483-x] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
388 Grasso RF, Andresciani F, Altomare C, Pacella G, Castiello G, Carassiti M, Quattrocchi CC, Faiella E, Beomonte Zobel B. Lung Thermal Ablation: Comparison between an Augmented Reality Computed Tomography (CT) 3D Navigation System (SIRIO) and Standard CT-Guided Technique. Biology (Basel) 2021;10:646. [PMID: 34356501 DOI: 10.3390/biology10070646] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
389 Kim SY, Kim K, Cho SH, Chun SM, Tak E, Hong YS, Kim JE, Kim TW. Longitudinal change of genetic variations in cetuximab-treated metastatic colorectal cancer. Cancer Genet 2021;258-259:27-36. [PMID: 34315006 DOI: 10.1016/j.cancergen.2021.06.007] [Reference Citation Analysis]
390 Moretto R, Rossini D, Capone I, Boccaccino A, Perrone F, Tamborini E, Masi G, Antoniotti C, Marmorino F, Conca V, Borelli B, Martignetti A, Pecora I, Simionato F, Cupini S, Ambrosini M, Manca P, Pietrantonio F, Falcone A, Cremolini C. Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients. Clin Colorectal Cancer 2021:S1533-0028(21)00066-9. [PMID: 34364814 DOI: 10.1016/j.clcc.2021.07.001] [Reference Citation Analysis]
391 Laimer G, Schullian P, Bale R. Stereotactic Thermal Ablation of Liver Tumors: 3D Planning, Multiple Needle Approach, and Intraprocedural Image Fusion Are the Key to Success-A Narrative Review. Biology (Basel) 2021;10:644. [PMID: 34356499 DOI: 10.3390/biology10070644] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
392 Gupta MK, Lipner SR. Review of chemotherapy-associated paronychia. Int J Dermatol 2021. [PMID: 34242408 DOI: 10.1111/ijd.15740] [Reference Citation Analysis]
393 Shen Y, Yang T, Zeng H, Meng W, Wang Z. Efficacy of Pelvic Peritoneum Closure After Laparoscopic Extralevator Abdominoperineal Excision for Rectal Cancer. J Gastrointest Surg 2021. [PMID: 34244951 DOI: 10.1007/s11605-021-05046-6] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
394 Liu W, Hu P, Liu J, Chen L. mSEPT9 Can Monitor the Response and Predict the Prognosis of Stage IV colorectal cancer Patients with Liver Metastasis Undergoing Potentially Curative Surgery. J Surg Res 2021;267:485-94. [PMID: 34246842 DOI: 10.1016/j.jss.2021.06.008] [Reference Citation Analysis]
395 Hou M, Sun JH. Emerging applications of radiomics in rectal cancer: State of the art and future perspectives. World J Gastroenterol 2021; 27(25): 3802-3814 [PMID: 34321845 DOI: 10.3748/wjg.v27.i25.3802] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
396 Truelsen SLB, Mousavi N, Wei H, Harvey L, Stausholm R, Spillum E, Hagel G, Qvortrup K, Thastrup O, Harling H, Mellor H, Thastrup J. The cancer angiogenesis co-culture assay: In vitro quantification of the angiogenic potential of tumoroids. PLoS One 2021;16:e0253258. [PMID: 34234354 DOI: 10.1371/journal.pone.0253258] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
397 Xiao L, Ge X, Yang L, Chen X, Xu Q, Rui X, Fan X, Feng L, Zhang Q, Dong M, Li W. Anticancer potential of an exopolysaccharide from Lactobacillus helveticus MB2-1 on human colon cancer HT-29 cells via apoptosis induction. Food Funct 2020;11:10170-81. [PMID: 33164019 DOI: 10.1039/d0fo01345e] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
398 Engstrand J, Abreu de Carvalho LF, Aghayan D, Balakrishnan A, Belli A, Björnsson B, Dasari BVM, Detry O, Di Martino M, Edwin B, Erdmann J, Fristedt R, Fusai G, Gimenez-Maurel T, Hemmingsson O, Hidalgo Salinas C, Isaksson B, Ivanecz A, Izzo F, Knoefel WT, Kron P, Lehwald-Tywuschik N, Lesurtel M, Lodge JPA, Machairas N, Marino MV, Martin V, Paterson A, Rystedt J, Sandström P, Serrablo A, Siriwardena AK, Taflin H, van Gulik TM, Yaqub S, Özden I, Ramia JM, Sturesson C; E-AHPBA Scientific and Research Committee. Liver resection and ablation for squamous cell carcinoma liver metastases. BJS Open 2021;5:zrab060. [PMID: 34426830 DOI: 10.1093/bjsopen/zrab060] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
399 Diener MK, Fichtner-Feigl S. Biomarkers in colorectal liver metastases: Rising complexity and unknown clinical significance? Ann Gastroenterol Surg 2021;5:477-83. [PMID: 34337296 DOI: 10.1002/ags3.12454] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
400 Diehl TM, Abbott DE. Molecular Determinants and Other Factors to Guide Selection of Patients for Hepatic Resection of Metastatic Colorectal Cancer. Curr Treat Options Oncol 2021;22:82. [PMID: 34224023 DOI: 10.1007/s11864-021-00878-5] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
401 Kawamura H, Ogawa Y, Yamazaki H, Honda M, Kono K, Konno S, Fukuhara S, Yamamoto Y. Impact of Primary Tumor Resection on Mortality in Patients with Stage IV Colorectal Cancer with Unresectable Metastases: A Multicenter Retrospective Cohort Study. World J Surg 2021;45:3230-9. [PMID: 34223985 DOI: 10.1007/s00268-021-06233-x] [Reference Citation Analysis]
402 Liao MZ, Prenen H, Dutta S, Upreti VV. The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancer. Cancer Chemother Pharmacol 2021;88:665-72. [PMID: 34213592 DOI: 10.1007/s00280-021-04319-w] [Reference Citation Analysis]
403 Avallone A, Piccirillo MC, Nasti G, Rosati G, Carlomagno C, Di Gennaro E, Romano C, Tatangelo F, Granata V, Cassata A, Silvestro L, De Stefano A, Aloj L, Vicario V, Nappi A, Leone A, Bilancia D, Arenare L, Petrillo A, Lastoria S, Gallo C, Botti G, Delrio P, Izzo F, Perrone F, Budillon A. Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA Netw Open 2021;4:e2118475. [PMID: 34309665 DOI: 10.1001/jamanetworkopen.2021.18475] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
404 Giuliante F, Viganò L, De Rose AM, Mirza DF, Lapointe R, Kaiser G, Barroso E, Ferrero A, Isoniemi H, Lopez-Ben S, Popescu I, Ouellet JF, Hubert C, Regimbeau JM, Lin JK, Skipenko OG, Ardito F, Adam R. Liver-First Approach for Synchronous Colorectal Metastases: Analysis of 7360 Patients from the LiverMetSurvey Registry. Ann Surg Oncol 2021. [PMID: 34212254 DOI: 10.1245/s10434-021-10220-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
405 Akabane M, Shindoh J, Kobayashi Y, Umino R, Kojima K, Okubo S, Hashimoto M, Matoba S, Kuroyanagi H. Significance of preoperative nutritional status as a predictor for short-term and long-term outcomes of patients undergoing surgery for stage IV colorectal cancer. Langenbecks Arch Surg 2021. [PMID: 34196790 DOI: 10.1007/s00423-021-02255-0] [Reference Citation Analysis]
406 Tarpgaard LS, Qvortrup C, Nielsen SL, Stenvang J, Detlefsen S, Brünner N, Pfeiffer P. New use for old drugs: Epirubicin in colorectal cancer. Acta Oncol 2021;60:954-6. [PMID: 33783307 DOI: 10.1080/0284186X.2021.1904519] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
407 Van Raemdonck D, Treasure T, Van Cutsem E, Macbeth F. Pulmonary Metastasectomy in Colorectal Cancer: has the randomized controlled trial brought enough reliable evidence to convince believers in metastasectomy to reconsider their oncological practice? Eur J Cardiothorac Surg 2021;59:517-21. [PMID: 33332567 DOI: 10.1093/ejcts/ezaa450] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
408 Inoue H, Kawaguchi T, Ikoma H, Morimura R, Yamamoto Y, Ochiai T, Shimizu H, Arita T, Konishi H, Shiozaki A, Kuriu Y, Kubota T, Fujiwara H, Okamoto K, Takahashi H, Takabe K, Tsung A, Otsuji E. Oligometastasis scoring system for predicting survival of patients with colorectal liver metastasis after hepatectomy. J Surg Oncol 2021;124:791-800. [PMID: 34196000 DOI: 10.1002/jso.26575] [Reference Citation Analysis]
409 Peeters M, Planchard D, Pegram M, Gonçalves J, Bocquet F, Jang H. Biosimilars in an era of rising oncology treatment options. Future Oncol 2021. [PMID: 34189937 DOI: 10.2217/fon-2021-0546] [Reference Citation Analysis]
410 Lee KH, Chen WS, Jiang JK, Yang SH, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, Huang SC, Cheng HH, Chao Y, Teng HW. The efficacy of anti-EGFR therapy in treating metastatic colorectal cancer differs between the middle/low rectum and the left-sided colon. Br J Cancer 2021;125:816-25. [PMID: 34188197 DOI: 10.1038/s41416-021-01470-2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
411 Nakayama I, Takahari D, Wakatsuki T, Osumi H, Chin K, Ogura M, Sato T, Suzuki T, Kamiimabeppu D, Ooki A, Suenaga M, Shinozaki E, Yamaguchi K. Single-institute comparison of the efficacy of systemic chemotherapy for oesophagogastric junction adenocarcinoma and stomach adenocarscinoma in a metastatic setting. ESMO Open 2020;5:e000595. [PMID: 32273288 DOI: 10.1136/esmoopen-2019-000595] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
412 Lastraioli E, Lavacchi D, Palmieri VE, Castiglione F, Messerini L, Di Costanzo F, Antonuzzo L. Evaluation of RAS mutational status through BEAMing assay to monitor disease progression of metastatic colorectal cancer: a case report. Anticancer Drugs 2020;31:979-82. [PMID: 32889896 DOI: 10.1097/CAD.0000000000000923] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
413 Chen HM, Lin CC, Chen WS, Jiang JK, Yang SH, Chang SC, Ho CL, Yang CC, Huang SC, Chao Y, Liao TT, Hwang WL, Teng HW. Insulin-Like Growth Factor 2 mRNA-Binding Protein 1 (IGF2BP1) Is a Prognostic Biomarker and Associated with Chemotherapy Responsiveness in Colorectal Cancer. Int J Mol Sci 2021;22:6940. [PMID: 34203267 DOI: 10.3390/ijms22136940] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
414 Huang L, Jansen L, Verhoeven RHA, Ruurda JP, Van Eycken L, De Schutter H, Johansson J, Lindblad M, Johannesen TB, Zadnik V, Žagar T, Mägi M, Lagarde SM, Bastiaannet E, van de Velde CJH, Schrotz-King P, Brenner H. Largely varying patterns and trends of primary cancer-directed resection for gastric carcinoma with synchronous distant metastasis in Europe and the US: a population-based study calling for further standardization of care. Ther Adv Med Oncol 2021;13:17588359211027837. [PMID: 34262618 DOI: 10.1177/17588359211027837] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
415 Fiz F, Costa G, Gennaro N, la Bella L, Boichuk A, Sollini M, Politi LS, Balzarini L, Torzilli G, Chiti A, Viganò L. Contrast Administration Impacts CT-Based Radiomics of Colorectal Liver Metastases and Non-Tumoral Liver Parenchyma Revealing the "Radiological" Tumour Microenvironment. Diagnostics (Basel) 2021;11:1162. [PMID: 34202253 DOI: 10.3390/diagnostics11071162] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
416 Guarini C, Grassi T, Pezzicoli G, Porta C. Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer. Int J Mol Sci 2021;22:6813. [PMID: 34202896 DOI: 10.3390/ijms22136813] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
417 Pastor B, André T, Henriques J, Trouilloud I, Tournigand C, Jary M, Mazard T, Louvet C, Azan S, Bauer A, Roch B, Sanchez C, Vernerey D, Thierry AR, Adenis A. Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment. Mol Oncol 2021;15:2401-11. [PMID: 33934494 DOI: 10.1002/1878-0261.12972] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
418 Choi BW, Kang S, Bae SU, Jeong WK, Baek SK, Song BI, Won KS, Kim HW. Prognostic value of metabolic parameters on 18F-fluorodeoxyglucose positron tomography/computed tomography in classical rectal adenocarcinoma. Sci Rep 2021;11:12947. [PMID: 34155222 DOI: 10.1038/s41598-021-92118-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
419 Alabraba E, Gomez D; Nottingham HPB Surgery Group. Systematic Review of Treatments for Colorectal Metastases in Elderly Patients to Guide Surveillance Cessation Following Hepatic Resection for Colorectal Liver Metastases. Am J Clin Oncol 2021;44:210-23. [PMID: 33710135 DOI: 10.1097/COC.0000000000000803] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
420 Komen J, Westerbeek EY, Kolkman RW, Roesthuis J, Lievens C, van den Berg A, van der Meer AD. Controlled pharmacokinetic anti-cancer drug concentration profiles lead to growth inhibition of colorectal cancer cells in a microfluidic device. Lab Chip 2020;20:3167-78. [PMID: 32729598 DOI: 10.1039/d0lc00419g] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
421 Costa G, Cavinato L, Masci C, Fiz F, Sollini M, Politi LS, Chiti A, Balzarini L, Aghemo A, di Tommaso L, Ieva F, Torzilli G, Viganò L. Virtual Biopsy for Diagnosis of Chemotherapy-Associated Liver Injuries and Steatohepatitis: A Combined Radiomic and Clinical Model in Patients with Colorectal Liver Metastases. Cancers (Basel) 2021;13:3077. [PMID: 34203103 DOI: 10.3390/cancers13123077] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
422 Faviana P, Boldrini L, Musco B, Ferrari M, Greco A, Fornaro L, Masi G, Forfori F, Ricci S, Brogi A, Basolo F, Falcone A, Gadducci A, Lippolis PV. Management of Peritoneal Carcinomatosis With Cytoreductive Surgery Combined With Intraperitoneal Chemohyperthermia at a Novel Italian Center. In Vivo 2020;34:2061-6. [PMID: 32606183 DOI: 10.21873/invivo.12008] [Reference Citation Analysis]
423 Osumi H, Vecchione L, Keilholz U, Vollbrecht C, Alig AHS, von Einem JC, Stahler A, Striefler JK, Kurreck A, Kind A, Modest DP, Stintzing S, Jelas I. NeoRAS wild-type in metastatic colorectal cancer: Myth or truth?-Case series and review of the literature. Eur J Cancer 2021;153:86-95. [PMID: 34153718 DOI: 10.1016/j.ejca.2021.05.010] [Reference Citation Analysis]
424 Nakajima H, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Negoro Y, Komoda M, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Ando K, Yuki S, Okuyama H, Kusaba H, Sakai D, Okamoto K, Tamura T, Yamashita K, Gosho M, Moriwaki T. Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment. Front Oncol 2021;11:688709. [PMID: 34211856 DOI: 10.3389/fonc.2021.688709] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
425 Schulz C, Heinemann V, Heinrich K, Haas M, Holch JW, Fraccaroli A, Held S, von Einem JC, Modest DP, Fischer von Weikersthal L, Kullmann F, Moehler M, Scheithauer W, Jung A, Stintzing S. Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study. Anticancer Drugs 2020;31:856-65. [PMID: 32639280 DOI: 10.1097/CAD.0000000000000965] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
426 Kamada Y, Hida K, Yonemura Y, Sugarbaker PH, Ghabra S, Ishihara S, Nagata H, Murono K, Goi T, Katayama K, Morikawa M, Rau B, Piso P, Acs M, Coccolini F, Canbay E, Hsieh MC, Bhatt A, Bonnot PE, Glehen O. The Characteristics of 206 Long-Term Survivors with Peritoneal Metastases from Colorectal Cancer Treated with Curative Intent Surgery: A Multi-Center Cohort from PSOGI. Cancers (Basel) 2021;13:2964. [PMID: 34199234 DOI: 10.3390/cancers13122964] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
427 Kvietkauskas M, Zitkute V, Leber B, Strupas K, Stiegler P, Schemmer P. Dietary Melatonin and Glycine Decrease Tumor Growth through Antiangiogenic Activity in Experimental Colorectal Liver Metastasis. Nutrients 2021;13:2035. [PMID: 34199311 DOI: 10.3390/nu13062035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
428 Mazard T, Cayrefourcq L, Perriard F, Senellart H, Linot B, de la Fouchardière C, Terrebonne E, François E, Obled S, Guimbaud R, Mineur L, Fonck M, Daurès JP, Ychou M, Assenat E, Alix-Panabières C. Clinical Relevance of Viable Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer: The COLOSPOT Prospective Study. Cancers (Basel) 2021;13:2966. [PMID: 34199250 DOI: 10.3390/cancers13122966] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
429 Palko-Łabuz A, Maksymowicz J, Sobieszczańska B, Wikiera A, Skonieczna M, Wesołowska O, Środa-Pomianek K. Newly Obtained Apple Pectin as an Adjunct to Irinotecan Therapy of Colorectal Cancer Reducing E. coli Adherence and β-Glucuronidase Activity. Cancers (Basel) 2021;13:2952. [PMID: 34204704 DOI: 10.3390/cancers13122952] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
430 Moretto R, Giordano M, Poma AM, Passardi A, Boccaccino A, Pietrantonio F, Tomasello G, Aprile G, Lonardi S, Conca V, Granetto C, Frassoldati A, Clavarezza M, Bertolini AS, Germani MM, Ugolini C, Fontanini G, Masi G, Falcone A, Cremolini C. Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study. Eur J Cancer 2021;153:16-26. [PMID: 34126333 DOI: 10.1016/j.ejca.2021.04.039] [Reference Citation Analysis]
431 Vitale P, Zanaletti N, Famiglietti V, De Falco V, Cervantes A, Rosellò S, Fenocchio E, Milanesio M, Lombardi P, Ciardiello D, Martini G, Martinelli E, Ciardiello F, Troiani T, Napolitano S. Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data. Clin Colorectal Cancer 2021:S1533-0028(21)00052-9. [PMID: 34226142 DOI: 10.1016/j.clcc.2021.06.002] [Reference Citation Analysis]
432 Cao Y, Zhang G, Zhang J, Yang Y, Ren J, Yan X, Wang Z, Zhao Z, Huang X, Bao H, Zhou J. Predicting Microsatellite Instability Status in Colorectal Cancer Based on Triphasic Enhanced Computed Tomography Radiomics Signatures: A Multicenter Study. Front Oncol 2021;11:687771. [PMID: 34178682 DOI: 10.3389/fonc.2021.687771] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
433 Sefrioui D, Beaussire L, Gillibert A, Blanchard F, Toure E, Bazille C, Perdrix A, Ziegler F, Gangloff A, Hassine M, Elie C, Bignon AL, Parzy A, Gomez P, Thill C, Clatot F, Sabourin JC, Frebourg T, Benichou J, Bouhier-Leporrier K, Gallais MP, Sarafan-Vasseur N, Michel P, Di Fiore F. CEA, CA19-9, circulating DNA and circulating tumour cell kinetics in patients treated for metastatic colorectal cancer (mCRC). Br J Cancer 2021;125:725-33. [PMID: 34112948 DOI: 10.1038/s41416-021-01431-9] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
434 Hasegawa T, Kuroda H, Sakakura N, Sato Y, Chatani S, Murata S, Yamaura H, Nakada T, Oya Y, Inaba Y. Novel strategy to treat lung metastases: Hybrid therapy involving surgery and radiofrequency ablation. Thorac Cancer 2021;12:2085-92. [PMID: 34106518 DOI: 10.1111/1759-7714.14041] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
435 Pan RJ, Hong HJ, Sun J, Yu CR, Liu HS, Li PY, Zheng MH. Detection and Clinical Value of Circulating Tumor Cells as an Assisted Prognostic Marker in Colorectal Cancer Patients. Cancer Manag Res 2021;13:4567-78. [PMID: 34135633 DOI: 10.2147/CMAR.S300554] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
436 Moslim MA, Bastawrous AL, Jeyarajah DR. Neoadjuvant Pelvic Radiotherapy in the Management of Rectal Cancer with Synchronous Liver Metastases: Is It Worth It? J Gastrointest Surg 2021. [PMID: 34100244 DOI: 10.1007/s11605-021-05042-w] [Reference Citation Analysis]
437 Li J, Cai Y, Deng Y. Selection of Oral Therapeutics in China for the Treatment of Colorectal Cancer. Curr Treat Options Oncol 2021;22:55. [PMID: 34097129 DOI: 10.1007/s11864-021-00852-1] [Reference Citation Analysis]
438 Nakayama Y, Kawamura H, Honda M, Takano Y, Takiguchi K, Kamiga T, Yamazaki S, Muto A, Shiraso S, Yamashita N, Iwao T, Kono K, Konno S. Benefit of intensive chemotherapy for elderly patients aged 80 years or older with metastatic colorectal cancer: a state-wide multicenter cohort study. Int J Clin Oncol 2021;26:1248-56. [PMID: 34089402 DOI: 10.1007/s10147-021-01909-9] [Reference Citation Analysis]
439 Durinikova E, Buzo K, Arena S. Preclinical models as patients' avatars for precision medicine in colorectal cancer: past and future challenges. J Exp Clin Cancer Res 2021;40:185. [PMID: 34090508 DOI: 10.1186/s13046-021-01981-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
440 Prager G, Köhne CH, O'Connor JM, Rivera F, Santini D, Wasan H, Phelip JM. The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program-Results of a Survey on Daily Practice Patterns for Patients with mCRC. Curr Oncol 2021;28:2097-106. [PMID: 34199694 DOI: 10.3390/curroncol28030194] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
441 Vera-Yunca D, Parra-Guillen ZP, Girard P, Trocóniz IF, Terranova N. Relevance of primary lesion location, tumour heterogeneity and genetic mutation demonstrated through tumour growth inhibition and overall survival modelling in metastatic colorectal cancer. Br J Clin Pharmacol 2021. [PMID: 34087010 DOI: 10.1111/bcp.14937] [Reference Citation Analysis]
442 Okuda S, Shimada Y, Tajima Y, Yuza K, Hirose Y, Ichikawa H, Nagahashi M, Sakata J, Ling Y, Miura N, Sugai M, Watanabe Y, Takeuchi S, Wakai T. Profiling of host genetic alterations and intra-tumor microbiomes in colorectal cancer. Comput Struct Biotechnol J 2021;19:3330-8. [PMID: 34188781 DOI: 10.1016/j.csbj.2021.05.049] [Reference Citation Analysis]
443 Sekizawa K, Nakagawa K, Ichikawa Y, Suwa H, Ozawa M, Momiyama M, Ishibe A, Watanabe J, Ota M, Kato I, Endo I. Relationship between stromal regulatory T cells and the response to neoadjuvant chemotherapy for locally advanced rectal cancer. Surg Today 2021. [PMID: 34081199 DOI: 10.1007/s00595-021-02311-8] [Reference Citation Analysis]
444 Temraz S, Mukherji D, Nassar F, Moukalled N, Shamseddine A. Treatment sequencing of metastatic colorectal cancer based on primary tumor location. Semin Oncol 2021:S0093-7754(21)00025-7. [PMID: 34120762 DOI: 10.1053/j.seminoncol.2021.05.001] [Reference Citation Analysis]
445 Ma X, Guan X, Ma C, Quan J, Zhao Z, Chen H, Huang H, Wei R, Liu Z, Jiang Z, Chen Y, Wang X. A novel risk stratification for predicting prognosis of colorectal cancer patients with bone metastasis. J Gastrointest Oncol 2021;12:933-43. [PMID: 34295546 DOI: 10.21037/jgo-20-586] [Reference Citation Analysis]
446 Bi Y, Shi X, Ren J, Yi M, Han X, Song M. Transarterial chemoembolization with doxorubicin-loaded beads for inoperable or recurrent colorectal cancer. Abdom Radiol (NY) 2021;46:2833-8. [PMID: 33386908 DOI: 10.1007/s00261-020-02877-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
447 Lenga L, Lange M, Arendt CT, Yel I, Booz C, Durden J, Leithner D, Vogl TJ, Albrecht MH, Martin SS. Can Dual-energy CT-based Virtual Monoenergetic Imaging Improve the Assessment of Hypodense Liver Metastases in Patients With Hepatic Steatosis? Acad Radiol 2021;28:769-77. [PMID: 32446765 DOI: 10.1016/j.acra.2020.03.044] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
448 Marchese U, Seux H, Garnier J, Ewald J, Piana G, Lelong B, Chaisemartin C, Meillat H, Delpero JR, Turrini O. Is percutaneous destruction of a solitary liver colorectal metastasis as effective as a resection? Ann Hepatobiliary Pancreat Surg 2021;25:198-205. [PMID: 34053922 DOI: 10.14701/ahbps.2021.25.2.198] [Reference Citation Analysis]
449 El-Khoury R, Hafliger E, Gallois C, Louafi S, Garinet S, Zaanan A, Taieb J. Treatment with encorafenib and cetuximab of a non-anti-epidermal growth factor receptor-naive patient for BRAF V600E-mutated metastatic colon cancer. Eur J Cancer 2021;152:1-3. [PMID: 34058699 DOI: 10.1016/j.ejca.2021.04.027] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
450 Kanter K, Fish M, Mauri G, Horick NK, Allen JN, Blaszkowsky LS, Clark JW, Ryan DP, Nipp RD, Giantonio BJ, Goyal L, Dubois J, Murphy JE, Franses J, Klempner SJ, Roeland EJ, Weekes CD, Wo JY, Hong TS, Van Seventer EE, Corcoran RB, Parikh AR. Care Patterns and Overall Survival in Patients With Early-Onset Metastatic Colorectal Cancer. JCO Oncol Pract 2021;:OP2001010. [PMID: 34043449 DOI: 10.1200/OP.20.01010] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
451 Budithi A, Su S, Kirshtein A, Shahriyari L. Data Driven Mathematical Model of FOLFIRI Treatment for Colon Cancer. Cancers (Basel) 2021;13:2632. [PMID: 34071939 DOI: 10.3390/cancers13112632] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
452 Amodio V, Mauri G, Reilly NM, Sartore-Bianchi A, Siena S, Bardelli A, Germano G. Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers. Cancers (Basel) 2021;13:2638. [PMID: 34072037 DOI: 10.3390/cancers13112638] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
453 Mauri G, Monfardini L, Garnero A, Zampino MG, Orsi F, Della Vigna P, Bonomo G, Varano GM, Busso M, Gazzera C, Fonio P, Veltri A, Calandri M. Optimizing Loco Regional Management of Oligometastatic Colorectal Cancer: Technical Aspects and Biomarkers, Two Sides of the Same Coin. Cancers (Basel) 2021;13:2617. [PMID: 34073585 DOI: 10.3390/cancers13112617] [Reference Citation Analysis]
454 Zhu J, Kong W, Xie Z. Expression and Prognostic Characteristics of Ferroptosis-Related Genes in Colon Cancer. Int J Mol Sci 2021;22:5652. [PMID: 34073365 DOI: 10.3390/ijms22115652] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
455 Patelli G, Tosi F, Amatu A, Mauri G, Curaba A, Patanè DA, Pani A, Scaglione F, Siena S, Sartore-Bianchi A. Strategies to tackle RAS-mutated metastatic colorectal cancer. ESMO Open 2021;6:100156. [PMID: 34044286 DOI: 10.1016/j.esmoop.2021.100156] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
456 Sartore-Bianchi A, García-Alfonso P, Geissler M, Köhne CH, Peeters M, Price T, Valladares-Ayerbes M, Zhang Y, Burdon P, Taieb J, Modest DP. Relationships Between Köhne Category/Baseline Tumor Load and Early Tumor Shrinkage, Depth of Response, and Outcomes in Metastatic Colorectal Cancer. Clin Colorectal Cancer 2021:S1533-0028(21)00049-9. [PMID: 34172397 DOI: 10.1016/j.clcc.2021.05.007] [Reference Citation Analysis]
457 Shindoh J. Risk stratification and goal of systemic therapy for successful surgical management of colorectal liver metastases: Oncological optimization. J Hepatobiliary Pancreat Sci 2021;28:461-9. [PMID: 33797853 DOI: 10.1002/jhbp.964] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
458 Jácome AA, Oliveira FA, Lino F, Lima JPSN. Effect of Adding Bevacizumab to Chemotherapy on Pathologic Response to Preoperative Systemic Therapy for Resectable Colorectal Liver Metastases: A Systematic Review and Meta-analysis. Clin Colorectal Cancer 2021;20:265-72. [PMID: 34158251 DOI: 10.1016/j.clcc.2021.05.006] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
459 Takahashi M, Sakamoto Y, Ohori H, Tsuji Y, Kuroki M, Kato S, Otsuka K, Komine K, Takahashi M, Takahashi S, Shirota H, Ouchi K, Takahashi Y, Imai H, Shibata H, Yoshioka T, Tanaka M, Yamaguchi H, Yamaguchi T, Shimodaira H, Ishioka C. Phase II study of trifluridine/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive biomarkers. Cancer Chemother Pharmacol 2021;88:393-402. [PMID: 34028598 DOI: 10.1007/s00280-021-04277-3] [Reference Citation Analysis]
460 Jimenez-Luna C, González-Flores E, Ortiz R, Martínez-González LJ, Antúnez-Rodríguez A, Expósito-Ruiz M, Melguizo C, Caba O, Prados J. Circulating PTGS2, JAG1, GUCY2C and PGF mRNA in Peripheral Blood and Serum as Potential Biomarkers for Patients with Metastatic Colon Cancer. J Clin Med 2021;10:2248. [PMID: 34067294 DOI: 10.3390/jcm10112248] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
461 Kotani D, Yoshino T, Kotaka M, Kawazoe A, Masuishi T, Taniguchi H, Yamazaki K, Yamanaka T, Oki E, Muro K, Komatsu Y, Bando H, Satake H, Kato T, Tsuji A. Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II study. Invest New Drugs 2021. [PMID: 34019214 DOI: 10.1007/s10637-021-01125-2] [Reference Citation Analysis]
462 Qin S, Li J, Bai Y, Shu Y, Li W, Yin X, Cheng Y, Sun G, Deng Y, Zhong H, Li Y, Qian X, Zhang L, Zhang J, Chen K, Kang W; HLX04-mCRC03 Investigators. Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study. BioDrugs 2021;35:445-58. [PMID: 34014555 DOI: 10.1007/s40259-021-00484-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
463 Hamfjord J, Guren TK, Glimelius B, Sorbye H, Pfeiffer P, Dajani O, Lingjaerde OC, Tveit KM, Pallisgaard N, Spindler KG, Kure EH. Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer. Int J Cancer 2021;149:1385-97. [PMID: 33961700 DOI: 10.1002/ijc.33672] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
464 Giglio MC, Garofalo E, Montalti R, Vanlander A, Troisi RI. The learning curve of laparoscopic ablation of liver tumors: A technically demanding procedure requiring dedicated training. Eur J Surg Oncol 2021;47:2579-85. [PMID: 34127330 DOI: 10.1016/j.ejso.2021.05.032] [Reference Citation Analysis]
465 Bocciarelli C, Caumont C, Samaison L, Cariou M, Aline-Fardin A, Doucet L, Roudié J, Terris B, Merlio JP, Marcorelles P, Cappellen D, Uguen A. MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories. Hum Pathol 2021;114:99-109. [PMID: 34019865 DOI: 10.1016/j.humpath.2021.05.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
466 Sur D, Balacescu L, Cainap SS, Visan S, Pop L, Burz C, Havasi A, Buiga R, Cainap C, Irimie A, Balacescu O. Predictive Efficacy of MiR-125b-5p, MiR-17-5p, and MiR-185-5p in Liver Metastasis and Chemotherapy Response Among Advanced Stage Colorectal Cancer Patients. Front Oncol 2021;11:651380. [PMID: 34084747 DOI: 10.3389/fonc.2021.651380] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
467 Burren S, Reche K, Blank A, Galvàn JA, Dawson H, Berger MD, Zlobec I, Lugli A. RHAMM in liver metastases of stage IV colorectal cancer with mismatch-repair proficient status correlates with tumor budding, cytotoxic T-cells and PD-1/PD-L1. Pathol Res Pract 2021;223:153486. [PMID: 34051513 DOI: 10.1016/j.prp.2021.153486] [Reference Citation Analysis]
468 Adenis A, Mazard T, Fraisse J, Chalbos P, Pastor B, Evesque L, Ghiringhelli F, Mollevi C, Delaine S, Ychou M. FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer. BMC Cancer 2021;21:564. [PMID: 34001059 DOI: 10.1186/s12885-021-08312-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
469 Moehler M, Michel M, Stein A, Trojan J, Marquardt J, Tintelnot J, Waidmann O, Weinmann A, Woerns MA, Schroeder H, Maenz M, Foerster F. A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer. Future Oncol 2021;17:3309-19. [PMID: 33993741 DOI: 10.2217/fon-2021-0278] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
470 Okamoto K, Nozawa H, Hongo K, Iida Y, Kawai K, Sasaki K, Murono K, Kita Y, Ishihara Y, Takabayashi N, Kobayashi R, Hiramatsu T, Ishihara S. Risk factors of mFOLFOX6-induced hyperammonemia in patients with colorectal cancer: an observational study. Int J Clin Oncol 2021;26:1477-84. [PMID: 33991268 DOI: 10.1007/s10147-021-01932-w] [Reference Citation Analysis]
471 Di Martino M, Primavesi F, Syn N, Dorcaratto D, de la Hoz Rodríguez Á, Dupré A, Piardi T, Rhaiem R, Blanco Fernández G, Prada Villaverde A, Rodríguez Sanjuán JC, Fernández Santiago R, Fernández-Moreno MC, Ferret G, López Ben S, Suárez Muñoz MÁ, Perez-Alonso AJ, Koh YX, Jones R, Martín-Pérez E. Perioperative chemotherapy versus surgery alone for resectable colorectal liver metastases: an international multicentre propensity score matched analysis on long-term outcomes according to established prognostic risk scores. HPB (Oxford) 2021:S1365-182X(21)00136-2. [PMID: 34103246 DOI: 10.1016/j.hpb.2021.04.026] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
472 Sumransub N, Vantanasiri K, Prakash A, Lou E. Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success? Mol Ther Oncolytics 2021;22:1-12. [PMID: 34307839 DOI: 10.1016/j.omto.2021.05.001] [Reference Citation Analysis]
473 Molla M, Fernandez-Plana J, Albiol S, Fondevila C, Vollmer I, Cases C, Garcia-Criado A, Capdevila J, Conill C, Fundora Y, Fernandez-Martos C, Pineda E. Limited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRT. J Clin Med 2021;10:2131. [PMID: 34069240 DOI: 10.3390/jcm10102131] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
474 Granata V, Fusco R, Setola SV, Avallone A, Palaia R, Grassi R, Izzo F, Petrillo A. Radiological assessment of secondary biliary tree lesions: an update. J Int Med Res 2020;48:300060519850398. [PMID: 32597280 DOI: 10.1177/0300060519850398] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
475 Chen B, Zheng D, Yu W, Huang C, Ye J, Han G, Zhuang J. Cetuximab versus bevacizumab maintenance following prior 8-cycle modified FOLFOXIRI plus cetuximab in Asian postmenopausal women with treatment-naive KRAS and BRAF wild-type metastatic colorectal cancer. J Int Med Res 2020;48:300060520930440. [PMID: 32993393 DOI: 10.1177/0300060520930440] [Reference Citation Analysis]
476 van de Vlasakker VCJ, Lurvink RJ, Cashin PH, Ceelen W, Deraco M, Goéré D, González-Moreno S, Lehmann K, Li Y, Moran B, Morris DL, Piso P, Quadros CA, Rau B, Somashekhar SP, Sommariva A, van der Speeten K, Spiliotis J, Sugarbaker PH, Teo MCC, Verwaal VJ, Yonemura Y, Glehen O, de Hingh IHJT. The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI). Eur J Surg Oncol 2021:S0748-7983(21)00499-6. [PMID: 34020808 DOI: 10.1016/j.ejso.2021.05.023] [Reference Citation Analysis]
477 Zhao Q, Cheng Z, Han Z, Liu F, Yu X, Tan X, Han B, Dou J, Yu J, Liang P. Percutaneous Microwave Ablation Versus Open Surgical Resection for Colorectal Cancer Liver Metastasis. Front Oncol 2021;11:638165. [PMID: 34046342 DOI: 10.3389/fonc.2021.638165] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
478 Lai E, Cascinu S, Scartozzi M. Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice. Front Oncol 2021;11:637823. [PMID: 34041019 DOI: 10.3389/fonc.2021.637823] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
479 Ginghină O, Hudiță A, Zaharia C, Tsatsakis A, Mezhuev Y, Costache M, Gălățeanu B. Current Landscape in Organic Nanosized Materials Advances for Improved Management of Colorectal Cancer Patients. Materials (Basel) 2021;14:2440. [PMID: 34066710 DOI: 10.3390/ma14092440] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
480 Zhang Z, Shen L, Wang Y, Wang J, Zhang H, Xia F, Wan J, Zhang Z. MRI Radiomics Signature as a Potential Biomarker for Predicting KRAS Status in Locally Advanced Rectal Cancer Patients. Front Oncol 2021;11:614052. [PMID: 34026605 DOI: 10.3389/fonc.2021.614052] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
481 Hummel M, Hegewisch-Becker S, Neumann J, Vogel A. [BRAF-V600E testing in metastatic colorectal cancer and new, chemotherapy-free therapy options. German version]. Pathologe 2021. [PMID: 33956173 DOI: 10.1007/s00292-021-00942-9] [Reference Citation Analysis]
482 Zhao J, Zhu J, Sun R, Huang C, Yuan R, Zhu Z. Primary tumor resection improves prognosis of unresectable carcinomas of the transverse colon including flexures with liver metastasis: a preliminary population-based analysis. BMC Cancer 2021;21:503. [PMID: 33957871 DOI: 10.1186/s12885-021-08157-0] [Reference Citation Analysis]
483 Jayaprakasam VS, Paroder V, Schöder H. Variants and Pitfalls in PET/CT Imaging of Gastrointestinal Cancers. Semin Nucl Med 2021;51:485-501. [PMID: 33965198 DOI: 10.1053/j.semnuclmed.2021.04.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
484 Glimelius B, Stintzing S, Marshall J, Yoshino T, de Gramont A. Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone. Cancer Treat Rev 2021;98:102218. [PMID: 34015686 DOI: 10.1016/j.ctrv.2021.102218] [Reference Citation Analysis]
485 Siena S, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, Yamaguchi K, Nishina T, Fakih M, Elez E, Rodriguez J, Ciardiello F, Komatsu Y, Esaki T, Chung K, Wainberg Z, Sartore-Bianchi A, Saxena K, Yamamoto E, Bako E, Okuda Y, Shahidi J, Grothey A, Yoshino T; DESTINY-CRC01 investigators. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol 2021;22:779-89. [PMID: 33961795 DOI: 10.1016/S1470-2045(21)00086-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
486 Kelm M, Schollbach J, Anger F, Wiegering A, Klein I, Germer CT, Schlegel N, Kunzmann V, Löb S. Prognostic impact of additive chemotherapy after curative resection of metachronous colorectal liver metastasis: a single-centre retrospective study. BMC Cancer 2021;21:490. [PMID: 33941104 DOI: 10.1186/s12885-021-07941-2] [Reference Citation Analysis]
487 Tie J, Wang Y, Cohen J, Li L, Hong W, Christie M, Wong HL, Kosmider S, Wong R, Thomson B, Choi J, Fox A, Field K, Burge M, Shannon J, Kotasek D, Tebbutt NC, Karapetis C, Underhill C, Haydon A, Schaeffer J, Ptak J, Tomasetti C, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. PLoS Med 2021;18:e1003620. [PMID: 33939694 DOI: 10.1371/journal.pmed.1003620] [Cited by in Crossref: 3] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
488 Lee SF, Choi HCW, Chan SK, Lam KO, Lee VHF, Wong IOL, Chiang CL. Cost-Effectiveness of Anti-Epidermal Growth Factor Receptor Therapy Versus Bevacizumab in KRAS Wild-Type (WT), Pan-RAS WT, and Pan-RAS WT Left-Sided Metastatic Colorectal Cancer. Front Oncol 2021;11:651299. [PMID: 34012917 DOI: 10.3389/fonc.2021.651299] [Reference Citation Analysis]
489 Guiu B, Deshayes E, Panaro F, Sanglier F, Cusumano C, Herrerro A, Sgarbura O, Molinari N, Quenet F, Cassinotto C. 99mTc-mebrofenin hepatobiliary scintigraphy and volume metrics before liver preparation: correlations and discrepancies in non-cirrhotic patients. Ann Transl Med 2021;9:795. [PMID: 34268408 DOI: 10.21037/atm-20-7372] [Reference Citation Analysis]
490 Doah KY, Shin US, Jeon BH, Cho SS, Moon SM. The Impact of Primary Tumor Resection on Survival in Asymptomatic Colorectal Cancer Patients With Unresectable Metastases. Ann Coloproctol 2021;37:94-100. [PMID: 33979907 DOI: 10.3393/ac.2020.09.15.1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
491 Jin B, Wu X, Xu G, Xing J, Wang Y, Yang H, Du S, Mao Y. Evolutions of the Management of Colorectal Cancer Liver Metastasis: A Bibliometric Analysis. J Cancer 2021;12:3660-70. [PMID: 33995641 DOI: 10.7150/jca.52842] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
492 Trullas A, Delgado J, Genazzani A, Mueller-Berghaus J, Migali C, Müller-Egert S, Zander H, Enzmann H, Pignatti F. The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer. ESMO Open 2021;6:100145. [PMID: 33940347 DOI: 10.1016/j.esmoop.2021.100145] [Cited by in Crossref: 3] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
493 Ardito F, Razionale F, Salvatore L, Cenci T, Vellone M, Basso M, Panettieri E, Calegari MA, Tortora G, Martini M, Giuliante F. Discordance of KRAS Mutational Status between Primary Tumors and Liver Metastases in Colorectal Cancer: Impact on Long-Term Survival Following Radical Resection. Cancers (Basel) 2021;13:2148. [PMID: 33946899 DOI: 10.3390/cancers13092148] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
494 García-Alfonso P, Muñoz Martín AJ, Ortega Morán L, Soto Alsar J, Torres Pérez-Solero G, Blanco Codesido M, Calvo Ferrandiz PA, Grasso Cicala S. Oral drugs in the treatment of metastatic colorectal cancer. Ther Adv Med Oncol 2021;13:17588359211009001. [PMID: 33995592 DOI: 10.1177/17588359211009001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
495 Al-Salama ZT. Encorafenib: A Review in Metastatic Colorectal Cancer with a BRAF V600E Mutation. Drugs 2021;81:849-56. [PMID: 33914242 DOI: 10.1007/s40265-021-01501-5] [Reference Citation Analysis]
496 Páez-Carpio A, Gómez FM, Isus Olivé G, Paredes P, Baetens T, Carrero E, Sánchez M, Vollmer I. Image-guided percutaneous ablation for the treatment of lung malignancies: current state of the art. Insights Imaging 2021;12:57. [PMID: 33914187 DOI: 10.1186/s13244-021-00997-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
497 Appalanaido GK, Bahajjaj SIBZ, Shukor SA, Ahmad MZ, Francis HCH. Case Report-Staged brachytherapy achieving complete metabolic response in unresectable oligometastatic colorectal cancer to the liver. Oxf Med Case Reports 2021;2021:omab016. [PMID: 33948189 DOI: 10.1093/omcr/omab016] [Reference Citation Analysis]
498 Xu H, Lu L, Lu T, Xu Y, Zong J, Huang C, Lin F, Zheng Y, Lin C, Lin S, Qiu S, Pan J, Lin S, Guo Q. Identifying the optimal candidates for locoregional radiation therapy in patients with de novo metastatic nasopharyngeal carcinoma. Head Neck 2021;43:2602-10. [PMID: 33904617 DOI: 10.1002/hed.26726] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
499 Liang YH, Tsai JH, Cheng YM, Chan KY, Hsu WL, Lee CC, Chen KH, Yeh KH. Chemotherapy agents stimulate dendritic cells against human colon cancer cells through upregulation of the transporter associated with antigen processing. Sci Rep 2021;11:9080. [PMID: 33907276 DOI: 10.1038/s41598-021-88648-z] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
500 Niedersüß-Beke D, Orlinger M, Falch D, Heiler C, Piringer G, Thaler J, Hilbe W, Petzer A, Rumpold H. Clinical Effectiveness of Oncological Treatment in Metastatic Colorectal Cancer Is Independent of Comorbidities and Age. Cancers (Basel) 2021;13:2091. [PMID: 33925931 DOI: 10.3390/cancers13092091] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
501 Sasaki M, Ishikawa T, Ishiguro M, Okazaki S, Yamauchi S, Kikuchi A, Matsuyama T, Kawada K, Tokunaga M, Uetake H, Kinugasa Y. The effectiveness of plasma miR-33a-5p as a predictive biomarker for the efficacy of colorectal cancer chemotherapy. Oncol Lett 2021;21:489. [PMID: 33968205 DOI: 10.3892/ol.2021.12749] [Reference Citation Analysis]
502 de Castro E Gloria H, Jesuíno Nogueira L, Bencke Grudzinski P, da Costa Ghignatti PV, Guecheva TN, Motta Leguisamo N, Saffi J. Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells. BMC Cancer 2021;21:448. [PMID: 33888065 DOI: 10.1186/s12885-021-08188-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
503 Bosma NA, Cheung WY, Thiessen M, Speers C, Renouf DJ, Tilley D, Tang PA, Ball CG, Dixon E, Lee-Ying RM. Real-World Outcomes of Oxaliplatin-Based Chemotherapy on R0 Resected Colonic Liver Metastasis. Clin Colorectal Cancer 2021;20:e201-9. [PMID: 34016533 DOI: 10.1016/j.clcc.2021.04.004] [Reference Citation Analysis]
504 Sutton PA, O'Dwyer ST, Barriuso J, Aziz O, Selvasekar CR, Renehan AG, Wilson MS. Indications and outcomes for repeat cytoreductive surgery and heated intra-peritoneal chemotherapy in peritoneal surface malignancy. Surg Oncol 2021;38:101572. [PMID: 33915487 DOI: 10.1016/j.suronc.2021.101572] [Reference Citation Analysis]
505 Ciardiello D, Martini G, Famiglietti V, Napolitano S, De Falco V, Troiani T, Latiano TP, Ros J, Elez Fernandez E, Vitiello PP, Maiello E, Ciardiello F, Martinelli E. Biomarker-Guided Anti-Egfr Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers (Basel) 2021;13:1941. [PMID: 33920531 DOI: 10.3390/cancers13081941] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
506 Zhu J, Hao J, Ma Q, Shi T, Wang S, Yan J, Chen R, Xu D, Jiang Y, Zhang J, Li J. A Novel Prognostic Model and Practical Nomogram for Predicting the Outcomes of Colorectal Cancer: Based on Tumor Biomarkers and Log Odds of Positive Lymph Node Scheme. Front Oncol 2021;11:661040. [PMID: 33937076 DOI: 10.3389/fonc.2021.661040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
507 Di Nicolantonio F, Vitiello PP, Marsoni S, Siena S, Tabernero J, Trusolino L, Bernards R, Bardelli A. Precision oncology in metastatic colorectal cancer - from biology to medicine. Nat Rev Clin Oncol 2021;18:506-25. [PMID: 33864051 DOI: 10.1038/s41571-021-00495-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
508 Tsilimigras DI, Brodt P, Clavien PA, Muschel RJ, D'Angelica MI, Endo I, Parks RW, Doyle M, de Santibañes E, Pawlik TM. Liver metastases. Nat Rev Dis Primers 2021;7:27. [PMID: 33859205 DOI: 10.1038/s41572-021-00261-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
509 Zhou Y, Han Z, Dou F, Yan T. Pre-colectomy location and TNM staging of colon cancer by the computed tomography colonography: a diagnostic performance study. World J Surg Oncol 2021;19:120. [PMID: 33858443 DOI: 10.1186/s12957-021-02215-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
510 Pilleron S, Maringe C, Charvat H, Atkinson J, Morris EJA, Sarfati D. The impact of timely cancer diagnosis on age disparities in colon cancer survival. J Geriatr Oncol 2021;12:1044-51. [PMID: 33863698 DOI: 10.1016/j.jgo.2021.04.003] [Reference Citation Analysis]
511 Xu K, He J, Zhang J, Liu T, Yang F, Ren T. A novel prognostic risk score model based on immune-related genes in patients with stage IV colorectal cancer. Biosci Rep 2020;40:BSR20201725. [PMID: 33034614 DOI: 10.1042/BSR20201725] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
512 Mas L, Bachet JB, Jooste V, Lepage C, Bouvier AM. Chemotherapy of metastatic colon cancer in France: A population-based study. Dig Liver Dis 2021:S1590-8658(21)00135-3. [PMID: 33865721 DOI: 10.1016/j.dld.2021.03.019] [Reference Citation Analysis]
513 Rodrigues JG, Duarte HO, Gomes C, Balmaña M, Martins ÁM, Hensbergen PJ, de Ru AH, Lima J, Albergaria A, van Veelen PA, Wuhrer M, Gomes J, Reis CA. Terminal α2,6-sialylation of epidermal growth factor receptor modulates antibody therapy response of colorectal cancer cells. Cell Oncol (Dordr) 2021;44:835-50. [PMID: 33847896 DOI: 10.1007/s13402-021-00606-z] [Reference Citation Analysis]
514 Kalligosfyri P, Nikou S, Bravou V, Kalogianni DP. Liquid biopsy genotyping by a simple lateral flow strip assay with visual detection. Anal Chim Acta 2021;1163:338470. [PMID: 34024417 DOI: 10.1016/j.aca.2021.338470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
515 Andrei P, Battuello P, Grasso G, Rovera E, Tesio N, Bardelli A. Integrated approaches for precision oncology in colorectal cancer: The more you know, the better. Semin Cancer Biol 2021:S1044-579X(21)00108-5. [PMID: 33848627 DOI: 10.1016/j.semcancer.2021.04.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
516 Sugimoto K, Sakamoto K, Ii Y, Amemiya K, Sugo H, Ito T, Munakata S, Takahashi M, Kojima Y, Tomiki Y, Sato K, Saiura A, Kawasaki S. Significance of postoperative adjuvant chemotherapy with an oxaliplatin-based regimen after simultaneous curative resection for colorectal cancer and synchronous colorectal liver metastasis: a propensity score matching analysis. BMC Surg 2021;21:188. [PMID: 33836701 DOI: 10.1186/s12893-021-01193-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
517 Meltzer S, Torgunrud A, Abrahamsson H, Solbakken AM, Flatmark K, Dueland S, Bakke KM, Bousquet PA, Negård A, Johansen C, Lyckander LG, Larsen FO, Schou JV, Redalen KR, Ree AH. The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer. Br J Cancer 2021;125:240-6. [PMID: 33837301 DOI: 10.1038/s41416-021-01377-y] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
518 Collettini F, Brangsch J, Reimann C, Chapiro J, Savic LJ, Buchholz R, Keller S, Hamm B, Goldberg SN, Makowski MR. Hepatic Radiofrequency Ablation: Monitoring of Ablation-Induced Macrophage Recruitment in the Periablational Rim Using SPION-Enhanced Macrophage-Specific Magnetic Resonance Imaging. Invest Radiol 2021;56:591-8. [PMID: 33787536 DOI: 10.1097/RLI.0000000000000777] [Reference Citation Analysis]
519 Ono K, Abe T, Oshita A, Sumi Y, Yano T, Okuda H, Kurayoshi M, Kobayashi T, Ohdan H, Noriyuki T, Nakahara M. Efficacy of upfront hepatectomy without neoadjuvant chemotherapy for resectable colorectal liver metastasis. World J Surg Oncol 2021;19:97. [PMID: 33820549 DOI: 10.1186/s12957-021-02210-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
520 Pramil E, Dillard C, Escargueil AE. Colorectal Cancer and Immunity: From the Wet Lab to Individuals. Cancers (Basel) 2021;13:1713. [PMID: 33916641 DOI: 10.3390/cancers13071713] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
521 Baretti M, Karunasena E, Zahurak M, Walker R, Zhao Y, Pisanic TR 2nd, Wang TH, Greten TF, Duffy AG, Gootjes E, Meijer G, Verheul HMW, Ahuja N, Herman JG, Azad NS. A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype. Clin Transl Sci 2021;14:954-63. [PMID: 33811727 DOI: 10.1111/cts.12960] [Reference Citation Analysis]
522 Lund-Andersen C, Torgunrud A, Fleten KG, Flatmark K. Omics analyses in peritoneal metastasis-utility in the management of peritoneal metastases from colorectal cancer and pseudomyxoma peritonei: a narrative review. J Gastrointest Oncol 2021;12:S191-203. [PMID: 33968437 DOI: 10.21037/jgo-20-136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
523 Andre T, Amonkar M, Norquist JM, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt CJA, Smith D, Garcia-Carbonero R, Sevilla I, De La Fouchardiere C, Rivera F, Elez E, Diaz LA Jr, Yoshino T, Van Cutsem E, Yang P, Farooqui M, Le DT. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. Lancet Oncol 2021;22:665-77. [PMID: 33812497 DOI: 10.1016/S1470-2045(21)00064-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
524 Joharatnam-Hogan N, Khan K. Thermal ablation in colorectal liver metastases-the paradox of equipoise. Hepatobiliary Surg Nutr 2021;10:276-8. [PMID: 33898577 DOI: 10.21037/hbsn-21-1] [Reference Citation Analysis]
525 Kovács A, Bischoff P, Haddad H, Kovács G, Schaefer A, Zhou W, Pinkawa M. Personalized Image-Guided Therapies for Local Malignencies: Interdisciplinary Options for Interventional Radiology and Interventional Radiotherapy. Front Oncol 2021;11:616058. [PMID: 33869002 DOI: 10.3389/fonc.2021.616058] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
526 Mahmood RD, Shaw D, Descamps T, Zhou C, Morgan RD, Mullamitha S, Saunders M, Mescallado N, Backen A, Morris K, Little RA, Cheung S, Watson Y, O'Connor JPB, Jackson A, Parker GJM, Dive C, Jayson GC. Effect of oxaliplatin plus 5-fluorouracil or capecitabine on circulating and imaging biomarkers in patients with metastatic colorectal cancer: a prospective biomarker study. BMC Cancer 2021;21:354. [PMID: 33794823 DOI: 10.1186/s12885-021-08097-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
527 Salvatore L, Bria E, Sperduti I, Hinke A, Hegewisch-Becker S, Aparicio T, Le Malicot K, Boige V, Koeberle D, Baertschi D, Dietrich D, Tortora G, Arnold D. Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase III studies. Cancer Treat Rev 2021;97:102202. [PMID: 33838596 DOI: 10.1016/j.ctrv.2021.102202] [Reference Citation Analysis]
528 Lurvink RJ, Rauwerdink P, Rovers KP, Wassenaar ECE, Deenen MJ, Nederend J, Huysentruyt CJR, van 't Erve I, Fijneman RJA, van der Hoeven EJRJ, Seldenrijk CA, Constantinides A, Kranenburg O, Los M, Herbschleb KH, Thijs AMJ, Creemers GM, Burger JWA, Wiezer MJ, Nienhuijs SW, Boerma D, de Hingh IHJT. First-line palliative systemic therapy alternated with electrostatic pressurised intraperitoneal aerosol chemotherapy (oxaliplatin) for isolated unresectable colorectal peritoneal metastases: protocol of a multicentre, single-arm, phase II study (CRC-PIPAC-II). BMJ Open 2021;11:e044811. [PMID: 33785492 DOI: 10.1136/bmjopen-2020-044811] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
529 Fathi M, Pustokhina I, Kuznetsov SV, Khayrullin M, Hojjat-Farsangi M, Karpisheh V, Jalili A, Jadidi-Niaragh F. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer. IUBMB Life 2021;73:726-38. [PMID: 33686787 DOI: 10.1002/iub.2461] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
530 Ottaiano A, Nasti G, Santorsola M, Altieri V, Di Fruscio G, Circelli L, Luce A, Cossu AM, Scognamiglio G, Perri F, Correra M, Belli A, Delrio P, Botti G, Caraglia M. KRAS Mutational Regression Is Associated With Oligo-Metastatic Status and Good Prognosis in Metastatic Colorectal Cancer. Front Oncol 2021;11:632962. [PMID: 33854968 DOI: 10.3389/fonc.2021.632962] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
531 Taiji R, Nishiofuku H, Tanaka T, Minamiguchi K, Fukuoka Y, Saito N, Taguchi H, Matsumoto T, Marugami N, Hirai T, Kichikawa K. Useful Parameters in Dynamic Contrast-enhanced Ultrasonography for Identifying Early Response to Chemotherapy in a Rat Liver Tumor Model. J Clin Imaging Sci 2021;11:15. [PMID: 33767907 DOI: 10.25259/JCIS_6_2020] [Reference Citation Analysis]
532 Ye P, Cai P, Xie J, Wei Y. The diagnostic accuracy of digital PCR, ARMS and NGS for detecting KRAS mutation in cell-free DNA of patients with colorectal cancer: A systematic review and meta-analysis. PLoS One 2021;16:e0248775. [PMID: 33770081 DOI: 10.1371/journal.pone.0248775] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
533 Piasecki P, Wierzbicki M, Majewska A, Kieda C, Narloch J. Initial experience with novel Embocure Plus microspheres for transarterial chemoembolization (TACE) of liver metastatic colorectal cancer tumours - a clinical and in vitro study. Pol J Radiol 2021;86:e136-42. [PMID: 33758639 DOI: 10.5114/pjr.2021.104056] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
534 Froelich MF, Schnitzer ML, Rathmann N, Tollens F, Unterrainer M, Rennebaum S, Seidensticker M, Ricke J, Rübenthaler J, Kunz WG. Cost-Effectiveness Analysis of Local Ablation and Surgery for Liver Metastases of Oligometastatic Colorectal Cancer. Cancers (Basel) 2021;13:1507. [PMID: 33806059 DOI: 10.3390/cancers13071507] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
535 Larroque M, Mounicou S, Sgarbura O, Arnaudguilhem C, Rebel L, Leaha C, Faye PA, Enjalbal C, Quénet F, Bouyssiere B, Carrere S. Study of oxaliplatin penetration into ovaries of patients treated with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastases of colorectal and appendiceal origin using mass spectrometry imaging. Pleura Peritoneum 2021;6:67-74. [PMID: 34179340 DOI: 10.1515/pp-2020-0149] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
536 Ottaiano A, Scala S, Santorsola M, Trotta AM, D'Alterio C, Portella L, Clemente O, Nappi A, Zanaletti N, De Stefano A, Avallone A, Granata V, Notariello C, Luce A, Lombardi A, Picone C, Petrillo A, Perri F, Tatangelo F, Di Mauro A, Albino V, Izzo F, Rega D, Pace U, Di Marzo M, Chiodini P, De Feo G, Del Prete P, Botti G, Delrio P, Caraglia M, Nasti G. Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol. Ther Adv Med Oncol 2021;13:1758835921989223. [PMID: 33854566 DOI: 10.1177/1758835921989223] [Reference Citation Analysis]
537 Deng Y, Zhao Y, Qin J, Huang X, Wu R, Zhou C, Pan Z. Prognostic Value of the C-Reactive Protein/Albumin Ratio and Systemic Immune-Inflammation Index for Patients With Colorectal Liver Metastasis Undergoing Curative Resection. Pathol Oncol Res 2021;27:633480. [PMID: 34257601 DOI: 10.3389/pore.2021.633480] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
538 Bohlok A, Duran Derijckere I, Azema H, Lucidi V, Vankerckhove S, Hendlisz A, Van Laethem JL, Vierasu I, Goldman S, Flamen P, Larsimont D, Demetter P, Dirix L, Vermeulen P, Donckier V. Clinico-metabolic characterization improves the prognostic value of histological growth patterns in patients undergoing surgery for colorectal liver metastases. J Surg Oncol 2021;123:1773-83. [PMID: 33751583 DOI: 10.1002/jso.26466] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
539 Zhao Y, Chen C, Xu X, Ge X, Ding K, Zheng S, Wang J, Sun L. An Efficient Prognostic Immune Scoring System For Colorectal Cancer Patients With Peritoneal Metastasis. Oncoimmunology 2021;10:1901464. [PMID: 33796414 DOI: 10.1080/2162402X.2021.1901464] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
540 Isoniemi H, Uutela A, Nordin A, Lantto E, Kellokumpu I, Ovissi A, Kosunen J, Kallio R, Soveri LM, Salminen T, Ålgars A, Lamminmäki A, Halonen P, Ristamäki R, Räsänen J, Karjula H, Vaalavuo Y, Lavonius M, Osterlund P. Centralized repeated resectability assessment of patients with colorectal liver metastases during first-line treatment: prospective study. Br J Surg 2021;108:817-25. [PMID: 33749772 DOI: 10.1093/bjs/znaa145] [Cited by in Crossref: 2] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
541 Prejac J, Kekez D, Belev B, Prejac M, Pleština S. Frequency of Body Weight Loss is an Independent Prognostic Factor of First-Line Treatment Outcomes in Metastatic Colorectal Cancer. Nutr Cancer 2021;:1-7. [PMID: 33739208 DOI: 10.1080/01635581.2021.1900300] [Reference Citation Analysis]
542 Chan RH, Lin PC, Chen SH, Lin SC, Chen PC, Lin BW, Shen MR, Yeh YM. Clinical Utility of a Cell-Free DNA Assay in Patients With Colorectal Cancer. Front Oncol 2021;11:589673. [PMID: 33816227 DOI: 10.3389/fonc.2021.589673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
543 Takahashi T, Yamazaki K, Oki E, Shiozawa M, Mitsugi K, Makiyama A, Nakamura M, Ojima H, Kagawa Y, Matsuhashi N, Okuda H, Asayama M, Yuasa Y, Shimada Y, Manaka D, Watanabe J, Oba K, Yoshino T, Yoshida K, Maehara Y. Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7. ESMO Open 2021;6:100093. [PMID: 33744811 DOI: 10.1016/j.esmoop.2021.100093] [Reference Citation Analysis]
544 Kwan J, Pua U. Review of Intra-Arterial Therapies for Colorectal Cancer Liver Metastasis. Cancers (Basel) 2021;13:1371. [PMID: 33803606 DOI: 10.3390/cancers13061371] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
545 Patelli G, Vaghi C, Tosi F, Mauri G, Amatu A, Massihnia D, Ghezzi S, Bonazzina E, Bencardino K, Cerea G, Siena S, Sartore-Bianchi A. Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA. Target Oncol 2021;16:309-24. [PMID: 33738696 DOI: 10.1007/s11523-021-00795-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
546 Meijerink MR, Ruarus AH, Vroomen LGPH, Puijk RS, Geboers B, Nieuwenhuizen S, van den Bemd BAT, Nielsen K, de Vries JJJ, van Lienden KP, Lissenberg-Witte BI, van den Tol MP, Scheffer HJ. Irreversible Electroporation to Treat Unresectable Colorectal Liver Metastases (COLDFIRE-2): A Phase II, Two-Center, Single-Arm Clinical Trial. Radiology 2021;299:470-80. [PMID: 33724066 DOI: 10.1148/radiol.2021203089] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
547 Hou MM, Ho CL, Lin HY, Zhu Y, Zhang X. Phase I first-in-human study of HLX07, a novel and improved recombinant anti-EGFR humanized monoclonal antibody, in patients with advanced solid cancers. Invest New Drugs 2021;39:1315-23. [PMID: 33713216 DOI: 10.1007/s10637-021-01099-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
548 Căinap C, Bochiş OV, Vlad C, Popita R, Achimaş-Cadariu P, Havasi A, Vidrean A, Dranca A, Piciu A, Constantin AM, Tat T, Dana M, Crişan O, Cioban CV, Bălăcescu O, Coza O, Bălăcescu L, Marta MM, Bota M, Căinap S. Doubling the Dose of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer-the Experience of a Tertiary Cancer Center. Front Pharmacol 2021;12:487316. [PMID: 33776758 DOI: 10.3389/fphar.2021.487316] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
549 Díez-Alonso M, Mendoza-Moreno F, Jiménez-Álvarez L, Nuñez O, Blazquez-Martín A, Sanchez-Gollarte A, Matías-García B, Molina R, San-Juan A, Gutierrez-Calvo A. Prognostic factors of survival in stage IV colorectal cancer with synchronous liver metastasis: Negative effect of the KRAS mutation. Mol Clin Oncol 2021;14:93. [PMID: 33767862 DOI: 10.3892/mco.2021.2255] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
550 Kiritani S, Yoshimura K, Arita J, Kokudo T, Hakoda H, Tanimoto M, Ishizawa T, Akamatsu N, Kaneko J, Takeda S, Hasegawa K. A new rapid diagnostic system with ambient mass spectrometry and machine learning for colorectal liver metastasis. BMC Cancer 2021;21:262. [PMID: 33691644 DOI: 10.1186/s12885-021-08001-5] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
551 Auber ML, Wen S, Hobbs G, Higa GM. Capecitabine as Maintenance Therapy for High-Risk, Resected Colorectal Cancer. Gastrointest Tumors 2021;8:81-6. [PMID: 33981686 DOI: 10.1159/000513960] [Reference Citation Analysis]
552 Mustachio LM, Chelariu-Raicu A, Szekvolgyi L, Roszik J. Targeting KRAS in Cancer: Promising Therapeutic Strategies. Cancers (Basel) 2021;13:1204. [PMID: 33801965 DOI: 10.3390/cancers13061204] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
553 Pilleron S, Gower H, Janssen-Heijnen M, Signal VC, Gurney JK, Morris EJ, Cunningham R, Sarfati D. Patterns of age disparities in colon and lung cancer survival: a systematic narrative literature review. BMJ Open 2021;11:e044239. [PMID: 33692182 DOI: 10.1136/bmjopen-2020-044239] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
554 Ratti F, Cipriani F, Fiorentini G, Burgio V, Ronzoni M, Della Corte A, Cascinu S, De Cobelli F, Aldrighetti L. Evolution of Surgical Treatment of Colorectal Liver Metastases in the Real World: Single Center Experience in 1212 Cases. Cancers (Basel) 2021;13:1178. [PMID: 33803257 DOI: 10.3390/cancers13051178] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
555 Yamazaki K, Yuki S, Oki E, Sano F, Makishima M, Aoki K, Hamano T, Yamanaka T. Real-World Evidence on Second-Line Treatment of Metastatic Colorectal Cancer Using Fluoropyrimidine, Irinotecan, and Angiogenesis Inhibitor. Clin Colorectal Cancer 2021;20:e173-84. [PMID: 33875364 DOI: 10.1016/j.clcc.2021.03.001] [Reference Citation Analysis]
556 Galindo-Pumariño C, Collado M, Herrera M, Peña C. Tumor Microenvironment in Metastatic Colorectal Cancer: The Arbitrator in Patients' Outcome. Cancers (Basel) 2021;13:1130. [PMID: 33800796 DOI: 10.3390/cancers13051130] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
557 Hervieu C, Christou N, Battu S, Mathonnet M. The Role of Cancer Stem Cells in Colorectal Cancer: From the Basics to Novel Clinical Trials. Cancers (Basel) 2021;13:1092. [PMID: 33806312 DOI: 10.3390/cancers13051092] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
558 Rigamonti A, Feuerhake F, Donadon M, Locati M, Marchesi F. Histopathological and Immune Prognostic Factors in Colo-Rectal Liver Metastases. Cancers (Basel) 2021;13:1075. [PMID: 33802446 DOI: 10.3390/cancers13051075] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
559 Rosati G, Aprile G, Basile D, Avallone A. Perspectives in the Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer Patients. Front Oncol 2021;11:602596. [PMID: 33738249 DOI: 10.3389/fonc.2021.602596] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
560 Padder RA, Bhat ZI, Ahmad Z, Singh N, Husain M. DRP1 Promotes BRAFV600E-Driven Tumor Progression and Metabolic Reprogramming in Colorectal Cancer. Front Oncol 2020;10:592130. [PMID: 33738242 DOI: 10.3389/fonc.2020.592130] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
561 Bourhis J, Stein A, Paul de Boer J, Van Den Eynde M, Gold KA, Stintzing S, Becker JC, Moran M, Schroeder A, Pennock G, Salmio S, Esser R, Ciardiello F. Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer. Cancer Treat Rev 2021;97:102172. [PMID: 33989949 DOI: 10.1016/j.ctrv.2021.102172] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
562 Robinson H, Karpe M, Edidi I, Fisher A, Drew Y, Ralte A, O'Donnell RL. Enteric Type Bartholin Gland Adenocarcinoma: An Unusual Variant of a Rare Neoplasm. Int J Gynecol Pathol 2021;40:190-5. [PMID: 31985580 DOI: 10.1097/PGP.0000000000000667] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
563 Wensink E, Bond M, Kucukkose E, May A, Vink G, Koopman M, Kranenburg O, Roodhart J. A review of the sensitivity of metastatic colorectal cancer patients with deficient mismatch repair to standard-of-care chemotherapy and monoclonal antibodies, with recommendations for future research. Cancer Treat Rev 2021;95:102174. [PMID: 33721596 DOI: 10.1016/j.ctrv.2021.102174] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
564 Uhlig J, Lukovic J, Dawson LA, Patel RA, Cavnar MJ, Kim HS. Locoregional Therapies for Colorectal Cancer Liver Metastases: Options Beyond Resection. Am Soc Clin Oncol Educ Book 2021;41:133-46. [PMID: 34010047 DOI: 10.1200/EDBK_320519] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
565 Reese T, Makridis G, Raptis D, Malagó M, Hernandez-Alejandro R, Tun-Abraham M, Ardiles V, de Santibañes E, Fard-Aghaie M, Li J, Kuemmerli C, Petrowsky H, Linecker M, Clavien PA, Oldhafer KJ. Repeated hepatectomy after ALPPS for recurrence of colorectal liver metastasis: the edge of limits? HPB (Oxford) 2021:S1365-182X(21)00046-0. [PMID: 33726975 DOI: 10.1016/j.hpb.2021.02.008] [Reference Citation Analysis]
566 Tudela-lerma M, Orcajo-rincón J, Ramón-botella E, Álvarez-luque A, Gonzalez-leyte M, Rotger-regi A, Velasco-sánchez E, Colón-rodriguez A. Efficacy and safety of Yttrium-90 radioembolization in the treatment of neuroendocrine liver metastases. Long-term monitoring and impact on survival. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 2021;40:82-90. [DOI: 10.1016/j.remnie.2021.01.009] [Reference Citation Analysis]
567 Breton C, Meyer A, Malka D, Matias M, De Baere T, Hammel P, Sa Cunha A, Lucchese A, Fuks D, Coriat R, Gallois C, Touchefeu Y, Maillet M, Trouilloud I, Rompteaux P, Carbonnel F, Soularue E. Local treatment of pancreatic cancer metastases: A multicenter French study of the AGEO group. Clin Res Hepatol Gastroenterol 2021;45:101607. [PMID: 33662776 DOI: 10.1016/j.clinre.2020.101607] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
568 Hansen TF, Qvortrup C, Pfeiffer P. Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data. Cancers (Basel) 2021;13:1031. [PMID: 33804554 DOI: 10.3390/cancers13051031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
569 Bagchi A, Madaj Z, Engel KB, Guan P, Rohrer DC, Valley DR, Wolfrum E, Feenstra K, Roche N, Hostetter G, Moore HM, Jewell SD. Impact of Preanalytical Factors on the Measurement of Tumor Tissue Biomarkers Using Immunohistochemistry. J Histochem Cytochem 2021;69:297-320. [PMID: 33641490 DOI: 10.1369/0022155421995600] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
570 Takahashi S, Sakamoto Y, Denda T, Takashima A, Komatsu Y, Nakamura M, Ohori H, Yamaguchi T, Kobayashi Y, Baba H, Kotake M, Amagai K, Kondo H, Shimada K, Sato A, Yuki S, Okita A, Ouchi K, Komine K, Watanabe M, Morita S, Ishioka C. Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin-based or irinotecan-based therapy for colorectal cancer. Cancer Sci 2021;112:1567-78. [PMID: 33548159 DOI: 10.1111/cas.14841] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
571 González Astorga B, Salvà Ballabrera F, Aranda Aguilar E, Élez Fernández E, García-Alfonso P, González Flores E, Vera García R, Fernández Montes A, López Muñoz AM, Salud Salvia A. Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept. Clin Transl Oncol 2021;23:1520-8. [PMID: 33630242 DOI: 10.1007/s12094-021-02568-y] [Reference Citation Analysis]
572 Liu C, Hu C, Huang J, Xiang K, Li Z, Qu J, Chen Y, Yang B, Qu X, Liu Y, Zhang G, Wen T. A Prognostic Nomogram of Colon Cancer With Liver Metastasis: A Study of the US SEER Database and a Chinese Cohort. Front Oncol 2021;11:591009. [PMID: 33738248 DOI: 10.3389/fonc.2021.591009] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
573 Badic B, Tixier F, Cheze Le Rest C, Hatt M, Visvikis D. Radiogenomics in Colorectal Cancer. Cancers (Basel) 2021;13:973. [PMID: 33652647 DOI: 10.3390/cancers13050973] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
574 Li S, Dong D, Geng J, Zhu X, Shi C, Zhang Y, Wang H, Zhou S, Wu H, Cai Y, Li Y, Wang W. Stereotactic body radiotherapy prolongs the progression-free survival and delays the change of systemic therapy regimen in patients with lung oligoprogressive metastatic colorectal cancer. Asia Pac J Clin Oncol 2021. [PMID: 33629479 DOI: 10.1111/ajco.13557] [Reference Citation Analysis]
575 García-Alfonso P, Díaz-Rubio E, Abad A, Carrato A, Massutí B, Ortiz-Morales MJ, Manzano Mozo JL, Muñoz A, Durán G, Sastre J, Safont MJ, Ferreiro R, Rivera F, González E, Valladares-Ayerbes M, Grávalos C, Alonso-Orduña V, Viéitez JM, Yubero A, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis. Drugs Aging 2021;38:219-31. [PMID: 33615402 DOI: 10.1007/s40266-021-00834-w] [Reference Citation Analysis]
576 Mulens-Arias V, Nicolás-Boluda A, Pinto A, Balfourier A, Carn F, Silva AKA, Pocard M, Gazeau F. Tumor-Selective Immune-Active Mild Hyperthermia Associated with Chemotherapy in Colon Peritoneal Metastasis by Photoactivation of Fluorouracil-Gold Nanoparticle Complexes. ACS Nano 2021;15:3330-48. [PMID: 33528985 DOI: 10.1021/acsnano.0c10276] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
577 Ros J, Baraibar I, Sardo E, Mulet N, Salvà F, Argilés G, Martini G, Ciardiello D, Cuadra JL, Tabernero J, Élez E. BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer. Ther Adv Med Oncol 2021;13:1758835921992974. [PMID: 33747149 DOI: 10.1177/1758835921992974] [Cited by in Crossref: 2] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
578 Delpla A, de Baere T, Varin E, Deschamps F, Roux C, Tselikas L. Role of Thermal Ablation in Colorectal Cancer Lung Metastases. Cancers (Basel) 2021;13:908. [PMID: 33671510 DOI: 10.3390/cancers13040908] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
579 Li S, Zhang Y, Yu Y, Zhu X, Geng J, Teng H, Wang Z, Sun T, Wang L, Wang H, Li Y, Wu A, Cai Y, Wang W. Simultaneous Integrated Boost Intensity-Modulated Radiation Therapy Can Benefit the Locally Advanced Rectal Cancer Patients With Clinically Positive Lateral Pelvic Lymph Node. Front Oncol 2020;10:627572. [PMID: 33692945 DOI: 10.3389/fonc.2020.627572] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
580 Villard C, Habib M, Nordenvall C, Nilsson PJ, Jorns C, Sparrelid E. Conversion therapy in patients with colorectal liver metastases. Eur J Surg Oncol 2021;47:2038-45. [PMID: 33640172 DOI: 10.1016/j.ejso.2021.02.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
581 Zmrzljak UP, Košir R, Krivokapić Z, Radojković D, Nikolić A. Detection of Somatic Mutations with ddPCR from Liquid Biopsy of Colorectal Cancer Patients. Genes (Basel) 2021;12:289. [PMID: 33669856 DOI: 10.3390/genes12020289] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
582 Frank MH, Wilson BJ, Gold JS, Frank NY. Clinical Implications of Colorectal Cancer Stem Cells in the Age of Single-Cell Omics and Targeted Therapies. Gastroenterology 2021;160:1947-60. [PMID: 33617889 DOI: 10.1053/j.gastro.2020.12.080] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
583 Whelton SP, Berning P, Blumenthal RS, Marshall CH, Martin SS, Mortensen MB, Blaha MJ, Dzaye O. Multidisciplinary prevention and management strategies for colorectal cancer and cardiovascular disease. Eur J Intern Med 2021;87:3-12. [PMID: 33610416 DOI: 10.1016/j.ejim.2021.02.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
584 Voogt ELK, van Zoggel DMGI, Kusters M, Nieuwenhuijzen GAP, Cnossen JS, Creemers GJ, van Lijnschoten G, Nederend J, Roef MJ, Burger JWA, Rutten HJT. Impact of a history of metastases or synchronous metastases on survival in patients with locally recurrent rectal cancer. Colorectal Dis 2021;23:1120-31. [PMID: 33474793 DOI: 10.1111/codi.15537] [Reference Citation Analysis]
585 Sari AN, Elwakeel A, Dhanjal JK, Kumar V, Sundar D, Kaul SC, Wadhwa R. Identification and Characterization of MortaparibPlus-A Novel Triazole Derivative That Targets Mortalin-p53 Interaction and Inhibits Cancer-Cell Proliferation by Wild-Type p53-Dependent and -Independent Mechanisms. Cancers (Basel) 2021;13:835. [PMID: 33671256 DOI: 10.3390/cancers13040835] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
586 Derksen JWG, Vink GR, Elferink MAG, Roodhart JML, Verkooijen HM, van Grevenstein WMU, Siersema PD, May AM, Koopman M; PLCRC Study Group. The Prospective Dutch Colorectal Cancer (PLCRC) cohort: real-world data facilitating research and clinical care. Sci Rep 2021;11:3923. [PMID: 33594104 DOI: 10.1038/s41598-020-79890-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
587 Chang HL, Jones AL. Current Status of Biologics in Perioperative Treatment for Resectable or Borderline Resectable Liver Metastases. Curr Colorectal Cancer Rep 2021;17:10-22. [DOI: 10.1007/s11888-021-00464-9] [Reference Citation Analysis]
588 Filippiadis DK, Velonakis G, Kelekis A, Sofocleous CT. The Role of Percutaneous Ablation in the Management of Colorectal Cancer Liver Metastatic Disease. Diagnostics (Basel) 2021;11:308. [PMID: 33672993 DOI: 10.3390/diagnostics11020308] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
589 Rodriguez A, Esposito F, Oliveres H, Torres F, Maurel J. Are Quality of Randomized Clinical Trials and ESMO-Magnitude of Clinical Benefit Scale Two Sides of the Same Coin, to Grade Recommendations for Drug Approval? J Clin Med 2021;10:746. [PMID: 33668473 DOI: 10.3390/jcm10040746] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
590 Wang C, Fakih M. Targeting KRAS in Colorectal Cancer. Curr Oncol Rep 2021;23:28. [PMID: 33582927 DOI: 10.1007/s11912-021-01022-0] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
591 Filippi R, Depetris I, Satolli MA. Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion. Expert Opin Pharmacother 2021;22:677-84. [PMID: 33576301 DOI: 10.1080/14656566.2021.1876664] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
592 Tabernero J, Taieb J, Prager GW, Ciardiello F, Fakih M, Leger C, Fougeray R, Amellal N, van Cutsem E. Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design. Future Oncol 2021;17:1977-85. [PMID: 33569986 DOI: 10.2217/fon-2020-1238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
593 Qin S, Li J, Bai Y, Deng Y, Yang L, Xu RH, Zhong H, Chen Z, Pan H, Guo W, Shu Y, Xu J, Peng C, Chen Y, Li H, Wang N, Guo X, Peng M, Fan S, Shen L. Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in the FRESCO trial. Future Oncol 2021;17:1923-31. [PMID: 33563040 DOI: 10.2217/fon-2020-1215] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
594 Tomasova K, Kroupa M, Forsti A, Vodicka P, Vodickova L. Telomere maintenance in interplay with DNA repair in pathogenesis and treatment of colorectal cancer. Mutagenesis 2020;35:261-71. [PMID: 32083302 DOI: 10.1093/mutage/geaa005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
595 Wu XA, Shi Y, Du SD. Surgical treatment of colorectal liver metastasis. Shijie Huaren Xiaohua Zazhi 2021; 29(3): 110-115 [DOI: 10.11569/wcjd.v29.i3.110] [Reference Citation Analysis]
596 Shinozaki E, Makiyama A, Kagawa Y, Satake H, Tanizawa Y, Cai Z, Piao Y. Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database. PLoS One 2021;16:e0246160. [PMID: 33556095 DOI: 10.1371/journal.pone.0246160] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
597 Vogel WH, Minhas A, Baumrucker S. Dihydropyrimidine Dehydrogenase Deficiency: To Screen or Not to Screen? J Adv Pract Oncol 2020;11:68-73. [PMID: 33542850 DOI: 10.6004/jadpro.2020.11.1.4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
598 Vogl M, Rosenmayr A, Bohanes T, Scheed A, Brndiar M, Stubenberger E, Ghanim B. Biomarkers for Malignant Pleural Mesothelioma-A Novel View on Inflammation. Cancers (Basel) 2021;13:658. [PMID: 33562138 DOI: 10.3390/cancers13040658] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
599 Behrenbruch C, Prabhakaran S, Udayasiri D, Hollande F, Michael M, Hayes I, Heriot A, Knowles B, Thomson B. Survival benefit of neoadjuvant chemotherapy and surgery versus surgery first for resectable colorectal liver metastases: a cohort study. ANZ J Surg 2021;91:1196-202. [PMID: 33543551 DOI: 10.1111/ans.16613] [Reference Citation Analysis]
600 Liang JY, Lin HC, Liu J, Wang DS, Yuan YF, Li BK, Zheng Y, Wu XJ, Chen G, Wang FH, Wang ZQ, Pan ZZ, Wan DS, Xu RH, Li YH. A novel prognostic nomogram for colorectal cancer liver metastasis patients with recurrence after hepatectomy. Cancer Med 2021;10:1535-44. [PMID: 33539664 DOI: 10.1002/cam4.3697] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
601 Kawai S, Takeshima N, Hayasaka Y, Notsu A, Yamazaki M, Kawabata T, Yamazaki K, Mori K, Yasui H. Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis. BMC Cancer 2021;21:116. [PMID: 33541293 DOI: 10.1186/s12885-021-07823-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
602 Repullo DJ, Barbois S, Leonard D, Bohlok A, Van den Audenaeren ET, Hendlisz A, Van den Eynde M, Donckier V, Kartheuser A, Liberale G. The absence of benefit of perioperative chemotherapy in initially resectable peritoneal metastases of colorectal cancer origin treated with complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A retrospective analysis. Eur J Surg Oncol 2021;47:1661-7. [PMID: 33602530 DOI: 10.1016/j.ejso.2021.01.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
603 Zhou F, Ding J. Prognosis and factors affecting colorectal cancer with ovarian metastasis. Updates Surg 2021;73:391-8. [PMID: 33523414 DOI: 10.1007/s13304-021-00978-9] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
604 Okamoto K, Uetake H. Current status of treatment for colorectal liver metastases in the United Kingdom. Hepatobiliary Surg Nutr 2021;10:116-8. [PMID: 33575299 DOI: 10.21037/hbsn.2020.04.08] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
605 Behrenbruch C, Prabhakaran S, Udayasiri D D, Michael M, Hollande F, Hayes I, Heriot AG, Knowles B, Thomson BN. Association between imaging response and survival following neoadjuvant chemotherapy in patients with resectable colorectal liver metastases: A cohort study. J Surg Oncol 2021;123:1263-73. [PMID: 33524184 DOI: 10.1002/jso.26400] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
606 Jin KT, Chen B, Liu YY, Lan HU, Yan JP. Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer. Cancer Cell Int 2021;21:83. [PMID: 33522929 DOI: 10.1186/s12935-021-01763-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
607 Conway C, Collins DM, McCann A, Dean K. Research Strategies for Low-Survival Cancers. Cancers (Basel) 2021;13:528. [PMID: 33573275 DOI: 10.3390/cancers13030528] [Reference Citation Analysis]
608 Osterlund P, Salminen T, Soveri LM, Kallio R, Kellokumpu I, Lamminmäki A, Halonen P, Ristamäki R, Lantto E, Uutela A, Osterlund E, Ovissi A, Nordin A, Heervä E, Lehtomäki K, Räsänen J, Murashev M, Aroviita L, Jekunen A, Lindvall-Andersson R, Nyandoto P, Kononen J, Lepistö A, Poussa T, Muhonen T, Ålgars A, Isoniemi H; Members of The RAXO study group are collaborators of this study and are listed in Appendix Table 4B. Repeated centralized multidisciplinary team assessment of resectability, clinical behavior, and outcomes in 1086 Finnish metastatic colorectal cancer patients (RAXO): A nationwide prospective intervention study. Lancet Reg Health Eur 2021;3:100049. [PMID: 34557799 DOI: 10.1016/j.lanepe.2021.100049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
609 Storman D, Swierz MJ, Riemsma RP, Wolff R, Mitus JW, Pedziwiatr M, Kleijnen J, Bala MM. Electrocoagulation for liver metastases. Cochrane Database Syst Rev 2021;1:CD009497. [PMID: 33507555 DOI: 10.1002/14651858.CD009497.pub3] [Reference Citation Analysis]
610 Vigano L, Corleone P, Darwish SS, Turri N, Famularo S, Viggiani L, Rimassa L, Del Fabbro D, Di Tommaso L, Torzilli G. Hepatic and Extrahepatic Colorectal Metastases Have Discordant Responses to Systemic Therapy. Pathology Data from Patients Undergoing Simultaneous Resection of Multiple Tumor Sites. Cancers (Basel) 2021;13:464. [PMID: 33530435 DOI: 10.3390/cancers13030464] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
611 Martín-Richard M, Tobeña M. First-Line Maintenance Treatment in Metastatic Colorectal Cancer (mCRC): Quality and Clinical Benefit Overview. J Clin Med 2021;10:470. [PMID: 33530547 DOI: 10.3390/jcm10030470] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
612 Geng R, Wang G, Qiu L, Liu B, Yang F, Zhang J, Miao Y. Metronomic capecitabine as maintenance treatment after first line induction with XELOX for metastatic colorectal cancer patients. Medicine (Baltimore) 2020;99:e23719. [PMID: 33371122 DOI: 10.1097/MD.0000000000023719] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
613 Li S, Geng J, Wang L, Teng H, Wang Z, Zhu X, Zhang Y, Wang H, Li Y, Cai Y, Wu A, Wang W. Effect of Simultaneous Integrated Boost Intensity Modulated Radiation Therapy (SIB-IMRT) and Non-Operative Strategy on Outcomes of Distal Rectal Cancer Patients with Clinically Positive Lateral Pelvic Lymph Node. Cancer Manag Res 2021;13:537-46. [PMID: 33519233 DOI: 10.2147/CMAR.S286796] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
614 Kafatos G, Banks V, Burdon P, Neasham D, Lowe KA, Anger C, Manuguid F, Trojan J. Impact of biomarkers and primary tumor location on the metastatic colorectal cancer first-line treatment landscape in five European countries. Future Oncol 2021;17:1495-505. [PMID: 33464120 DOI: 10.2217/fon-2020-0976] [Reference Citation Analysis]
615 Kafatos G, Banks V, Burdon P, Neasham D, Anger C, Manuguid F, Lowe KA, Cheung P, Taieb J, van Krieken JH. Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database. Future Oncol 2021;17:1483-94. [PMID: 33464119 DOI: 10.2217/fon-2020-0975] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
616 Hendriks P, Berkhout WEM, Kaanen CI, Sluijter JH, Visser IJ, van den Dobbelsteen JJ, de Geus-Oei LF, Webb AG, Burgmans MC. Performance of the Emprint and Amica Microwave Ablation Systems in ex vivo Porcine Livers: Sphericity and Reproducibility Versus Size. Cardiovasc Intervent Radiol 2021;44:952-8. [PMID: 33462682 DOI: 10.1007/s00270-020-02742-9] [Reference Citation Analysis]
617 Martínez-Lago N, Fernández-Montes A, Covela M, Brozos EM, De la Cámara J, Méndez Méndez JC, Jorge-Fernández M, Cousillas Castiñeiras A, Reboredo C, Arias Ron D, Pellón Augusto ML, González Villarroel P, Graña B, Salgado Fernández M, Carral Maseda A, Vázquez Rivera F, Candamio Folgar S, Reboredo López M; Galician Research Group on Digestive Tumors (GITuD). Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain. BMC Cancer 2021;21:64. [PMID: 33446148 DOI: 10.1186/s12885-020-07758-5] [Reference Citation Analysis]
618 Mocan T, Stiufiuc R, Popa C, Nenu I, Pestean C, Nagy AL, Mocan LP, Leucuta DC, Hajjar NA, Sparchez Z. Percutaneous ultrasound guided PEG-coated gold nanoparticles enhanced radiofrequency ablation in liver. Sci Rep 2021;11:1316. [PMID: 33446793 DOI: 10.1038/s41598-020-79917-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
619 Vaugier L, Mirabel X, Martel-Lafay I, Racadot S, Carrie C, Vendrely V, Mahé MA, Senellart H, Raoul JL, Campion L, Rio E. Radiosensitizing Chemotherapy (Irinotecan) with Stereotactic Body Radiation Therapy for the Treatment of Inoperable Liver and/or Lung Metastases of Colorectal Cancer. Cancers (Basel) 2021;13:E248. [PMID: 33440832 DOI: 10.3390/cancers13020248] [Reference Citation Analysis]
620 Martínez AM, Ferrández MJA, Rello AP, Gimeno-Ballester V, Pueyo AE, Blanco OP, Malo S, Sazatornil MRA. Analysis of first-line treatment in older patients with metastasic colorectal cancer. J Oncol Pharm Pract 2021;:1078155220984229. [PMID: 33430690 DOI: 10.1177/1078155220984229] [Reference Citation Analysis]
621 Liu JM, Wang YY, Liu W, Xu D, Wang K, Xing BC. Preoperative CA19-9: a competitive predictor of recurrence in patients with colorectal cancer liver metastases after hepatectomy. Int J Colorectal Dis 2021;36:767-78. [PMID: 33420522 DOI: 10.1007/s00384-020-03828-z] [Reference Citation Analysis]
622 Detailleur S, Segelov E, Re MD, Prenen H. Dihydropyrimidine dehydrogenase deficiency in patients with severe toxicity after 5-fluorouracil: a retrospective single-center study. Ann Gastroenterol 2021;34:68-72. [PMID: 33414624 DOI: 10.20524/aog.2020.0551] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
623 Escalante PI, Quiñones LA, Contreras HR. Epithelial-Mesenchymal Transition and MicroRNAs in Colorectal Cancer Chemoresistance to FOLFOX. Pharmaceutics 2021;13:75. [PMID: 33429840 DOI: 10.3390/pharmaceutics13010075] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
624 Trullas A, Delgado J, Koenig J, Fuerstenau U, Dedorath J, Hausmann S, Stock T, Enzmann H, Pignatti F. The EMA assessment of encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal carcinoma harbouring the BRAFV600E mutation who have received prior therapy. ESMO Open 2021;6:100031. [PMID: 33422765 DOI: 10.1016/j.esmoop.2020.100031] [Reference Citation Analysis]
625 Martinelli E, Ciardiello D, Martini G, Troiani T, Cardone C, Vitiello PP, Normanno N, Rachiglio AM, Maiello E, Latiano T, De Vita F, Ciardiello F. Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives. Ann Oncol 2020;31:30-40. [PMID: 31912793 DOI: 10.1016/j.annonc.2019.10.007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 29.0] [Reference Citation Analysis]
626 Vitiello PP, Martini G, Mele L, Giunta EF, De Falco V, Ciardiello D, Belli V, Cardone C, Matrone N, Poliero L, Tirino V, Napolitano S, Della Corte C, Selvaggi F, Papaccio G, Troiani T, Morgillo F, Desiderio V, Ciardiello F, Martinelli E. Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer. J Exp Clin Cancer Res 2021;40:15. [PMID: 33407715 DOI: 10.1186/s13046-020-01811-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
627 Gamradt P, De La Fouchardière C, Hennino A. Stromal Protein-Mediated Immune Regulation in Digestive Cancers. Cancers (Basel) 2021;13:E146. [PMID: 33466303 DOI: 10.3390/cancers13010146] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
628 Deng H, Zhu HL, Li Y, Wang Y, Wu Y, Cui H, Wang JL, Li XP. Treatment of liver metastases in patients with epithelial ovarian cancer. Chin Med J (Engl) 2021;134:1236-8. [PMID: 33410622 DOI: 10.1097/CM9.0000000000001332] [Reference Citation Analysis]
629 Bragagnoli AC, Araujo RLC, Ferraz MW, Dos Santos LV, Abdalla KC, Comar F, Santos FA, Oliveira MA, Carvalheira JBC, Cárcano FM, da Silveira Nogueira Lima JP. Metformin plus lrinotecan in patients with refractory colorectal cancer: a phase 2 clinical trial. Br J Cancer 2021;124:1072-8. [PMID: 33398062 DOI: 10.1038/s41416-020-01208-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
630 Mauri G, Bonazzina E, Amatu A, Tosi F, Bencardino K, Gori V, Massihnia D, Cipani T, Spina F, Ghezzi S, Siena S, Sartore-Bianchi A. The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer. Cancers (Basel) 2021;13:E137. [PMID: 33406649 DOI: 10.3390/cancers13010137] [Cited by in Crossref: 2] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
631 Raimondi A, Corallo S, Lonardi S, Antoniotti C, Rimassa L, Amatu A, Tampellini M, Racca P, Murialdo R, Clavarezza M, Zaniboni A, Toscano G, Tomasello G, Petrelli F, Antonuzzo L, Giordano M, Cinieri S, Longarini R, Niger M, Antista M, Ambrosini M, Pagani F, Prisciandaro M, Randon G, de Braud F, Di Bartolomeo M, Pietrantonio F, Morano F. Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study. Support Care Cancer 2021;29:3971-80. [PMID: 33392769 DOI: 10.1007/s00520-020-05972-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
632 Bayda S, Amadio E, Cailotto S, Frión-herrera Y, Perosa A, Rizzolio F. Carbon dots for cancer nanomedicine: a bright future. Nanoscale Adv 2021;3:5183-221. [DOI: 10.1039/d1na00036e] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
633 Chen Q, Li X, Zhao J, Bi X, Li Z, Huang Z, Zhang Y, Zhou J, Zhao H, Cai J. What is the optimal number of neoadjuvant chemotherapy cycles for resectable colorectal liver oligometastases? Ann Transl Med 2021;9:7. [PMID: 33553300 DOI: 10.21037/atm-20-4289] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
634 Kim J, Kim H, Hong JY, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim ST. Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer. J Cancer 2021;12:460-6. [PMID: 33391442 DOI: 10.7150/jca.49176] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
635 Kasper S, Foch C, Messinger D, Esser R, Lamy FX, Rothe V, Chen W, Cheng AL, Rouyer M, Brodowicz T, Zielinski C. Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancer. Eur J Cancer 2021;144:291-301. [PMID: 33383349 DOI: 10.1016/j.ejca.2020.11.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
636 Araghi M, Arnold M, Rutherford MJ, Guren MG, Cabasag CJ, Bardot A, Ferlay J, Tervonen H, Shack L, Woods RR, Saint-Jacques N, De P, McClure C, Engholm G, Gavin AT, Morgan E, Walsh PM, Jackson C, Porter G, Møller B, Bucher O, Eden M, O'Connell DL, Bray F, Soerjomataram I. Colon and rectal cancer survival in seven high-income countries 2010-2014: variation by age and stage at diagnosis (the ICBP SURVMARK-2 project). Gut 2021;70:114-26. [PMID: 32482683 DOI: 10.1136/gutjnl-2020-320625] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 22.0] [Reference Citation Analysis]
637 Andreou A, Knitter S, Schmelzle M, Kradolfer D, Maurer MH, Auer TA, Fehrenbach U, Lachenmayer A, Banz V, Schöning W, Candinas D, Pratschke J, Beldi G. Recurrence at surgical margin following hepatectomy for colorectal liver metastases is not associated with R1 resection and does not impact survival. Surgery 2021;169:1061-8. [PMID: 33386128 DOI: 10.1016/j.surg.2020.11.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
638 Kishore C, Bhadra P. Current advancements and future perspectives of immunotherapy in colorectal cancer research. Eur J Pharmacol 2021;893:173819. [PMID: 33347822 DOI: 10.1016/j.ejphar.2020.173819] [Cited by in Crossref: 5] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
639 Alsultan AA, Braat AJAT, Smits MLJ, Barentsz MW, Bastiaannet R, Bruijnen RCG, de Keizer B, de Jong HWAM, Lam MGEH, Maccauro M, Chiesa C. Current Status and Future Direction of Hepatic Radioembolisation. Clin Oncol (R Coll Radiol) 2021;33:106-16. [PMID: 33358630 DOI: 10.1016/j.clon.2020.12.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
640 Jolivet C, Nassabein R, Soulières D, Weng X, Amireault C, Ayoub JP, Beauregard P, Blais N, Carrier C, Cloutier AS, Desnoyers A, Lemay AS, Lemay F, Loungnarath R, Jolivet J, Letendre F, Tehfé M, Vadnais C, Viens D, Aubin F. Implementing DPYD*2A Genotyping in Clinical Practice: The Quebec, Canada, Experience. Oncologist 2021;26:e597-602. [PMID: 33274825 DOI: 10.1002/onco.13626] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
641 Ostwal V, Kapoor A, Engineer R, Saklani A, deSouza A, Patil P, Arya S, Ankathi SK, Chopra S, Patil M, Jain S, Ramaswamy A. Systemic chemotherapy and short-course radiation in metastatic rectal cancers: A feasible paradigm in unresectable and potentially resectable cancers. South Asian J Cancer 2019;8:92-7. [PMID: 31069186 DOI: 10.4103/sajc.sajc_174_18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
642 Mineur L, François E, Plassot C, Phelip JM, Miglianico L, Dourthe LM, Bonichon N, Moreau L, Guimbaud R, Smith D, Achille E, Hervé R, Bons JM, Remy S, Faroux R, Villing AL, Mahamat A, Rabbia I, Soulié P, Baumgaertner I, Mathé N, Vazquez L, Boustany R. PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancer. PLoS One 2020;15:e0243997. [PMID: 33347495 DOI: 10.1371/journal.pone.0243997] [Reference Citation Analysis]
643 Sobrero A, Lenz HJ, Eng C, Scheithauer W, Middleton G, Chen W, Esser R, Nippgen J, Burris H. Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer. Oncologist 2021;26:e261-9. [PMID: 33191588 DOI: 10.1002/onco.13591] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
644 Fidelle M, Yonekura S, Picard M, Cogdill A, Hollebecque A, Roberti MP, Zitvogel L. Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota. Front Immunol 2020;11:600886. [PMID: 33381121 DOI: 10.3389/fimmu.2020.600886] [Cited by in Crossref: 5] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
645 Yamamoto M, Yoshida M, Furuse J, Sano K, Ohtsuka M, Yamashita S, Beppu T, Iwashita Y, Wada K, Nakajima TE, Sakamoto K, Hayano K, Mori Y, Asai K, Matsuyama R, Hirashita T, Hibi T, Sakai N, Tabata T, Kawakami H, Takeda H, Mizukami T, Ozaka M, Ueno M, Naito Y, Okano N, Ueno T, Hijioka S, Shikata S, Ukai T, Strasberg S, Sarr MG, Jagannath P, Hwang TL, Han HS, Yoon YS, Wang HJ, Luo SC, Adam R, Gimenez M, Scatton O, Oh DY, Takada T. Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021. J Hepatobiliary Pancreat Sci 2021;28:1-25. [PMID: 33200538 DOI: 10.1002/jhbp.868] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
646 Taghizadeh H, Mader RM, Müllauer L, Erhart F, Kautzky-Willer A, Prager GW. Precision Medicine for the Management of Therapy Refractory Colorectal Cancer. J Pers Med 2020;10:E272. [PMID: 33322358 DOI: 10.3390/jpm10040272] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
647 Michl M, Taverna F, Kumbrink J, Schiergens TS, Heinemann V, Engel J, Kirchner T, Neumann J. Biomarker alterations associated with distinct patterns of metastatic spread in colorectal cancer. Virchows Arch 2021;478:695-705. [PMID: 33300106 DOI: 10.1007/s00428-020-02983-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
648 He K, Wang Y, Zhong Y, Pan X, Si L, Lu J. KRAS Codon 12 Mutation is Associated with More Aggressive Invasiveness in Synchronous Metastatic Colorectal Cancer (mCRC): Retrospective Research. Onco Targets Ther 2020;13:12601-13. [PMID: 33335401 DOI: 10.2147/OTT.S279312] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
649 Buchler T, Kiss I, Hornova J, Fiala O, Wiesnerova M, Svoboda M, Silar J, Kopeckova K, Poprach A, Finek J, Petruzelka L, Melichar B. Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice. Target Oncol 2020;15:193-201. [PMID: 32052341 DOI: 10.1007/s11523-020-00705-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
650 Nicolazzo C, Barault L, Caponnetto S, Macagno M, De Renzi G, Gradilone A, Belardinilli F, Cortesi E, Di Nicolantonio F, Gazzaniga P. Circulating Methylated DNA to Monitor the Dynamics of RAS Mutation Clearance in Plasma from Metastatic Colorectal Cancer Patients. Cancers (Basel) 2020;12:E3633. [PMID: 33291569 DOI: 10.3390/cancers12123633] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
651 Fabritius MP, Holzgreve A, Knösel T, Tiling R, Rübenthaler J. Incidental Finding of Endobronchial Metastasis by 18F-FDG PET/CT Leads to Change in Management in a Patient With Rectal Adenocarcinoma. Clin Nucl Med 2020;45:980-1. [PMID: 33065625 DOI: 10.1097/RLU.0000000000003326] [Reference Citation Analysis]
652 Pavel MC, Casanova R, Estalella L, Memba R, Llàcer-Millán E, Achalandabaso M, Julià E, Geoghegan J, Jorba R. The effect of preoperative chemotherapy on liver regeneration after portal vein embolization/ligation or liver resection in patients with colorectal liver metastasis: a systematic review protocol. Syst Rev 2020;9:279. [PMID: 33276812 DOI: 10.1186/s13643-020-01545-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
653 Zhan T, Faehling V, Rauscher B, Betge J, Ebert MP, Boutros M. Multi-omics integration identifies a selective vulnerability of colorectal cancer subtypes to YM155. Int J Cancer 2021;148:1948-63. [PMID: 33186476 DOI: 10.1002/ijc.33393] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
654 Antoniotti C, Moretto R, Rossini D, Masi G, Falcone A, Cremolini C. Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm. Cancer Treat Rev 2021;92:102135. [PMID: 33307331 DOI: 10.1016/j.ctrv.2020.102135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
655 Lapeyre-prost A, Pernot S, Sigrand J, Le Malicot K, Mary F, Aparicio T, Dahan L, Caroli-bosc F, Lecomte T, Doat S, Marthey L, Desrame J, Lepage C, Taieb J. Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302). Clinical Colorectal Cancer 2020;19:285-90. [DOI: 10.1016/j.clcc.2020.06.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
656 Krasnodebski M, Kim BJ, Wei SH, Velasco JD, Nishioka Y, Vauthey JN. Chemotherapy in combination with resection for colorectal liver metastases – current evidence. Surgery in Practice and Science 2020;3:100021. [DOI: 10.1016/j.sipas.2020.100021] [Reference Citation Analysis]
657 Picard M, Yonekura S, Slowicka K, Petta I, Rauber C, Routy B, Richard C, Iebba V, Tidjani Alou M, Becharef S, Ly P, Pizzato E, Lehmann CHK, Amon L, Klein C, Opolon P, Gomperts Boneca I, Scoazec JY, Hollebecque A, Malka D, Ghiringhelli F, Dudziak D, Berx G, Vereecke L, van Loo G, Kroemer G, Zitvogel L, Roberti MP. Ileal immune tonus is a prognosis marker of proximal colon cancer in mice and patients. Cell Death Differ 2021;28:1532-47. [PMID: 33262469 DOI: 10.1038/s41418-020-00684-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
658 Aparicio J, Esposito F, Serrano S, Falco E, Escudero P, Ruiz-Casado A, Manzano H, Fernandez-Montes A. Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease. J Clin Med 2020;9:E3889. [PMID: 33265959 DOI: 10.3390/jcm9123889] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
659 Oki E, Makiyama A, Miyamoto Y, Kotaka M, Kawanaka H, Miwa K, Kabashima A, Noguchi T, Yuge K, Kashiwada T, Ando K, Shimokawa M, Saeki H, Akagi Y, Baba H, Maehara Y, Mori M. Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial. Cancer Med 2021;10:454-61. [PMID: 33249761 DOI: 10.1002/cam4.3618] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
660 Lueong SS, Herbst A, Liffers ST, Bielefeld N, Horn PA, Tannapfel A, Reinacher-Schick A, Hinke A, Hegewisch-Becker S, Kolligs FT, Siveke JT. Serial Circulating Tumor DNA Mutational Status in Patients with KRAS-Mutant Metastatic Colorectal Cancer from the Phase 3 AIO KRK0207 Trial. Clin Chem 2020;66:1510-20. [PMID: 33257977 DOI: 10.1093/clinchem/hvaa223] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
661 Tougeron D, Emambux S, Favot L, Lecomte T, Wierzbicka-Hainaut E, Samimi M, Frouin E, Azzopardi N, Chevrier J, Serres L, Godet J, Levillain P, Paintaud G, Ferru A, Rouleau L, Delwail A, Silvain C, Tasu JP, Morel F, Ragot S, Lecron JC. Skin inflammatory response and efficacy of anti-epidermal growth factor receptor therapy in metastatic colorectal cancer (CUTACETUX). Oncoimmunology 2020;9:1848058. [PMID: 33299659 DOI: 10.1080/2162402X.2020.1848058] [Reference Citation Analysis]
662 Pollack M, Keating K, Wissinger E, Jackson L, Sarnes E, Cuffel B. Transforming approaches to treating TRK fusion cancer: historical comparison of larotrectinib and histology-specific therapies. Curr Med Res Opin 2021;37:59-70. [PMID: 33148054 DOI: 10.1080/03007995.2020.1847057] [Reference Citation Analysis]
663 Joharatnam-Hogan N, Wilson W, Shiu KK, Fusai GK, Davidson B, Hochhauser D, Bridgewater J, Khan K. Multimodal Treatment in Metastatic Colorectal Cancer (mCRC) Improves Outcomes-The University College London Hospital (UCLH) Experience. Cancers (Basel) 2020;12:E3545. [PMID: 33261002 DOI: 10.3390/cancers12123545] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
664 Djanani A, Eller S, Öfner D, Troppmair J, Maglione M. The Role of BRAF in Metastatic Colorectal Carcinoma-Past, Present, and Future. Int J Mol Sci 2020;21:E9001. [PMID: 33256240 DOI: 10.3390/ijms21239001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
665 Chan G, Chee CE. Perioperative Chemotherapy for Liver Metastasis of Colorectal Cancer. Cancers (Basel) 2020;12:E3535. [PMID: 33256170 DOI: 10.3390/cancers12123535] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
666 Tudela-Lerma M, Orcajo-Rincón J, Ramón-Botella E, Álvarez-Luque A, González-Leyte M, Rotger-Regi A, Velasco-Sánchez E, Colón-Rodríguez A. Efficacy and safety of Yttrium-90 radioembolization in the treatment of neuroendocrine liver metastases. Long-term monitoring and impact on survival. Rev Esp Med Nucl Imagen Mol (Engl Ed) 2021;40:82-90. [PMID: 33239249 DOI: 10.1016/j.remn.2020.09.002] [Reference Citation Analysis]
667 Kondo T, Matsubara J, Quy PN, Fukuyama K, Nomura M, Funakoshi T, Doi K, Sakamori Y, Yoshioka M, Yokoyama A, Tamaoki M, Kou T, Hirohashi K, Yamada A, Yamamoto Y, Minamiguchi S, Nishigaki M, Yamada T, Kanai M, Matsumoto S, Muto M. Comprehensive genomic profiling for patients with chemotherapy-naïve advanced cancer. Cancer Sci 2021;112:296-304. [PMID: 33007138 DOI: 10.1111/cas.14674] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
668 Bovio F, Epistolio S, Mozzi A, Monti E, Fusi P, Forcella M, Frattini M. Role of NEU3 Overexpression in the Prediction of Efficacy of EGFR-Targeted Therapies in Colon Cancer Cell Lines. Int J Mol Sci 2020;21:E8805. [PMID: 33233823 DOI: 10.3390/ijms21228805] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
669 Pham DT, Saelim N, Tiyaboonchai W. Paclitaxel loaded EDC-crosslinked fibroin nanoparticles: a potential approach for colon cancer treatment. Drug Deliv Transl Res 2020;10:413-24. [PMID: 31701488 DOI: 10.1007/s13346-019-00682-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
670 Jácome AA, Vreeland TJ, Johnson B, Kawaguchi Y, Wei SH, Nancy You Y, Vilar E, Vauthey JN, Eng C. The prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients. Br J Cancer 2021;124:797-804. [PMID: 33208919 DOI: 10.1038/s41416-020-01169-w] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
671 Huijberts SCFA, Boelens MC, Bernards R, Opdam FL. Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/- binimetinib or alpelisib. Br J Cancer 2021;124:176-82. [PMID: 33204026 DOI: 10.1038/s41416-020-01147-2] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
672 Bruera G, Ricevuto E; Oncology Network ASL1 Abruzzo. Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments. Pharmgenomics Pers Med 2020;13:601-17. [PMID: 33235483 DOI: 10.2147/PGPM.S253586] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
673 Innocenti F, Mills SC, Sanoff H, Ciccolini J, Lenz HJ, Milano G. All You Need to Know About DPYD Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly Guide. JCO Oncol Pract 2020;16:793-8. [PMID: 33197222 DOI: 10.1200/OP.20.00553] [Cited by in Crossref: 12] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
674 Xiao B, Peng J, Wang Y, Deng Y, Ou Q, Wu X, Lin J, Pan Z, Zhang L. Prognostic value of tumor infiltrating lymphocytes combined with PD-L1 expression for patients with solitary colorectal cancer liver metastasis. Ann Transl Med 2020;8:1221. [PMID: 33178753 DOI: 10.21037/atm-20-2762a] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
675 Konstantinou I, Shapey IM, Papamichael D, de Liguori Carino N. Outcomes following potentially curative therapies for older patients with metastatic colorectal cancer. Eur J Surg Oncol 2021;47:591-6. [PMID: 33213959 DOI: 10.1016/j.ejso.2020.11.007] [Reference Citation Analysis]
676 Ren T, Wang S, Shen Z, Xu C, Zhang Y, Hui F, Qi X, Zhao Q. Efficacy and Safety of Bevacizumab Plus Oxaliplatin- or Irinotecan-Based Doublet Backbone Chemotherapy as the First-Line Treatment of Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis. Drug Saf 2021;44:29-40. [PMID: 33180265 DOI: 10.1007/s40264-020-00997-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
677 Bolhuis K, Kos M, van Oijen MGH, Swijnenburg RJ, Punt CJA. Conversion strategies with chemotherapy plus targeted agents for colorectal cancer liver-only metastases: A systematic review. Eur J Cancer 2020;141:225-38. [PMID: 33189037 DOI: 10.1016/j.ejca.2020.09.037] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
678 Takamizawa Y, Shida D, Boku N, Nakamura Y, Ahiko Y, Yoshida T, Tanabe T, Takashima A, Kanemitsu Y. Nutritional and inflammatory measures predict survival of patients with stage IV colorectal cancer. BMC Cancer 2020;20:1092. [PMID: 33176752 DOI: 10.1186/s12885-020-07560-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
679 Jhawat V, Gulia M, Gupta S, Maddiboyina B, Dutt R. Integration of pharmacogenomics and theranostics with nanotechnology as quality by design (QbD) approach for formulation development of novel dosage forms for effective drug therapy. J Control Release 2020;327:500-11. [PMID: 32858073 DOI: 10.1016/j.jconrel.2020.08.039] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
680 Rizzetto F, Calderoni F, De Mattia C, Defeudis A, Giannini V, Mazzetti S, Vassallo L, Ghezzi S, Sartore-Bianchi A, Marsoni S, Siena S, Regge D, Torresin A, Vanzulli A. Impact of inter-reader contouring variability on textural radiomics of colorectal liver metastases. Eur Radiol Exp 2020;4:62. [PMID: 33169295 DOI: 10.1186/s41747-020-00189-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
681 Roeder F, Meldolesi E, Gerum S, Valentini V, Rödel C. Recent advances in (chemo-)radiation therapy for rectal cancer: a comprehensive review. Radiat Oncol 2020;15:262. [PMID: 33172475 DOI: 10.1186/s13014-020-01695-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
682 Ignatavicius P, Oberkofler CE, Chapman WC, DeMatteo RP, Clary BM, D'Angelica MI, Tanabe KK, Hong JC, Aloia TA, Pawlik TM, Hernandez-Alejandro R, Shah SA, Vauthey JN, Torzilli G, Lang H, Line PD, Soubrane O, Pinto-Marques H, Robles-Campos R, Boudjema K, Lodge P, Adam R, Toso C, Serrablo A, Aldrighetti L, DeOliveira ML, Dutkowski P, Petrowsky H, Linecker M, Reiner CS, Braun J, Alikhanov R, Barauskas G, Chan ACY, Dong J, Kokudo N, Yamamoto M, Kang KJ, Fong Y, Rela M, De Aretxabala X, De Santibañes E, Mercado MÁ, Andriani OC, Torres OJM, Pinna AD, Clavien PA. Choices of Therapeutic Strategies for Colorectal Liver Metastases Among Expert Liver Surgeons: A Throw of the Dice? Ann Surg 2020;272:715-22. [PMID: 32833764 DOI: 10.1097/SLA.0000000000004331] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 6.5] [Reference Citation Analysis]
683 Osterman E, Hammarström K, Imam I, Osterlund E, Sjöblom T, Glimelius B. Recurrence Risk after Radical Colorectal Cancer Surgery-Less Than before, But How High Is It? Cancers (Basel) 2020;12:E3308. [PMID: 33182510 DOI: 10.3390/cancers12113308] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
684 Heinemann V, von Weikersthal LF, Decker T, Kiani A, Kaiser F, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Moehler M, Scheithauer W, Held S, Miller-Phillips L, Modest DP, Jung A, Kirchner T, Stintzing S. FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. Br J Cancer 2021;124:587-94. [PMID: 33154570 DOI: 10.1038/s41416-020-01140-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
685 Lastraioli E, Antonuzzo L, Fantechi B, Di Cerbo L, Di Costanzo A, Lavacchi D, Armenio M, Arcangeli A, Castiglione F, Messerini L, Di Costanzo F. KRAS and NRAS mutation detection in circulating DNA from patients with metastatic colorectal cancer using BEAMing assay: Concordance with standard biopsy and clinical evaluation. Oncol Lett 2021;21:15. [PMID: 33240421 DOI: 10.3892/ol.2020.12276] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
686 Masthoff M, Schindler P, Harders F, Heindel W, Wilms C, Schmidt HH, Pascher A, Stegger L, Rahbar K, Köhler M, Wildgruber M. Analysis of failed therapy evaluations in radioembolization of primary and secondary liver cancers. J Cancer Res Clin Oncol 2021;147:1537-45. [PMID: 33156407 DOI: 10.1007/s00432-020-03443-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
687 Ghosh S, Khanam R, Acharya Chowdhury A. The Evolving Roles of Bacopa monnieri as Potential Anti-Cancer Agent: A Review. Nutr Cancer 2020;:1-11. [PMID: 33148034 DOI: 10.1080/01635581.2020.1841248] [Reference Citation Analysis]
688 Masthoff M, Schindler P, Harders F, Heindel W, Wilms C, Schmidt HH, Pascher A, Stegger L, Rahbar K, Wildgruber M, Köhler M. Repeated radioembolization in advanced liver cancer. Ann Transl Med 2020;8:1055. [PMID: 33145274 DOI: 10.21037/atm-20-2658] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
689 Ragusa S, Prat-Luri B, González-Loyola A, Nassiri S, Squadrito ML, Guichard A, Cavin S, Gjorevski N, Barras D, Marra G, Lutolf MP, Perentes J, Corse E, Bianchi R, Wetterwald L, Kim J, Oliver G, Delorenzi M, De Palma M, Petrova TV. Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice. J Clin Invest 2020;130:1199-216. [PMID: 32015230 DOI: 10.1172/JCI129558] [Cited by in Crossref: 11] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
690 Nakayama I, Hirota T, Shinozaki E. BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation. Cancers (Basel) 2020;12:E3236. [PMID: 33152998 DOI: 10.3390/cancers12113236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
691 Gilabert M, Ries P, Chanez B, Triby S, Francois E, Lièvre A, Rousseau F. Place of anti-EGFR therapy in older patients with metastatic colorectal cancer in 2020. Journal of Geriatric Oncology 2020;11:1229-36. [DOI: 10.1016/j.jgo.2020.04.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
692 van Roekel C, van den Hoven AF, Bastiaannet R, Bruijnen RCG, Braat AJAT, de Keizer B, Lam MGEH, Smits MLJ. Use of an anti-reflux catheter to improve tumor targeting for holmium-166 radioembolization-a prospective, within-patient randomized study. Eur J Nucl Med Mol Imaging 2021;48:1658-68. [PMID: 33128132 DOI: 10.1007/s00259-020-05079-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
693 Loupakis F, Antonuzzo L, Bachet JB, Kuan FC, Macarulla T, Pietrantonio F, Xu RH, Taniguchi H, Winder T, Yuki S, Zeng S, Bekaii-Saab T. Practical considerations in the use of regorafenib in metastatic colorectal cancer. Ther Adv Med Oncol 2020;12:1758835920956862. [PMID: 33193826 DOI: 10.1177/1758835920956862] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
694 Abuderman AA, Harb OA, Gertallah LM. Prognostic and clinic-pathological significances of HOXB8, ILK and FAT4 expression in colorectal cancer. Contemp Oncol (Pozn) 2020;24:183-92. [PMID: 33235545 DOI: 10.5114/wo.2020.100281] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
695 Weiss J, Winkelmann MT, Gohla G, Kübler J, Clasen S, Nikolaou K, Hoffmann R. MR-guided microwave ablation in hepatic malignancies: clinical experiences from 50 procedures. Int J Hyperthermia 2020;37:349-55. [PMID: 32286087 DOI: 10.1080/02656736.2020.1750713] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
696 Mouillet-Richard S, Laurent-Puig P. YAP/TAZ Signalling in Colorectal Cancer: Lessons from Consensus Molecular Subtypes. Cancers (Basel) 2020;12:E3160. [PMID: 33126419 DOI: 10.3390/cancers12113160] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
697 Kurilova I, Bendet A, Petre EN, Boas FE, Kaye E, Gonen M, Covey A, Brody LA, Brown KT, Kemeny NE, Yarmohammadi H, Ziv E, D'Angelica MI, Kingham TP, Cercek A, Solomon SB, Beets-Tan RGH, Sofocleous CT. Factors Associated With Local Tumor Control and Complications After Thermal Ablation of Colorectal Cancer Liver Metastases: A 15-year Retrospective Cohort Study. Clin Colorectal Cancer 2021;20:e82-95. [PMID: 33246789 DOI: 10.1016/j.clcc.2020.09.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
698 Taflin H, Odin E, Carlsson G, Tell R, Gustavsson B, Wettergren Y. Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin. Cancer Chemother Pharmacol 2021;87:31-41. [PMID: 33099678 DOI: 10.1007/s00280-020-04173-2] [Reference Citation Analysis]
699 Martin J, Petrillo A, Smyth EC, Shaida N, Khwaja S, Cheow H, Duckworth A, Heister P, Praseedom R, Jah A, Balakrishnan A, Harper S, Liau S, Kosmoliaptsis V, Huguet E. Colorectal liver metastases: Current management and future perspectives. World J Clin Oncol 2020; 11(10): 761-808 [PMID: 33200074 DOI: 10.5306/wjco.v11.i10.761] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 21] [Article Influence: 13.0] [Reference Citation Analysis]
700 Amrane K, le Pennec R, Schick U, Metges JP, Abgral R. Complete Metabolic Response Assessed by FDG PET/CT to FOLFOXIRI-Bevacizumab in First-Line Treatment of BRAFV600E Mutated Metastatic Colorectal Cancer. Clin Nucl Med 2020;45:707-8. [PMID: 32657876 DOI: 10.1097/RLU.0000000000003190] [Reference Citation Analysis]
701 Shinozaki K, Yamada T, Nasu J, Matsumoto T, Yuasa Y, Shiraishi T, Nagano H, Moriyama I, Fujiwara T, Miguchi M, Yoshida R, Nozaka K, Tanioka H, Nagasaka T, Kurisu Y, Kobayashi M, Tsuchihashi K, Inukai M, Kikuchi T, Nishina T. A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI). Int J Clin Oncol 2021;26:399-408. [PMID: 33097971 DOI: 10.1007/s10147-020-01811-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
702 Smolenschi C, Perret A, Dall'Armellina F, Boige V, Malka D, Hollebecque A, Ducreux M. An appraisal of emerging second line therapies for metastatic colorectal cancer. Expert Rev Gastroenterol Hepatol 2021;15:165-79. [PMID: 33085557 DOI: 10.1080/17474124.2021.1840975] [Reference Citation Analysis]
703 Brennan VK, Colaone F, Shergill S, Pollock RF. A cost-utility analysis of SIR-Spheres Y-90 resin microspheres versus best supportive care in the treatment of unresectable metastatic colorectal cancer refractory to chemotherapy in the UK. J Med Econ 2020;23:1588-97. [PMID: 33084466 DOI: 10.1080/13696998.2020.1839273] [Reference Citation Analysis]
704 Arici S, Hamdard J, Sakin A, Sengiz Erhan S, Atci MM, Cekin R, Saka B, Köse E, Saydam T, Geredeli C, Cihan S, Bilici A. The conversion of RAS status in metastatic colorectal cancer patients after first-line biological agent treatment. Colorectal Dis 2021;23:206-12. [PMID: 33002301 DOI: 10.1111/codi.15389] [Reference Citation Analysis]
705 Mo X, Huang X, Feng Y, Wei C, Liu H, Ru H, Qin H, Lai H, Wu G, Xie W, Jeen F, Lin Y, Liu J, Tang W. Immune infiltration and immune gene signature predict the response to fluoropyrimidine-based chemotherapy in colorectal cancer patients. Oncoimmunology 2020;9:1832347. [PMID: 33117604 DOI: 10.1080/2162402X.2020.1832347] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
706 Shu P, Ouyang G, Wang F, Zhou J, Shen Y, Li Z, Wang X. The Role of Radiotherapy in the Treatment of Retroperitoneal Lymph Node Metastases from Colorectal Cancer. Cancer Manag Res 2020;12:8913-21. [PMID: 33061587 DOI: 10.2147/CMAR.S249248] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
707 Navarro S, Cuatrecasas M, Hernández-Losa J, Landolfi S, Musulén E, Ramón Y Cajal S, García-Carbonero R, García-Foncillas J, Pérez-Segura P, Salazar R, Vera R, García-Alfonso P. [Update of the recommendations for the determination of biomarkers in colorectal carcinoma. National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology]. Rev Esp Patol 2021;54:41-54. [PMID: 33455693 DOI: 10.1016/j.patol.2020.07.004] [Reference Citation Analysis]
708 Ma ZH, Wang YP, Zheng WH, Ma J, Bai X, Zhang Y, Wang YH, Chi D, Fu XB, Hua XD. Prognostic factors and therapeutic effects of different treatment modalities for colorectal cancer liver metastases. World J Gastrointest Oncol 2020; 12(10): 1177-1194 [PMID: 33133385 DOI: 10.4251/wjgo.v12.i10.1177] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
709 Pilleron S, Charvat H, Araghi M, Arnold M, Fidler-Benaoudia MM, Bardot A, Grønlie Guren M, Tervonen H, Little A, O'Connell DL, Gavin A, De P, Aagard Thomsen L, Møller B, Jackson C, Bucher O, Walsh PM, Vernon S, Bray F, Soerjomataram I. Age disparities in stage-specific colon cancer survival across seven countries: An International Cancer Benchmarking Partnership SURVMARK-2 population-based study. Int J Cancer 2021;148:1575-85. [PMID: 33006395 DOI: 10.1002/ijc.33326] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
710 Xu D, Yan XL, Liu JM, Li J, Xing BC. The characteristics and long-term survival of patients with colorectal liver metastases with pathological complete response after chemotherapy. J Cancer 2020;11:6256-63. [PMID: 33033509 DOI: 10.7150/jca.47911] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
711 Mauri G, Gori V, Bonazzina E, Amatu A, Tosi F, Bencardino K, Ruggieri L, Patelli G, Arena S, Bardelli A, Siena S, Sartore-Bianchi A. Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities. Cancer Treat Rev 2020;91:102112. [PMID: 33091698 DOI: 10.1016/j.ctrv.2020.102112] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
712 Ishizuka M, Shimizu T, Shibuya N, Takagi K, Hachiya H, Nishi Y, Suda K, Aoki T, Kubota K. Impact of Primary Tumor Location on Survival After Curative Resection in Patients with Colon Cancer: A Meta-Analysis of Propensity Score-Matching Studies. Oncologist 2021;26:196-207. [PMID: 33031622 DOI: 10.1002/onco.13555] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
713 Maffione AM, Rubello D, Caroli P, Colletti PM, Matteucci F. Is It Time to Introduce PET/CT in Colon Cancer Guidelines? Clin Nucl Med 2020;45:525-30. [PMID: 32433179 DOI: 10.1097/RLU.0000000000003076] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
714 Fiz F, Viganò L, Gennaro N, Costa G, La Bella L, Boichuk A, Cavinato L, Sollini M, Politi LS, Chiti A, Torzilli G. Radiomics of Liver Metastases: A Systematic Review. Cancers (Basel) 2020;12:E2881. [PMID: 33036490 DOI: 10.3390/cancers12102881] [Cited by in Crossref: 11] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
715 Price T, Ang A, Boedigheimer M, Kim TW, Li J, Cascinu S, Ruff P, Satya Suresh A, Thomas A, Tjulandin S, Peeters M. Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy. Cancer Biol Ther 2020;21:891-8. [PMID: 33026965 DOI: 10.1080/15384047.2020.1798695] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
716 Rossini D, Lonardi S, Antoniotti C, Santini D, Tomasello G, Ermacora P, Germani MM, Bergamo F, Ricci V, Caponnetto S, Moretto R, Zaniboni A, Pietrantonio F, Buonadonna A, Ritorto G, Masi G, Latiano TP, Rapisardi S, Falcone A, Cremolini C. Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO. Br J Cancer 2021;124:183-90. [PMID: 33024268 DOI: 10.1038/s41416-020-01089-9] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
717 Pietrantonio F, Fucà G, Manca P, Pagani F, Raimondi A, Prisciandaro M, Randon G, Corti F, de Braud F, Cremolini C, Miceli R. Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECOURSE trial. Tumori 2021;107:353-9. [PMID: 33021466 DOI: 10.1177/0300891620960808] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
718 Lei P, Ruan Y, Tan L, Wei H, Chen T. Laparoscopic colorectal resection combined with simultaneous thermal ablation or surgical resection of liver metastasis: a retrospective comparative study. Int J Hyperthermia 2020;37:137-43. [PMID: 31986941 DOI: 10.1080/02656736.2020.1716086] [Reference Citation Analysis]
719 Tsitskari M, Filippiadis D, Zavridis P, Mazioti A, Vrachliotis T, Alevizos L, Brountzos E, Kelekis N. Efficacy and safety of percutaneous computed tomography-guided microwave ablation for colorectal cancer, oligometastatic liver-only disease: a single center's experience. Ann Gastroenterol 2021;34:61-7. [PMID: 33414623 DOI: 10.20524/aog.2020.0545] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
720 Ricke J, Westphalen CB, Seidensticker M. Therapeutic Concepts for Oligometastatic Gastrointestinal Tumours. Visc Med 2020;36:359-63. [PMID: 33178732 DOI: 10.1159/000509897] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
721 Yoshikawa M, Morine Y, Yamada S, Miyazaki K, Tokuda K, Saito Y, Arakawa Y, Ikemoto T, Imura S, Shimada M. Prognostic prediction of resectable colorectal liver metastasis using the apparent diffusion coefficient from diffusion-weighted magnetic resonance imaging. Ann Gastroenterol Surg 2021;5:252-8. [PMID: 33860146 DOI: 10.1002/ags3.12404] [Reference Citation Analysis]
722 Zoetemelk M, Ramzy GM, Rausch M, Koessler T, van Beijnum JR, Weiss A, Mieville V, Piersma SR, de Haas RR, Delucinge-Vivier C, Andres A, Toso C, Henneman AA, Ragusa S, Petrova TV, Docquier M, McKee TA, Jimenez CR, Daali Y, Griffioen AW, Rubbia-Brandt L, Dietrich PY, Nowak-Sliwinska P. Optimized low-dose combinatorial drug treatment boosts selectivity and efficacy of colorectal carcinoma treatment. Mol Oncol 2020;14:2894-919. [PMID: 33021054 DOI: 10.1002/1878-0261.12797] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
723 Conci S, Ruzzenente A, Pedrazzani C, Isa G, Turri G, Campagnaro T, Valdegamberi A, Bagante F, Marchitelli I, Guglielmi A. Simultaneous approach for patients with synchronous colon and rectal liver metastases: Impact of site of primary on postoperative and oncological outcomes. Eur J Surg Oncol 2021;47:842-9. [PMID: 33011004 DOI: 10.1016/j.ejso.2020.09.015] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
724 Boysen AK, Schou JV, Jensen BV, Nielsen D, Sørensen BS, Johansen JS, Spindler KG. Prognostic and predictive value of circulating DNA for hepatic arterial infusion of chemotherapy for patients with colorectal cancer liver metastases. Mol Clin Oncol 2020;13:77. [PMID: 33005411 DOI: 10.3892/mco.2020.2147] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
725 Maravic Z, Rawicka I, Benedict A, Wyrwicz L, Horvath A, Fotaki V, Carrato A, Borras JM, Ruiz-Casado A, Petrányi A, Lemmens L, Espín-Basany E, Stanisic Trenevski J. A European survey on the insights of patients living with metastatic colorectal cancer: the patient journey before, during and after diagnosis - an Eastern European perspective. ESMO Open 2020;5:e000850. [PMID: 32998966 DOI: 10.1136/esmoopen-2020-000850] [Reference Citation Analysis]
726 Tselikas L, Garzelli L, Mercier O, Auperin A, Lamrani L, Deschamps F, Yevich S, Roux C, Mussot S, Delpla A, Varin F, Hakime A, Teriitehau C, Le Péchoux C, Pradère P, Caramella C, Besse B, Fadel E, de Baere T. Radiofrequency ablation versus surgical resection for the treatment of oligometastatic lung disease. Diagn Interv Imaging 2021;102:19-26. [PMID: 33020025 DOI: 10.1016/j.diii.2020.09.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
727 Lordick F, Ghadimi M, Gockel I, Graeven U, Westphalen CB. Precision Medicine. Visc Med 2020;36:407-10. [PMID: 33178738 DOI: 10.1159/000511534] [Reference Citation Analysis]
728 Manfredi S, Turpin A, Malka D, Barbier E, Laurent-puig P, Zaanan A, Dahan L, Lièvre A, Phelip J, Michel P, Hautefeuille V, Legoux J, Lepage C, Tougeron D, Aparicio T. Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study. Digestive and Liver Disease 2020;52:1143-7. [DOI: 10.1016/j.dld.2020.06.034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
729 Cheung WY, Kavan P, Dolley A. Quality of life in a real-world study of patients with metastatic colorectal cancer treated with trifluridine/tipiracil. Curr Oncol 2020;27:e451-8. [PMID: 33173384 DOI: 10.3747/co.27.6533] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
730 Narasimhan V, Cheung F, Waters P, Peacock O, Warrier S, Lynch C, Michael M, Ramsay R, Heriot A. Re-do cytoreductive surgery for peritoneal surface malignancy: Is it worthwhile? The Surgeon 2020;18:287-94. [DOI: 10.1016/j.surge.2019.11.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
731 Huemer F, Piringer G, Schlintl V, Hackl H, Rinnerthaler G, Thaler J, Greil R, Weiss L. Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy. Cancers (Basel) 2020;12:E2812. [PMID: 33007814 DOI: 10.3390/cancers12102812] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
732 Fontana E, Nyamundanda G, Cunningham D, Tu D, Cheang MCU, Jonker DJ, Siu LL, Sclafani F, Eason K, Ragulan C, Bali MA, Hulkki-Wilson S, Loree JM, Waring PM, Giordano M, Lawrence P, Rodrigues DN, Begum R, Shapiro JD, Price TJ, Cremolini C, Starling N, Pietrantonio F, Trusolino L, O'Callaghan CJ, Sadanandam A. Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial. JCO Precis Oncol 2020;4:PO. [PMID: 33015526 DOI: 10.1200/PO.20.00050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
733 Sommariva A, Ansaloni L, Baiocchi GL, Cascinu S, Cirocchi R, Coccolini F, Deraco M, Fiorentini G, Gelmini R, Di Giorgio A, Lippolis PV, Pasqual EM, Sassaroli C, Macrì A, Sammartino P, Scaringi S, Valle M, Vaira M. Diagnostic and therapeutic algorithm for colorectal peritoneal metastases. A consensus of the peritoneal surface malignancies onco-team of the Italian society of surgical oncology. Eur J Surg Oncol 2021;47:164-71. [PMID: 33028502 DOI: 10.1016/j.ejso.2020.09.035] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
734 Varughese LA, Lau-Min KS, Cambareri C, Damjanov N, Massa R, Reddy N, Oyer R, Teitelbaum U, Tuteja S. DPYD and UGT1A1 Pharmacogenetic Testing in Patients with Gastrointestinal Malignancies: An Overview of the Evidence and Considerations for Clinical Implementation. Pharmacotherapy 2020;40:1108-29. [PMID: 32985005 DOI: 10.1002/phar.2463] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
735 Cheng J, Qiu M, Zhang Y, Hong N, Shen D, Zhou J, Wang Y. Enhanced Rim on MDCT of Colorectal Liver Metastases: Assessment of Ability to Predict Progression-Free Survival and Response to Bevacizumab-Based Chemotherapy. AJR Am J Roentgenol 2020;215:1377-83. [PMID: 32991216 DOI: 10.2214/AJR.19.22280] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
736 Loffroy R, Ronot M, Greget M, Bouvier A, Mastier C, Sengel C, Tselikas L, Arnold D, Maleux G, Pelage JP, Pellerin O, Peynircioglu B, Sangro B, Schaefer N, Urdániz M, Kaufmann N, Bilbao JI, Helmberger T, Vilgrain V; CIRT-FR Principal Investigators. Short-term Safety and Quality of Life Outcomes Following Radioembolization in Primary and Secondary Liver Tumours: a Multi-centre Analysis of 200 Patients in France. Cardiovasc Intervent Radiol 2021;44:36-49. [PMID: 32975600 DOI: 10.1007/s00270-020-02643-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
737 Miyamoto Y, Schirripa M, Suenaga M, Cao S, Zhang W, Okazaki S, Berger MD, Matsusaka S, Yang D, Ning Y, Baba H, Loupakis F, Lonardi S, Pietrantonio F, Borelli B, Cremolini C, Yamaguchi T, Lenz HJ. A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer. PLoS One 2020;15:e0239439. [PMID: 32970737 DOI: 10.1371/journal.pone.0239439] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
738 Baratti D, Kusamura S, Niger M, Perrone F, Milione M, Cattaneo L, Guaglio M, Bartolini V, Pietrantonio F, Deraco M. Prognostic Impact of Primary Side and RAS/RAF Mutations in a Surgical Series of Colorectal Cancer with Peritoneal Metastases. Ann Surg Oncol 2021;28:3332-42. [PMID: 32974694 DOI: 10.1245/s10434-020-09161-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
739 Huang J, Chen G, Liu H, Zhang Y, Tang R, Huang Q, Fu K, Peng X, Xiao S. Surgery improves the prognosis of colon mucinous adenocarcinoma with liver metastases: a SEER-based study. BMC Cancer 2020;20:908. [PMID: 32967651 DOI: 10.1186/s12885-020-07400-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
740 Dyhl-Polk A, Schou M, Vistisen KK, Sillesen AS, Serup-Hansen E, Faber J, Klausen TW, Bojesen SE, Vaage-Nilsen M, Nielsen DL. Myocardial Ischemia Induced by 5-Fluorouracil: A Prospective Electrocardiographic and Cardiac Biomarker Study. Oncologist 2021;26:e403-13. [PMID: 32959474 DOI: 10.1002/onco.13536] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
741 Deng L, Li T, Liao Y, Liu S, Xie Z, Huang Z, Dai H, Li J, Lei X. Peritumoral activated hepatic stellate cells are associated with hepatic recurrence for resectable colorectal adenocarcinoma liver metastasis following resection. Oncol Lett 2020;20:287. [PMID: 33014165 DOI: 10.3892/ol.2020.12150] [Reference Citation Analysis]
742 van Roekel C, Jongen JMJ, Smits MLJ, Elias SG, Koopman M, Kranenburg O, Borel Rinkes IHM, Lam MGEH. Mode of progression after radioembolization in patients with colorectal cancer liver metastases. EJNMMI Res 2020;10:107. [PMID: 32960390 DOI: 10.1186/s13550-020-00697-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
743 Pimenta JR, Racy DJ, Zapata LM, D'Alpino Peixoto R. Durable Disease Control with Regorafenib in a Patient with Metastatic KIT-Mutated Colorectal Cancer. J Gastrointest Cancer 2021;52:784-7. [PMID: 32944848 DOI: 10.1007/s12029-020-00523-8] [Reference Citation Analysis]
744 Ruffinelli JC, Santos Vivas C, Sanz-Pamplona R, Moreno V. New advances in the clinical management of RAS and BRAF mutant colorectal cancer patients. Expert Rev Gastroenterol Hepatol 2021;15:65-79. [PMID: 32946312 DOI: 10.1080/17474124.2021.1826305] [Reference Citation Analysis]
745 Johdi NA, Sukor NF. Colorectal Cancer Immunotherapy: Options and Strategies. Front Immunol 2020;11:1624. [PMID: 33042104 DOI: 10.3389/fimmu.2020.01624] [Cited by in Crossref: 7] [Cited by in F6Publishing: 55] [Article Influence: 3.5] [Reference Citation Analysis]
746 Batra A, Rigo R, Hannouf MB, Cheung WY. Real-world Safety and Efficacy of Raltitrexed in Patients With Metastatic Colorectal Cancer. Clin Colorectal Cancer 2021;20:e75-81. [PMID: 33268287 DOI: 10.1016/j.clcc.2020.09.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
747 Padia SA, Johnson GE, Agopian VG, DiNorcia J, Srinivasa RN, Sayre J, Shin DS. Yttrium-90 radiation segmentectomy for hepatic metastases: A multi-institutional study of safety and efficacy. J Surg Oncol 2021;123:172-8. [PMID: 32944980 DOI: 10.1002/jso.26223] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
748 Maleux G, Prenen H, Helmberger T, Spriet I, Isailovic TV, Pereira P. LifePearl microspheres loaded with irinotecan in the treatment of Liver-dominant metastatic colorectal carcinoma: feasibility, safety and pharmacokinetic study. Anticancer Drugs 2020;31:1084-90. [PMID: 32932279 DOI: 10.1097/CAD.0000000000000980] [Reference Citation Analysis]
749 Ruiz de Porras V, Layos L, Martínez-Balibrea E. Curcumin: A therapeutic strategy for colorectal cancer? Semin Cancer Biol 2021;73:321-30. [PMID: 32942023 DOI: 10.1016/j.semcancer.2020.09.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
750 Suenaga M, Mashima T, Kawata N, Wakatsuki T, Dan S, Seimiya H, Yamaguchi K. Serum IL-8 level as a candidate prognostic marker of response to anti-angiogenic therapy for metastatic colorectal cancer. Int J Colorectal Dis 2021;36:131-9. [PMID: 32920703 DOI: 10.1007/s00384-020-03748-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
751 Marin JJG, Macias RIR, Monte MJ, Herraez E, Peleteiro-Vigil A, Blas BS, Sanchon-Sanchez P, Temprano AG, Espinosa-Escudero RA, Lozano E, Briz O, Romero MR. Cellular Mechanisms Accounting for the Refractoriness of Colorectal Carcinoma to Pharmacological Treatment. Cancers (Basel) 2020;12:E2605. [PMID: 32933095 DOI: 10.3390/cancers12092605] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
752 Griffiths CD, Xu K, Wang J, McKechnie T, Gafni A, Parpia S, Ruo L, Serrano PE. Laparoscopic hepatectomy is safe and effective for the management of patients with colorectal cancer liver metastases in a population-based analysis in Ontario, Canada. A retrospective cohort study. Int J Surg 2020;83:47-52. [PMID: 32927139 DOI: 10.1016/j.ijsu.2020.08.052] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
753 Kleinjan JP, Brinkman I, Bakema R, van Zanden JJ, van Rooijen JM. Tolerance-based capecitabine dose escalation after DPYD genotype-guided dosing in heterozygote DPYD variant carriers: a single-center observational study. Anticancer Drugs 2019;30:410-5. [PMID: 30628914 DOI: 10.1097/CAD.0000000000000748] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
754 Baldin P, Van den Eynde M, Mlecnik B, Bindea G, Beniuga G, Carrasco J, Haicheur N, Marliot F, Lafontaine L, Fredriksen T, Lanthier N, Hubert C, Navez B, Huyghe N, Pagès F, Jouret-Mourin A, Galon J, Komuta M. Prognostic assessment of resected colorectal liver metastases integrating pathological features, RAS mutation and Immunoscore. J Pathol Clin Res 2021;7:27-41. [PMID: 32902189 DOI: 10.1002/cjp2.178] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
755 Iezzi R, Bilhim T, Crocetti L, Peynircioglu B, Goldberg S, Bilbao JI, Sami A, Akhan O, Scalise P, Giuliante F, Pompili M, Valentini V, Gasbarrini A, Colosimo C, Manfredi R. "Primum Non Nocere" in Interventional Oncology for Liver Cancer: How to Reduce the Risk for Complications? Life (Basel) 2020;10:E180. [PMID: 32899925 DOI: 10.3390/life10090180] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
756 Johnson B, Kopetz S. Applying Precision to the Management of BRAF-Mutant Metastatic Colorectal Cancer.Target Oncol. 2020;15:567-577. [PMID: 32889679 DOI: 10.1007/s11523-020-00747-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
757 Haiduk T, Brockmann M, Schmitt C, Tillmann R, Pieper M, Lüsebrink J, Schildgen O, Schildgen V. Are Microsatellite Patterns Specific for Tumor Types? A Pilot Investigation. JMP 2020;1:3-8. [DOI: 10.3390/jmp1010002] [Reference Citation Analysis]
758 Chen Q, Mao R, Zhao J, Bi X, Li Z, Huang Z, Zhang Y, Zhou J, Zhao H, Cai J. From the completion of neoadjuvant chemotherapy to surgery for colorectal cancer liver metastasis: What is the optimal timing? Cancer Med 2020;9:7849-62. [PMID: 32886456 DOI: 10.1002/cam4.3283] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
759 Liu Y, Li L, Tian Y, Zhu X, Sun A, Sun Y, Qiao Y, Qi X, Wang T. Analysis of KRAS mutations in circulating tumor DNA and colorectal cancer tissue. Biotech Histochem 2021;96:376-83. [PMID: 32876508 DOI: 10.1080/10520295.2020.1810775] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
760 Zhang J, Miller Z, Musich PR, Thomas AE, Yao ZQ, Xie Q, Howe PH, Jiang Y. DSTYK Promotes Metastasis and Chemoresistance via EMT in Colorectal Cancer. Front Pharmacol 2020;11:1250. [PMID: 32982725 DOI: 10.3389/fphar.2020.01250] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
761 Mercier F, Kerioui M, Desmée S, Guedj J, Krieter O, Bruno R. Longitudinal analysis of organ-specific tumor lesion sizes in metastatic colorectal cancer patients receiving first line standard chemotherapy in combination with anti-angiogenic treatment. J Pharmacokinet Pharmacodyn 2020;47:613-25. [DOI: 10.1007/s10928-020-09714-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
762 O'Cathail SM, Smith T, Owens R, Zeniou A, Tsang Y, Holyoake DLP, Murray L, Harrison M, Hawkins MA. Superior outcomes of nodal metastases compared to visceral sites in oligometastatic colorectal cancer treated with stereotactic ablative radiotherapy. Radiother Oncol 2020;151:280-6. [PMID: 32866563 DOI: 10.1016/j.radonc.2020.08.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
763 Murakawa T. Past, present, and future perspectives of pulmonary metastasectomy for patients with advanced colorectal cancer. Surg Today 2021;51:204-11. [PMID: 32857252 DOI: 10.1007/s00595-020-02119-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
764 Polivka J, Windrichova J, Pesta M, Houfkova K, Rezackova H, Macanova T, Vycital O, Kucera R, Slouka D, Topolcan O. The Level of Preoperative Plasma KRAS Mutations and CEA Predict Survival of Patients Undergoing Surgery for Colorectal Cancer Liver Metastases. Cancers (Basel) 2020;12:E2434. [PMID: 32867151 DOI: 10.3390/cancers12092434] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
765 Sorrentino L, Serra F, Cabry F, Cauteroq N, Zmora O, Gelmini R. Peritoneal carcinomatosis from colorectal cancer in the pediatric population: Cytoreductive surgery and HIPEC. A systematic review. Eur J Surg Oncol 2021;47:211-5. [PMID: 32888733 DOI: 10.1016/j.ejso.2020.08.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
766 Reynolds IS, Thomas V, O'Connell E, Fichtner M, McNamara DA, Kay EW, Prehn JHM, Burke JP, Furney SJ. Mucinous Adenocarcinoma of the Rectum: A Whole Genome Sequencing Study. Front Oncol 2020;10:1682. [PMID: 32984045 DOI: 10.3389/fonc.2020.01682] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
767 Lyu N, Rajendran VK, Diefenbach RJ, Charles K, Clarke SJ, Engel A, Rizos H, Molloy MP, Wang Y; Sydney 1000 Colorectal Cancer Study Investigators*. Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay. Nanotheranostics 2020;4:224-32. [PMID: 32923312 DOI: 10.7150/ntno.48905] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
768 Schimanski CC, Kasper S, Hegewisch-Becker S, Schröder J, Overkamp F, Kullmann F, Bechstein WO, Vöhringer M, Öllinger R, Lordick F, Heinemann V, Geißler M, Schulz-Abelius A, Bernhard H, Schön MR, Greil R, Galle P, Lang H, Schmidtmann I, Moehler M. Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC). Oncoimmunology 2020;9:1806680. [PMID: 32923171 DOI: 10.1080/2162402X.2020.1806680] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
769 Tsai HL, Huang CW, Lin YW, Wang JH, Wu CC, Sung YC, Chen TL, Wang HM, Tang HC, Chen JB, Ke TW, Tsai CS, Huang HY, Wang JY. Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST). Eur J Cancer 2020;138:19-29. [PMID: 32829105 DOI: 10.1016/j.ejca.2020.05.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
770 Cohen R, Pudlarz T, Delattre JF, Colle R, André T. Molecular Targets for the Treatment of Metastatic Colorectal Cancer. Cancers (Basel) 2020;12:E2350. [PMID: 32825275 DOI: 10.3390/cancers12092350] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
771 Jo MJ, Kim BG, Park SH, Kim HJ, Jeong S, Kim BR, Kim JL, Na YJ, Jeong YA, Yun HK, Kim DY, Han J, Heo JY, Yoo YD, Lee DH, Oh SC. Romo1 Inhibition Induces TRAIL-Mediated Apoptosis in Colorectal Cancer. Cancers (Basel) 2020;12:E2358. [PMID: 32825500 DOI: 10.3390/cancers12092358] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
772 Cremolini C, Antoniotti C, Stein A, Bendell J, Gruenberger T, Rossini D, Masi G, Ongaro E, Hurwitz H, Falcone A, Schmoll HJ, Di Maio M. Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer. J Clin Oncol 2020;:JCO2001225. [PMID: 32816630 DOI: 10.1200/JCO.20.01225] [Cited by in Crossref: 30] [Cited by in F6Publishing: 55] [Article Influence: 15.0] [Reference Citation Analysis]
773 Bianconi D, Herac M, Posch F, Schmeidl M, Unseld M, Kieler M, Brettner R, Müllauer L, Riedl J, Gerger A, Scheithauer W, Prager G. Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC. Ther Adv Med Oncol 2020;12:1758835920928635. [PMID: 32922518 DOI: 10.1177/1758835920928635] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
774 Zhong J, Palkhi E, Ng H, Wang K, Milton R, Chaudhuri N, Lenton J, Smith J, Bhartia B, Wah TM. Long-Term Outcomes in Percutaneous Radiofrequency Ablation for Histologically Proven Colorectal Lung Metastasis. Cardiovasc Intervent Radiol 2020;43:1900-7. [PMID: 32812121 DOI: 10.1007/s00270-020-02623-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
775 Marmorino F, Boccaccino A, Germani MM, Falcone A, Cremolini C. Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge. Cancers (Basel). 2020;12. [PMID: 32824490 DOI: 10.3390/cancers12082317] [Cited by in Crossref: 10] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
776 Cardone C, Blauensteiner B, Moreno-Viedma V, Martini G, Simeon V, Vitiello PP, Ciardiello D, Belli V, Matrone N, Troiani T, Morgillo F, Zito Marino F, Dentice M, Nappi A, Boccaccino A, Antoniotti C, Cremolini C, Pietrantonio F, Prager GW, Normanno N, Maiello E, Argiles G, Elez E, Signoriello G, Franco R, Falcone A, Tabernero J, Sibilia M, Ciardiello F, Martinelli E. AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. Eur J Cancer 2020;138:1-10. [PMID: 32818762 DOI: 10.1016/j.ejca.2020.07.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
777 Stahler A, Stintzing S, von Einem JC, Westphalen CB, Heinrich K, Krämer N, Michl M, Modest DP, von Weikersthal LF, Decker T, Kiani A, Heintges T, Kahl C, Kullmann F, Scheithauer W, Moehler M, Kaiser F, Kirchner T, Jung A, Heinemann V. Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial. Eur J Cancer 2020;137:250-9. [PMID: 32810748 DOI: 10.1016/j.ejca.2020.07.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
778 Vera R, Salgado M, Safont MJ, Gallego J, González E, Élez E, Aranda E. Controversies in the treatment of RAS wild-type metastatic colorectal cancer. Clin Transl Oncol 2021;23:827-39. [PMID: 32789773 DOI: 10.1007/s12094-020-02475-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
779 Peltonen R, Ahopelto K, Hagström J, Böckelman C, Haglund C, Isoniemi H. High TKTL1 expression as a sign of poor prognosis in colorectal cancer with synchronous rather than metachronous liver metastases. Cancer Biol Ther 2020;21:826-31. [PMID: 32795237 DOI: 10.1080/15384047.2020.1803008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
780 Smeby J, Kryeziu K, Berg KCG, Eilertsen IA, Eide PW, Johannessen B, Guren MG, Nesbakken A, Bruun J, Lothe RA, Sveen A. Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity. EBioMedicine 2020;59:102923. [PMID: 32799124 DOI: 10.1016/j.ebiom.2020.102923] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
781 Pollett A. Colorectal Cancer: Microsatellite Instability/Mismatch Repair Testing in the Era of Digital Pathology. Gastroenterology 2020;159:1235-7. [PMID: 32800777 DOI: 10.1053/j.gastro.2020.08.008] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
782 Lindner AU, Carberry S, Monsefi N, Barat A, Salvucci M, O'byrne R, Zanella ER, Cremona M, Hennessy BT, Bertotti A, Trusolino L, Prehn JHM. Systems analysis of protein signatures predicting cetuximab responses in KRAS , NRAS , BRAF and PIK3CA wild‐type patient‐derived xenograft models of metastatic colorectal cancer. Int J Cancer 2020;147:2891-901. [DOI: 10.1002/ijc.33226] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
783 Yonemura Y, Iahibashi H, Sako S, Mizumoto A, Takao N, Ichinose M, Motoi S, Liu Y, Wakama S, Kamada Y, Nishihara K. Advances with pharmacotherapy for peritoneal metastasis. Expert Opin Pharmacother 2020;21:2057-66. [PMID: 32783786 DOI: 10.1080/14656566.2020.1793957] [Reference Citation Analysis]
784 Vera R, Gómez ML, Ayuso JR, Figueras J, García-Alfonso P, Martínez V, Lacasta A, Ruiz-Casado A, Safont MJ, Aparicio J, Campos JM, Cámara JC, Martín-Richard M, Montagut C, Pericay C, Vieitez JM, Falcó E, Jorge M, Marín M, Salgado M, Viúdez A. Correlation of RECIST, Computed Tomography Morphological Response, and Pathological Regression in Hepatic Metastasis Secondary to Colorectal Cancer: The AVAMET Study. Cancers (Basel) 2020;12:E2259. [PMID: 32806731 DOI: 10.3390/cancers12082259] [Cited by in Crossref: 1] [